

Wednesday, October 15, 2025

*Pre-conference workshop/course*

09:30 - 09:35

AMPHITHEATRE BORDEAUX

**Introduction**

**Introduction**

09:30 - 09:35

Tristan Barber (United Kingdom)  
Agnès Libois (Belgium)

*Pre-conference workshop/course*

09:30 - 09:40

ROOM MAILLOT

**Opening and update**

**Opening and update**

09:30 - 09:40

Annette Haberl (Germany)

*Pre-conference workshop/course*

09:35 - 10:20

AMPHITHEATRE BORDEAUX

**Non AIDS Malignancies**

**Non AIDS Malignancies**

09:35 - 09:55

Maria Mazzitelli (Italy)

**Case Presentation**

09:55 - 10:10

Risa Fukuoka (Japan)

**Q&A/Discussion**

10:10 - 10:20

*Pre-conference workshop/course*

09:40 - 10:20

ROOM MAILLOT

**A Continental View: Epidemiology & Empowerment**

**Women with HIV: European Epidemiology**

09:40 - 10:00

Charlotte Doegan (Sweden)

**Current situation of women with HIV in Ukraine**

10:00 - 10:10

Sergii Antoniuk (Ukraine)

**Discussion**

10:10 - 10:20

Dagny Krankowska (Poland)

*Pre-conference workshop/course*

10:20 - 10:40

AMPHITHEATRE BORDEAUX

**Break**

*Pre-conference workshop/course*

10:20 - 10:50

ROOM MAILLOT

**Journeys of Strength: Migrant Women's Realities**

**SERAY Project**

10:20 - 10:30

Giota Lourida (Greece)

**Personal journey**

10:30 - 10:40

**Discussion**

10:40 - 10:50

Melvina Woode-Owusu (United Kingdom)  
Cristiana Oprea (Romania)

*Pre-conference workshop/course*

10:40 - 11:25

AMPHITHEATRE BORDEAUX

**HIV and Virology****HIV and Virology**

10:40 - 11:00

Toshibumi Taniguchi (Japan)

**Case Presentation**

11:00 - 11:15

Matthew Valentino (Malta)

**Q&A/Discussion**

11:15 - 11:25

*Pre-conference workshop/course*

10:50 - 11:10

ROOM MAILLOT

**Moving forward: Feeding Choices for Parents living with HIV****European guidelines on HIV and breastfeeding**

10:50 - 11:00

Amy Keane (Ireland)

**Discussion**

11:00 - 11:10

Mojgan Hessamfar (France)

Yvonne Gilleece (United Kingdom)

*Pre-conference workshop/course*

11:10 - 11:50

ROOM MAILLOT

**Her Future, Her Terms: Ageing with HIV****Improving care for women with HIV as they age**

11:10 - 11:30

Anna Hachfeld (Switzerland)

Nneka Nwokolo (United Kingdom)

Susan Cole-Haley (United Kingdom)

**Models of care for women living with HIV in Europe: a scoping review**

11:30 - 11:40

Duaa Rao (Germany)

**Discussion**

11:40 - 11:50

Nneka Nwokolo (United Kingdom)

Ellen Moseholm (Denmark)

Susan Cole-Haley (United Kingdom)

*Pre-conference workshop/course*

11:25 - 12:10

AMPHITHEATRE BORDEAUX

**HIV Stigma in Healthcare Settings****HIV Stigma in Healthcare Settings**

11:25 - 11:45

Agata Skrzat-Klapaczyńska (Poland)

**Case Presentation**

11:45 - 12:00

Yasmin Walters (United Kingdom)

**Q&A/Discussion**

12:00 - 12:10

*Pre-conference workshop/course*

11:50 - 12:10

ROOM MAILLOT

**Break***Pre-conference workshop/course*

12:10 - 12:45

AMPHITHEATRE BORDEAUX

**Break**

*Pre-conference workshop/course*  
12:10 - 15:00

AMPHITHEATRE BORDEAUX

### Afternoon Chairs

Jose I Bernardino (Spain)  
Oana Sandulescu (Romania)

*Pre-conference workshop/course*  
12:10 - 12:50

ROOM MAILLOT

### Protection, Possibility, Power: Rewriting the Narrative with PrEP

**Prevention of HIV, PrEP options for women** 12:10 - 12:30

Yvonne Gilleece (United Kingdom)

**Educational needs assessment: PrEP in transcommunities** 12:30 - 12:40

Paulie "Amanita" Calderón-Cifuentes (Germany)

**Discussion** 12:40 - 12:50

Ben Collins (United Kingdom)  
Maria Jesus Perez Elías (Spain)

*Pre-conference workshop/course*  
12:45 - 13:30

AMPHITHEATRE BORDEAUX

### HIV and Weight/GLP-1 Agonists

**HIV and Weight/GLP-1 Agonists** 12:45 - 13:05

Marie-Angélique De Scheerder (Belgium)

**Case Presentation** 13:05 - 13:20

Carmen Busca (Spain)

**Q&A/Discussion** 13:20 - 13:30

*Pre-conference workshop/course*  
12:50 - 13:20

ROOM MAILLOT

### Silent Threat: HPV in Women living with HIV

**HPV screening in women with HIV** 12:50 - 13:10

Christina Carlander (Sweden)

**Discussion** 13:10 - 13:20

Nina Weis (Denmark)  
Karoline Aebi-Popp (Switzerland)

*Pre-conference workshop/course*  
13:20 - 13:30

ROOM MAILLOT

### Closing remarks & next steps

**Closing remarks & next steps** 13:20 - 13:30

Nina Weis (Denmark)

*Pre-conference workshop/course*  
13:30 - 13:40

AMPHITHEATRE BORDEAUX

### Break

*Pre-conference workshop/course*  
13:40 - 14:25

AMPHITHEATRE BORDEAUX

### The Future of HIV Treatment

**The Future of HIV Treatment** 13:40 - 14:00

Jose Arribas (Spain)	
<b>Case Presentation</b>	14:00 - 14:15
Alexandra Riczu (Hungary)	
<b>Q&amp;A/Discussion</b>	14:15 - 14:25
<i>Pre-conference workshop/course</i>	
14:25 - 14:50	AMPHITHEATRE BORDEAUX
<b>Partner Presentations</b>	
<b>EACS- European Diploma in HIV Medicine</b>	14:25 - 14:33
<b>NEAT-ID</b>	14:33 - 14:41
Esteban Martínez (Spain)	
<b>WEEPI</b>	14:41 - 14:49
Jens D. Lundgren (Denmark)	
<i>Pre-conference workshop/course</i>	
14:50 - 14:55	AMPHITHEATRE BORDEAUX
<b>Summary</b>	
Oana Sandulescu (Romania)	
<i>Pre-conference workshop/course</i>	
14:55 - 15:00	AMPHITHEATRE BORDEAUX
<b>Future of YING, and Close</b>	
Jose I Bernardino (Spain)	
<i>Pre-conference workshop/course</i>	
10:00 - 12:00	ROOM 242AB
<b>EATG STEPS Cure Workshop:</b>	
<b>STEPS 11: The Giulio Maria Corbelli Workshop - A Community Initiative to Design the Pathway to a Durable ART-Free Control of HIV Infection.</b>	
<b>Welcome Note &amp; Introduction to the Programme</b>	10:00 - 10:05
Daniela Rojas Castro (France)	
Brian West (United Kingdom)	
<b>The Path to a functional HIV Cure: Fundamental Concepts &amp; Current Updates, and an introduction to the EU2Control Platform</b>	10:05 - 10:25
Mark Janse (Netherlands)	
Evy Blomme (Belgium)	
<b>Clinical Trials in the RHIVIERA Initiative</b>	10:25 - 10:40
Cécile Goujard (France)	
<b>What French people with HIV can teach us about HIV Cure Research</b>	10:40 - 10:55
Christele Protière (France)	
<b>RT TACK Mechanism</b>	10:55 - 11:10
Luisa Stamm (United States)	
<b>Update on therapeutic vaccines and immunotherapies for an ART-free control</b>	11:10 - 11:25
Beatriz Mothe (Spain)	
<b>Community Perspective</b>	11:25 - 11:40
Alain Volny-Anne (France)	
<b>Discussion</b>	11:40 - 12:00

*Industry sponsored session*

11:30 - 12:30

AMPHITHEATRE BLEU

**Industry sponsored session***Industry sponsored session*

13:00 - 14:00

AMPHITHEATRE BLEU

**Industry sponsored session***Industry sponsored session*

15:00 - 16:00

AMPHITHEATRE BLEU

**Industry sponsored session***Ceremony*

16:45 - 18:00

GRAND AMPHITHEATRE

**Opening ceremony**

Milesz Parczewski (Poland)

Karine Lacombe (France)

Jean-Michel Molina (France)

Bruno Spire (France)

**Welcome & Introduction**

16:45 - 17:05

**Elton John AIDS Foundation**

17:05 - 17:10

**Global Health Center**

17:10 - 17:20

**Public Health Department of the City of Paris**

17:20 - 17:30

**Declaration EACS 2025 Paris**

17:30 - 17:35

**EACS award**

17:35 - 17:45

**Welcome to Paris**

17:45 - 18:00

Thursday, October 16, 2025

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP01- From Diagnosis to Retention**

Sophie Grabar (France)

MeP01.1	<b>Trends in late diagnosis of HIV and its association with education and income: a nationwide cohort study from 2003 to 2023 in Sweden</b> Sara Falk (Sweden)	12:05 - 12:10
MeP01.2	<b>Factors associated with loss to follow-up among PWH-1: Analysis through linkage of the ANRS PRIMO, CODEX, and COPANA to the ANRS CO4 FHDH: the PDVCOH study</b> Charlène Mafuta (France)	12:10 - 12:15
MeP01.3	<b>Personalized dynamic predictions of the time-to-next visit: identifying individuals more prone to disengage from care</b> Giota Touloumi (Greece)	12:15 - 12:20
MeP01.4	<b>Understanding drivers of HIV-related stigma in Romanian healthcare settings</b> OANA MIHAELA INESCU (Romania)	12:20 - 12:25

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP05 - Triple therapy forever**

Silvia Nozza (Italy)

MeP05.1	<b>Real-World Effectiveness of Bictegravir- versus Dolutegravir-Based Triple regimens in High-Viremia HIV Infection: The BicDol Study</b> Antoine Chéret (France)	14:05 - 14:05
MeP05.2	<b>Long-term viral suppression, and cardiometabolic benefits of switch to ainoovirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study</b> Hong Qin (China)	14:05 - 14:05
MeP05.3	<b>Five-year extended follow-up of the observational BICSTaR cohort: Final analysis in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice</b> Benoit Trottier (Canada)	14:05 - 14:05
MeP05.4	<b>ART persistence among treatment-experienced people with HIV and mental health disorders in the US</b> James Jarrett (United Kingdom)	14:05 - 14:05

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP09 - From bench to community: New evidence shaping the future of HIV treatment and prevention**

Juan Ambrosioni (Spain)

MeP09.1.LB	<b>Q4ddPCR Enhances Specificity in HIV Reservoir Quantification and Predicts Inducible Reservoir Size</b> Rachel Scheck (United States)	15:35 - 15:40
MeP09.3.LB	<b>Impact of doxycycline adherence on bacterial STI incidence in the ANRS 174 DOXYVAC trial</b> Lauriane Goldwirt (France)	15:40 - 15:45

MeP09.4.LB	<b>High Risk of Renal Complications After Type 2 Diabetes Mellitus Diagnosis in People with HIV Compared with People Without HIV: Findings From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS)</b> Isabela Killander Möller (Sweden)	15:45 - 15:50
MeP09.5.LB	<b>'Ask Us' Europe, a community co-produced study: PLWH perspectives on treatment optimisation discussions with healthcare providers in 18 countries- an interim analysis</b> Megan Devonald (United Kingdom)	15:50 - 15:55
MeP09.6.LB	<b>Generic lenacapavir HIV pre-exposure prophylaxis could be produced for \$25 per person per year</b> Cassandra Fairhead (United Kingdom)	15:55 - 16:00
MeP09.7.LB	<b>PrEP cascade and HIV prevention methods preference amongst migrant women: Comparison between undocumented migrants, asylum seekers, refugees, naturalised citizens/documentated residents, and their sex work engagement status in 11 European countries, June-July, 2025</b> Haoyi Wang (Netherlands)	16:00 - 16:05

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP02 - Biomarkers and Inflammation**

Casper Rokx (Netherlands)

MeP02.1	<b>Temporal multi-omics approach in well treated PHIV youth and healthy controls: insights into soluble factors that could lead to accelerated inflammaging</b> Julie van der Post (Netherlands)	12:05 - 12:08
MeP02.2	<b>Exploring Impact of Inflammation and Body Composition on Frailty Dynamics Among Older People with HIV</b> Win Min Han (Thailand)	12:08 - 12:11
MeP02.3	<b>Plasma proteomic assessment of mitochondrial protein degradation in people aging with HIV and elite controllers</b> Brian Epling (United States)	12:11 - 12:14
MeP02.4	<b>Neurocognitive and Plasma Biomarker Changes Following Antiretroviral Therapy Initiation in Treatment-Naïve People Living with HIV: A Prospective 18-Month Study</b> Charalampos D. Moschopoulos (Greece)	12:14 - 12:17
MeP02.5	<b>Metformin prevents weight gain in non-diabetic adults with HIV: results from a randomized, placebo-controlled trial</b> Cristina Marcelo Calvo (Spain)	12:17 - 12:20
	<b>Discussion</b>	12:20 - 12:25

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP06 - Sex, bugs and prevention**

Gilles Wandeler (Switzerland)

MeP06.1	<b>The Impact of 4CMenB Vaccination and Doxycycline post-exposure prophylaxis on Pharyngeal Meningococcal Carriage among MSM using HIV PrEP</b> Ala-Eddine Deghmane (France)	14:05 - 14:10
MeP06.2	<b>Pharmacokinetics and efficacy of a single dose of 200 mg of doxycycline in men who have sex with men using PrEP</b> Lauriane Goldwirt (France)	14:10 - 14:15

MeP06.3	<b>Modeling DoxyPEP impact amongst PrEP users: an opportunity for prevention in low-middle income countries</b> Mariana Ariadna Paolini (Argentina)	14:15 - 14:20
MeP06.4	<b>Risk Factors Associated with Bacterial Sexually Transmitted Infections (STIs) Among Men Who Have Sex with Men (MSM) During the Pre-Exposure Prophylaxis (PrEP) era: a Systematic Review and Meta-Analysis in High-Income Countries</b> Mathieu Castry (France)	14:20 - 14:25
<i>Moderated ePosters</i> 15:35 - 16:10		ePoster Exhibition
<b>MeP10 - Drug-resistance and defective virus</b> Silvia Nozza (Italy)		
MeP10.1	<b>Population Pharmacokinetics, Antidrug Antibodies and Exposure-Response of VH3810109 (N6LS) in Virologically Suppressed Adults Living With HIV From the Phase 2b EMBRACE Study</b> A. Yin Edwards (United States)	15:35 - 15:40
MeP10.2	<b>High <i>in vitro</i> resistance barrier for the bictegravir/lenacapavir combination</b> Michelle L. D'Antoni (United States)	15:40 - 15:45
MeP10.3	<b>Genotypic susceptibility to broadly neutralizing antibodies and fostemsavir of transmitted viruses, and evolution over time in the French acute HIV infection PRIMO cohort</b> Hegger Machado Fritsch (France)	15:45 - 15:50
MeP10.4	<b>Evolution of Proviral DNA M184V/I Over 96 Weeks Does Not Predict Virologic Failure of Dolutegravir/Lamivudine in the VOLVER Trial</b> Jose Arribas (Spain)	15:50 - 15:55
MeP10.5	<b>How Should APOBEC3-induced Resistance Mutations be Considered in the Management of Antiretroviral Therapy?</b> Marie Gilbert (France)	15:55 - 16:00
MeP10.6	<b>Nucleocapsid mutations at time of virological failure with an integrase inhibitor</b> Quentin Le Hingrat (France)	16:00 - 16:05
MeP10.7.LB	<b>Virological success with long-acting cabotegravir and rilpivirine in individuals with historical rilpivirine resistance: a real-world case series</b> Félix Gutiérrez Rodero (Spain)	16:05 - 16:10
<i>Moderated ePosters</i> 12:05 - 12:25		ePoster Exhibition
<b>MeP03 - Sexual health among people living with HIV</b> Robert Hejzák (Czech Republic)		
MeP03.1	<b>Sexual Dissatisfaction in People Living With HIV, results from the Vive+ project</b> Beatriz Julieta Blanco Rojas (Spain)	12:05 - 12:10
MeP03.2.LB	<b>Educational Needs Assessment on HIV Prevention and PrEP Knowledge among People who Are Trans and Non-Binary in Europe</b>  Paulie "Amanita" Calderón-Cifuentes (Germany)	12:10 - 12:15
MeP03.3	<b>From Pilot to Practice: Strengthening Sexual Health Care</b>	12:15 - 12:20



<b>Counseling in HIV clinical practice through Education and Training</b>		
Suzanne de Munnik (Netherlands)		
MeP03.4	<b>"I didn't think it was serious": understanding sexual dysfunction care needs of gay, bisexual and other men who have sex with men living with HIV in Montreal, Canada</b>	12:20 - 12:25
Bertrand Lebouché (Canada)		
<i>Moderated ePosters</i>		
14:05 - 14:25		ePoster Exhibition
<b>MeP07 - How to optimize patient-provider relationship: stigma and understanding</b>		
Robert Hejzak (Czech Republic)		
MeP07.1	<b>Developing, delivering and evaluating a bespoke HIV Knowledge and Stigma training program for healthcare workers; changes in knowledge and attitudes towards people with HIV</b>	14:05 - 14:10
Linda Cheyenne Vaccari (United Kingdom)		
MeP07.2	<b>HIV-RELATED STIGMA AND DISCRIMINATION AMONGST HEALTH CARE PROVIDERS IN ARGENTINA: RESULTS OF A CROSS-SECTIONAL STUDY EMPLOYING AN ONLINE SURVEY</b>	14:10 - 14:15
José A. E. Barletta (Argentina)		
MeP07.3	<b>Implementation of Mobile Clinics in Ukraine During Wartime: Early Outcomes of a Nationwide Program</b>	14:15 - 14:20
Svitlana Vynohradova (Ukraine)		
MeP07.4	<b>Structural factors associated with viral suppression among transgender women living with HIV in France, ANRS-Trans&amp;HIV: a nationwide retrospective life-event survey</b>	14:20 - 14:25
Margot Annequin (France)		
<i>Moderated ePosters</i>		
15:35 - 16:10		ePoster Exhibition
<b>MeP11 - Cardiovascular and metabolic diseases</b>		
Casper Rokx (Netherlands)		
MeP11.1	<b>HIV infection is strongly associated with acute myocardial infarction, independently of age, gender, and comorbidities: a population-based cohort study</b>	15:35 - 15:40
Robert Güerri-Fernández (Spain)		
MeP11.2	<b>Systolic inter-arm blood pressure difference and coronary artery disease in people with HIV</b>	15:40 - 15:45
Sávio Amaral (Brazil)		
MeP11.3	<b>Healthcare Utilization and Costs in People Living with HIV With and Without Hypertension and Type 2 Diabetes Mellitus in the United States</b>	15:45 - 15:50
Sean P. Fleming (United States)		
MeP11.4	<b>Rethinking obesity: applying the Lancet Commission framework on clinical obesity to people living with HIV in South Africa</b>	15:50 - 15:55
Joana Woods (South Africa)		
MeP11.5	<b>Comparable gut microbiome composition and diversity in people living with HIV with and without metabolic dysfunction-associated steatotic liver disease</b>	15:55 - 16:00
Magnus Søltøft Lindhardt (Denmark)		
MeP11.6	<b>Prevalence and associated risk factors for MASLD in people living with HIV: highlighting metabolic syndrome components</b>	16:00 - 16:05
Adrian Rodriguez (Spain)		

MeP11.7	<b>Prevalence of Addictive behaviours in MSM practicing Chemsex, and impact on their sexuality: results of the PACmen study</b> Thomas L'yavanc (France)	16:05 - 16:10
---------	---	---------------

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP04 - Antiviral drugs: viral escape and immunological failure**

Antonella Castagna (Italy)

MeP04.1	<b>HIV persistence in deep tissues on dolutegravir based antiretroviral therapy is not associated with the selection of drug resistance mutations to second generation INSTI (ANRS DOLUVOIR)</b> Gilbert Mchantaf (France)	12:05 - 12:10
---------	---	---------------

MeP04.2	<b>HIV-1 cell-to-cell Transmission to macrophages escapes type I interferon and host restriction factors, and is resistant to antiretroviral drugs</b> Sen Yan (France)	12:10 - 12:15
---------	--	---------------

MeP04.3	<b>DOLUTEGRAVIR IMPACT IN CARDIOVASCULAR GENES USING ZEBRAFISH EMBRYO MODEL</b> Giorgio Tiecco (Italy)	12:15 - 12:20
---------	---	---------------

MeP04.4	<b>Dysregulated Neutrophil Apoptosis and Emergence of Inflammatory Subsets in people living with HIV: Mechanisms of Immunological Failure</b> Aiwei Zhu (China)	12:20 - 12:25
---------	--	---------------

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP08 - Pregnancy, children and adolescents**

Nicolas Nagot (France)

MeP08.1	<b>Socio-demographic and socio-economic characteristics of women diagnosed with HIV during the pregnancy, using registry data from Statistic Netherlands</b> Colette Smit (Netherlands)	14:05 - 14:10
---------	--	---------------

MeP08.2	<b>Breastfeeding and HIV in High-Income Settings: Exploring Women living with HIV and Health-care Providers' Perspectives in Belgium</b> H'ava Masquelier (Belgium)	14:10 - 14:15
---------	--	---------------

MeP08.3	<b>Semi-structured interviews with women living with HIV and their health care professionals to determine factors influencing counseling on infant feeding options: a qualitative study</b> Lena van der Wekken-Pas (Netherlands)	14:15 - 14:20
---------	--	---------------

MeP08.4	<b>Transition experiences of young adults with perinatal HIV in the Netherlands</b> Annouschka Weijsenfeld (Netherlands)	14:20 - 14:25
---------	---	---------------

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP12 - Co-infections and vaccination**

Gilles Wandeler (Switzerland)

MeP12.1	<b>Prevalence, Incidence, and Clearance of Anal HPV Infection Among MSM in Japan: A Longitudinal Cohort Study</b> Naokatsu Ando (Japan)	15:35 - 15:40
---------	--	---------------

MeP12.2	<b>The Impact of COVID-19 on HIV Care Disruption and Return to Treatment in Mauritius: Findings from the COVIH-OI Qualitative Study</b>	15:40 - 15:45
---------	---	---------------

	Kenny Emmanuel Eleonore (Mauritius)	
MeP12.3	<b>A case series of acute hepatitis B among PLWH switched to long acting (LA) Cabotegravir (CAB)/ Rilpivirine (RPV)</b> Sophie Seang (France)	15:45 - 15:50
MeP12.4	<b>Prevalence and Factors Associated with Liver Cirrhosis in People with HIV and Chronic Hepatitis B: A Cross-sectional Study in Spain, Germany, and Poland</b> Juan Berenguer (Spain)	15:50 - 15:55
MeP12.5	<b>Understanding why modelling studies by the Center for Disease Analysis Foundation fail to provide reliable estimates of Hepatitis C prevalence in Northern and Western Europe</b> Barbara Bertisch (Switzerland)	15:55 - 16:00
MeP12.6	<b>Significantly More HIV-Seropositive Adults(PLWHA) Lack Detectable Anti-Measles IgG After Childhood Measles, Mumps, Rubella (MMR) Vaccinations When Compared to HIV-Seronegative Controls</b> Gary Blick (United States)	16:00 - 16:05
MeP12.7	<b>Impact of Antimicrobial Prophylaxis on AIDS-Defining Events in People with HIV: a Multicenter Experience</b> Chiara Fusesti (Italy)	16:05 - 16:10

*Industry sponsored session*

08:00 - 09:00

AMPHITHEATRE BLEU

**Industry sponsored session***Roundtable Discussion*

08:00 - 09:00

AMPHITHEATRE BORDEAUX

**RT1 - Community-based and participatory research in the field of HIV**

Paulie "Amanita" Calderón-Cifuentes (Germany)

**Roundtable Discussion on Community-based and participatory research in the field of HIV**

08:00 - 09:00

Nicolas Lorente (Spain)  
Grzegorz Jezierski (Poland)  
Perrine Roux (France)

*Meet-the-expert*

08:00 - 09:00

ROOM MAILLOT

**MTE1 - Statin guidelines implementation after REPRIEVE: one year later**

Esteban Martínez (Spain)

Franck Boccara (France)

**ESC Recommendations**

08:00 - 08:05

Franck Boccara (France)

**EACS Recommendations**

08:05 - 08:10

Esteban Martínez (Spain)

MTE1.1

**Impact of REPRIEVE indications on statin prescription in people with HIV in a real-life setting**

08:10 - 08:19

Rebecka Papaioannu Borjesson (Italy)

**Interactive discussion with the audience**

08:19 - 09:00

*Meet-the-expert*

08:00 - 09:00

ROOM 242AB

**MTE2 - Tuberculosis in 2025**

Nathalie De Castro (France)

Daria Podlekareva (Denmark)

MTE.C2.1	<b>A diagnostic and therapeutic odyssey in advanced HIV: disseminated tuberculosis with hematologic and renal involvement</b> Sabri Atalay (Turkey)	08:00 - 08:09
MTE.C2.2	<b>Use of anakinra for corticosteroid-refractory paradoxical IRIS in patients with HIV and tuberculous lymphadenitis: two case reports</b> Alberto Díaz-de Santiago (Spain)	08:09 - 08:18
MTE.C2.3	<b>The case of cutaneous TB in person living with HIV from Eastern European country of Georgia</b> Shorena DVALI (Georgia)	08:18 - 08:27
	<b>Interactive discussion with the audience</b>	08:27 - 08:57

*ePosters*

09:00 - 18:00

ePoster Exhibition

**ePosters on Display**

	<b>A. Basic and Translational Science</b>	09:00 - 09:00
eP001	<b>Refining the resistance landscape of lenacapavir in HIV-1 through cell-based selection</b> Jolieke A. T. van Osch (Netherlands)	09:00 - 09:00
eP002	<b>Dasatinib enhances innate macrophage restriction and limits HIV-1 replication</b> Clara Sánchez Menéndez (Spain)	09:00 - 09:00
eP003	<b>HIV persistence in cisgender women after long periods on ART: could be shaped by the route and moment of HIV acquisition?</b> Lucia Baquero (Argentina)	09:00 - 09:00
eP004	<b>HIV-specific CD8+ T-cell response drives viral selection and integration site in silent regions in individuals treated during the acute phase of HIV acquisition</b> Pien van Paassen (Netherlands)	09:00 - 09:00
eP005	<b>HIV-specific T-cell immune response in elite controllers</b> Lucia Baquero (Argentina)	09:00 - 09:00
eP006	<b>Linking Gut Microbiome to HIV Reservoir Size in People Living with HIV</b> Oscar Kieri (Sweden)	09:00 - 09:00
eP007	<b>Longitudinal dynamics of virology, immunity, and HIV-1 reservoir in people living with HIV and cancer: impact of antitumor therapy and immune checkpoint inhibitors</b> Jingchun Mao (China)	09:00 - 09:00
eP008	<b>Machine learning identified genetic features associated with HIV Sequences in the Monocytes</b> Xiaorong Peng (China)	09:00 - 09:00
eP009	<b>Variations in sero-biomarkers of gut barrier dysfunction and sCD14 in ART-naïve PWH initiating ART</b> Valentina Iannone (Italy)	09:00 - 09:00
eP010	<b>Decoding HIV: two technologies, one genome</b> Nadia Randazzo (Italy)	09:00 - 09:00

eP011	<b>False Positivity in HIV Screening Using Fourth-Generation Assay: Performance and Potential Influencing Factors in a Low Prevalence Population</b> Lily Shui-kuen Cheng (Hong Kong)	09:00 - 09:00
eP012	<b>Feasibility and reliability of decentralized HIV-1 viral load monitoring on self-sampled blood</b> Kyra Mendes de Leon (Netherlands)	09:00 - 09:00
eP013	<b>Limited performance of FIB-4 and NAFLD fibrosis score for detecting liver fibrosis in people living with HIV</b> Ahmed Cordie (Egypt)	09:00 - 09:00
eP014	<b>Whole-genome sequencing for HIV-1 drug resistance testing: are we ready?</b> Federica Stefanelli (Italy)	09:00 - 09:00
eP015	<b>Dynamic Crosstalk Between MAIT Cells and NK Cells in Incomplete Immune Reconstitution of Individuals acquiring HIV</b> Zhuoya Deng (China)	09:00 - 09:00
eP016	<b>Dynamics and Immunological Signature of <math>\gamma\delta</math> T Cells Following Antiretroviral Therapy Initiation in Acute HIV-1 Infection</b> Zhen Li (China)	09:00 - 09:00
eP017	<b>Extracellular Acyl-CoA-Binding Protein prevents autophagy and T-cell function in people with HIV</b> Stephane Isnard (Canada)	09:00 - 09:00
eP018	<b>Immune checkpoint patterns in cerebrospinal fluid after ART initiation related to neurocognitive decline among PWH</b> ANA JOY LOZANO (Philippines)	09:00 - 09:00
eP019	<b>Modulation of TLR-Driven Monocyte Activation by JAK-STAT Inhibitors in People With HIV</b> Marion Camard (France)	09:00 - 09:00
eP020	<b>Reduction of immune- senescence in People with HIV (PWH) switching to long-acting injectable Cabotegravir plus Rilpivirine</b> Mariasilvia Guardiani (Italy)	09:00 - 09:00
eP021	<b>Tenascin-C Bridges Biomarker Discovery and Immune Modulation in Incomplete Immune Reconstitution Among People Living with HIV</b> Zhuoya Deng (China)	09:00 - 09:00
eP022	<b>Type I Interferon Drives Myeloid-Mediated T-Cell Activation in People Living with HIV Under Antiretroviral Therapy</b> Léo Plaçais (France)	09:00 - 09:00
eP023	<b>ANTIOXIDANT CAPACITY IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY</b> Radoslava Emilova (Bulgaria)	09:00 - 09:00
eP024	<b>Differential expression of ER-TR7 following challenge with more recent antiretroviral drugs: an <i>in vitro</i> model</b> Maria Aurora Carleo (Italy)	09:00 - 09:00
eP026	<b>Functional characterization of the HIV-2 V3 loop: Insights into host interaction and viral tropism</b> Paloma Gonçalves (Portugal)	09:00 - 09:00
eP027	<b>High levels of anti-HHV-8 IgG binding capacity are linked with low HHV-8 viremia in people with and without HIV</b> Stephane Isnard (Canada)	09:00 - 09:00

eP028	<b>Identification of transcriptional active SIV-infected cells in Rhesus Macaques</b> Jerome Estaquier (Canada)	09:00 - 09:00
eP029	<b>Impaired Immune Reconstitution in PLWH: the Role of CD4<sup>+</sup>T-Cell-Associated NKG2D Ligands and CD4<sup>+</sup>T-Cell Subsets Imbalance</b> Peng Xu (China)	09:00 - 09:00
eP030	<b>Markers of astroglial/monocyte activation and inflammation are associated with neurocognitive impairment in people with HIV on suppressive ART</b> Matteo Augello (Italy)	09:00 - 09:00
eP031	<b>Microglia cause HIV-induced transcriptional and metabolomic changes in human brain organoids leading to neurological impairment</b> Pamela E. Capendale (Netherlands)	09:00 - 09:00
eP032	<b>Myeloid production of the mitokine GDF15 is associated with HIV reservoir size and non-AIDS comorbidity marker in ART-treated people with HIV</b> Stephane Isnard (Canada)	09:00 - 09:00
eP033	<b>Single-Cell Transcriptomic Analysis Reveals Nef-Induced Dysregulation of Hematopoietic Stem Cell Development and Aging-Associated Pathways in HIV Infection</b> Wei Zou (China)	09:00 - 09:00
eP034	<b>A Systematic Analysis of Immune Responses Following BCG Vaccination in People with HIV</b> Johannes Nemeth (Switzerland)	09:00 - 09:00
eP035	<b>Optimized Expression of CD4-Inducible (CD4i) Epitopes in HIV-1 Vaccine Prototypes Based on Virus-Like Particles (VLPs)</b> ALMUDENA RUBIO-PEREZ (Spain)	09:00 - 09:00
eP036	<b>Development of diagnostic/prognostic marker and therapeutic target for HCV-mono- and HIV/HCV-co-infection-mediated liver diseases</b> IN-WOO PARK (United States)	09:00 - 09:00
eP037	<b>Low-level viraemia (LLV) in people living with HIV and its management at an HIV centre in London</b> Matthew Valentino (Malta)	09:00 - 09:00
eP038	<b>Novel NGS-based Pipeline for HIV-1 pol Region Analysis</b> Arina Syrkina (Russian Federation)	09:00 - 09:00
eP039	<b>Proviral DNA genotyping among patients living with HIV with Undetectable Viral Load or Low-Level Viral Load</b> Dan Turner (Israel)	09:00 - 09:00
eP040	<b>Exploration of the genetic diversity and the evolution of HIV-1 non-B subtypes in Serbia: phylogenetic information beyond viral spread</b> Marina Siljic (Serbia)	09:00 - 09:00
eP041	<b>Using Nanopore sequence data to analyse drug resistance profile and its association with phylodynamics from HIV quasispecies</b> Tsz Ho Kwan (Hong Kong)	09:00 - 09:00
	<b>B1. Clinical Science - Antiretroviral therapy</b>	09:00 - 09:00
eP042	<b>A Clinical Pathway for the Use of Long-Acting Injectable antiretroviral therapy (LAI-ART) in Adherence Challenged People Living with HIV</b>	09:00 - 09:00

	Siobhan Quirke (Ireland)	
eP043	<b>A combined dolutegravir-rilpivirine oral regimen as lead-in therapy for long-acting injectable antiretroviral treatment in people living with HIV</b> Mayda Rahi (France)	09:00 - 09:00
eP044	<b>Adverse events and treatment discontinuation in a large, observational cohort of PLHIV starting Dolutegravir or non-Dolutegravir-based antiretroviral therapy (ART) in Brazil: The CODE cohort</b> Carlos Brites (Brazil)	09:00 - 09:00
eP045	<b>Analysis of viral load and INSTI resistance in people with HIV-1A6 receiving oral second generation INSTI</b> Maarten van de Klundert (Sweden)	09:00 - 09:00
eP046	<b>Antiviral exposure and risk of Metabolic Dysfunction-Associated Steatotic Liver Disease</b> Magnus Søltoft Lindhardt (Denmark)	09:00 - 09:00
eP047	<b>B/F/TAF in Latin American Elderly PLWH: A 96-Week Analysis of Effectiveness, Safety, and Metabolic Outcomes from the BICTARG Cohort</b> Cinthia Lamaizon (Argentina)	09:00 - 09:00
eP048	<b>Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV Aged ≥50: Low Discontinuation Rates and Favorable Metabolic Outcomes Over 36 Months</b> Andrea De Vito (Italy)	09:00 - 09:00
eP049	<b>CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination in treatment-naïve adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France</b> Patrick Philibert (France)	09:00 - 09:00
eP050	<b>Changes in Neuronal Injury and Inflammation Biomarkers in CSF of People Switching to Doravirine plus Raltegravir</b> Analuz Fernández (Spain)	09:00 - 09:00
eP051	<b>CHANGES IN QUALITY OF LIFE IN PEOPLE LIVING WITH HIV SWITCHING TO DOLUTEGRAVIR-BASED REGIMENS, FROM STABLE OR FAILING CURRENT ANTIRETROVIRAL REGIMENS IN THE CODE COHORT</b> Liliane Lins-Kusterer (Brazil)	09:00 - 09:00
eP052	<b>Changes in weight and BMI associated with switching to doravirine/lamivudine/tenofovir disoproxil fumarate vs. continuing an integrase inhibitor- or protease inhibitor-based regimen- an observational prospective case-control study</b> Charlotte-Paige Rolle (United States)	09:00 - 09:00
eP053	<b>Characteristics and Outcomes of People with HIV (PWH) Virally Suppressed on Complex Regimens</b> Richard Elion (United States)	09:00 - 09:00
eP054	<b>Clinical and immunovirological outcomes in advanced people living with HIV receiving dual versus triple drug regimens: a real-world cohort study</b> Emanuela Zappulo (Italy)	09:00 - 09:00
eP055	<b>Comparable dynamics of cell-associated HIV-RNA, total and intact proviral HIV-1 DNA in virologically suppressed people with HIV switching to 2-drug or continuing 3-drug therapy over 18-months of follow-up</b>	09:00 - 09:00

	Lia Fiaschi (Italy)	
eP056	<b>Comparative Dynamics of Inflammatory Biomarkers in Antiretroviral-Naïve MSM with HIV initiating DTG/3TC versus BIC/FTC/TAF</b> Ran Wang (China)	09:00 - 09:00
eP057	<b>Comparison of HIV diagnosis and treatment features in cis- and trans-gender women in two different European Centres (London and Padua)</b> Maria Mazzitelli (Italy)	09:00 - 09:00
eP058	<b>COMPARISON OF THE RESPONSE TO ANTIRETROVIRAL TREATMENT BETWEEN LATE PRESENTING AND OTHER ADULT PEOPLE LIVING WITH HIV: A 13- YEAR SINGLE-CENTER EXPERIENCE</b> Figen Kaptan Aydoğmuş (Turkey)	09:00 - 09:00
eP059	<b>Differences on Clinical and Virological Outcomes of Cabotegravir + Rilpivirine Long Acting between Men and Women in the Dat'AIDS Cohort</b> Clotilde Allavena (France)	09:00 - 09:00
eP060	<b>Discontinuations of long-acting injectable cabotegravir and rilpivirine in observational cohorts</b> Chloe Pasin (United Kingdom)	09:00 - 09:00
eP061	<b>Does adherence to CAB + RPV decrease over time in real world? A substudy from the RELATIVITY cohort</b> Luis Buzon Martín (Spain)	09:00 - 09:00
eP062	<b>DOLAM-500: 48 and 96-Week Real-World Efficacy and Safety of Dolutegravir Plus Lamivudine in ART-Naïve Individuals with Baseline HIV-1 RNA <math>\geq 500,000</math> copies/mL</b> Asuman İnan (Turkey)	09:00 - 09:00
eP063	<b>DOLANKA: Real World Data on the use of two drug regimen Dolutegravir (DTG) + Lamivudine (3TC) in treatment-naïve people living with HIV in Ankara-Turkey: Interim analysis results</b> MELIHA CAGLA SONMEZER (Turkey)	09:00 - 09:00
eP064	<b>DTG/3TC AS INITIAL THERAPY IN PEOPLE LIVING WITH HIV AND VIRAL LOAD <math>&gt; 500,000</math> COPIES/ML AND CD4 CELL COUNT <math>\geq 200/\text{mm}^3</math></b> Juan Martin-Torres (Spain)	09:00 - 09:00
eP066	<b>Durability and reasons for treatment discontinuation of BIC/FTC/TAF in real life: data from 927 Persons With HIV in charge to "D. Cotugno" hospital, Naples, Southern Italy</b> Francesco Maria Fusco (Italy)	09:00 - 09:00
eP067	<b>Durability of Long-Acting Cabotegravir + Rilpivirine in virologically suppressed adults living with HIV: A Multicenter Observational Study in Tuscany (LAHIV)</b> Filippo Lagi (Italy)	09:00 - 09:00
eP068	<b>Durability of viral suppression following antiretroviral therapy optimization to TLD among treatment-experienced adults living with HIV in Tajikistan</b> Aziz Nabidzhonov (Tajikistan)	09:00 - 09:00
eP069	<b>Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV TR cohort</b> Halis Akalın (Turkey)	09:00 - 09:00
eP070	<b>Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide from NNRTI-based ART in virologically suppressed</b>	09:00 - 09:00



	<b>people with HIV (PWH): a retrospective analysis (DRIVE-SWITCH study)</b> Andrea Antinori (Italy)	
eP071	<b>Epidemiological situation of HIV treatment in Tunisia, 2024</b> Arwa Neffati (Tunisia)	09:00 - 09:00
eP072	<b>Equal risk of confirmed virological failure among individuals using long-acting injectable cabotegravir/rilpivirine during first and second year of follow-up: results from the Dutch ATHENA national observational cohort</b> Ferdinand W. N. M. Wit (Netherlands)	09:00 - 09:00
eP073	<b>High Uptake of Intermittent Drug-Reduced ART Strategies Among Virally Suppressed People Living with HIV (PWH) at an HIV Clinic in Paris, France</b> Christine Katlama (France)	09:00 - 09:00
eP074	<b>HIV-2: Viraemias in the course of untreated and treated "People Living With HIV-2" (PLWH2) in an observational cohort ("H2O") from Hamburg</b> Dirk Berzow (Germany)	09:00 - 09:00
eP075	<b>Impact of Antiretroviral Therapy (ART) Regimen Initiation or Switch in Virologically Suppressed People With Human Immunodeficiency Virus-1 (HIV-1) on Lipid Profile at 48 weeks: A Systematic Literature Review</b> Julián Olalla (Spain)	09:00 - 09:00
eP076	<b>Impact of bictegravir/emtricitabin/tenofovir alafenamid (BIC/TAF/FTC) and Dolutegravir/Lamivudine on Depression Symptoms in People Living with HIV: A Retrospective Analysis of Beck Depression Inventory Scores</b> Oguz Karabay (Turkey)	09:00 - 09:00
eP077	<b>Impact of nucleoside reverse transcriptase inhibitor resistance-associated mutations on long-term virologic suppression of bictegravir/emtricitabine/tenofovir alafenamide: real-world evidence</b> Cinthia Lamaizon (Argentina)	09:00 - 09:00
eP078	<b>IMPACT OF PREEXISTING K103N ON THE EFFECTIVINES OF LA-CAB+RPV: REAL-LIFE RELATIVITY COHORT</b> Luz Martín Carbonero (Spain)	09:00 - 09:00
eP080	<b>Implementation of a same-day ART start model in a real-life setting in Italy</b> Giulia Micheli (Italy)	09:00 - 09:00
eP081	<b>Implementation Outcomes and Preliminary Effectiveness of Digitally Administering an Electronic Patient-Reported Outcome Measure of Barriers to Adherence to Antiretrovirals (the I-Score) in HIV Care</b> David LESSARD (Canada)	09:00 - 09:00
eP082	<b>Increasing CD4/CD8 Ratio Confirmed after Two Years of Long-Acting Cabotegravir and Rilpivirine in the SCohoLART Study</b> Gabriele Loi (Italy)	09:00 - 09:00
eP083	<b>Living with HIV-2: Clinical and Therapeutic Profile of a Cohort Followed in a Portuguese Local Health Unit</b> Diana Briosas Reis (Portugal)	09:00 - 09:00
eP084	<b>Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV</b> Júlia Calvo (Spain)	09:00 - 09:00

eP085	<b>Long-Acting CAB + RPV: Safety, Efficacy, and Discontinuation Risks in ODOACRE Cohort</b> Andrea De Vito (Italy)	09:00 - 09:00
eP086	<b>Long-Acting Cabotegravir-Rilpivirine in Real-Life: Sex-based Characteristics and Effectiveness</b> Ana González-Cordón (Spain)	09:00 - 09:00
eP087	<b>Long-Acting Cabotegravir-Rilpivirine in Vulnerable Population: Chemsex Practices-based Analysis</b> Maria Martínez-Rebollar (Spain)	09:00 - 09:00
eP088	<b>Long-Acting HIV Treatment in Practice: Promising Outcomes and Real-World Challenges from the CACTUZ Cohort</b> Caroline Matthys (Belgium)	09:00 - 09:00
eP089	<b>Long-acting injectable cabotegravir and rilpivirine outcomes in HIV individuals with stable treatment with dolutegravir and rilpivirine</b> María José Galindo Puerto (Spain)	09:00 - 09:00
eP090	<b>LONG-TERM BIC/TAF/FTC DURABILITY AND IMPACT OF DTG/3TC OR LONG-ACTING CABO/RPV</b> Ana Moreno Zamora (Spain)	09:00 - 09:00
eP091	<b>Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed people with HIV across age strata: observational data from the ICONA-BIC Study</b> Alessandro Tavelli (Italy)	09:00 - 09:00
eP092	<b>Long-Term Metabolic and Safety Profiles of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in HIV Treatment: A Multicenter Retrospective Study Using Mixed-Effects Modeling</b> Oguz Karabay (Turkey)	09:00 - 09:00
eP093	<b>Modulation of biomarkers of CNS inflammation, immune activation and neuronal injury in PWH switching to long-acting injectable cabotegravir/rilpivirine therapy: 12 months of follow-up</b> Maria Antonella Zingaropoli (Italy)	09:00 - 09:00
eP094	<b>One-Year Clinical Outcomes of Second-generation Integrase Inhibitors Therapy in Late HIV Presenters in Egypt and Saudi Arabia</b> Hanan Hamdy (Egypt)	09:00 - 09:00
eP095	<b>Patient Reported Experiences and perceived benefit of treatment with dolutegravir/lamivudine in Europe (PAIRED Europe): Primary Analysis</b> Eva Fernvik (Sweden)	09:00 - 09:00
eP096	<b>Patient-Reported Health and Virological Outcomes Among People with HIV Switching to Long-Acting Injectable Cabotegravir and Rilpivirine (LANTERN)</b> CHIEN-YU Cheng (Taiwan)	09:00 - 09:00
eP097	<b>Patient-Reported Outcomes and Experiences in a Diverse HIV Cohort Initiating Rapid B/F/TAF: The ASAP Study</b> Dominic Chu (Canada)	09:00 - 09:00
eP098	<b>Profile of comorbidities in individuals who are receiving Long-Acting Cabotegravir and Rilpivirine: Real-World Insights from the RELATIVITY Cohort</b> María José Galindo Puerto (Spain)	09:00 - 09:00
eP099	<b>Real life data of people with HIV starting bictegravir/emtricitabine/tenofovir alafenamide with baseline</b>	09:00 - 09:00

	<b>CD4+ count below 200 cells/mL (BicAdvance study)</b> Laura Comi (Italy)	
eP100	<b>Real life experience with doravirine-based treatment: therapeutic efficacy and influence on lipid and T-cell immune profile</b> Giorgio Giannetta (Italy)	09:00 - 09:00
eP101	<b>Real world use of lenacapavir in France: a national, observational study</b> Romain Palich (France)	09:00 - 09:00
eP102	<b>Real-Life Effectiveness, Safety, and Patient-Reported Outcomes of Long-Acting Cabotegravir-Rilpivirine: Results from a large single center cohort</b> Ana González-Cordón (Spain)	09:00 - 09:00
eP103	<b>Real-World Effectiveness and Tolerability of Cabotegravir + Rilpivirine Long-Acting in People Living with HIV-1: A Meta-Analysis of Real-World Evidence</b> Chloe Orkin (United Kingdom)	09:00 - 09:00
eP104	<b>Real-world Effectiveness of DTG+3TC in PLHIV With Previous ART Experience but no Genotype Testing: The "AReTi" Study Results</b> Dimitrios Athanasopoulos (Greece)	09:00 - 09:00
eP105	<b>Real-world use of long-acting injectable cabotegravir and rilpivirine (LAI-CAB+RPV) in non-virally suppressed individuals: a systematic review of baseline characteristics, virological failure outcomes and discontinuations</b> Chloe Pasin (United Kingdom)	09:00 - 09:00
eP106	<b>Real-world utilization of cabotegravir/rilpivirine long-acting injectable: an observational analysis of adherence and persistence using a patient support program in Canada</b> Jean-Francois Fortin (Canada)	09:00 - 09:00
eP107	<b>Reasons for switching to long-acting injectable antiretroviral therapy with cabotegravir/rilpivirine among adult people living with HIV: the real-life PANTER study</b> Martin Duracinsky (France)	09:00 - 09:00
eP108	<b>Results at month 12 of CABO-CHANCE study: real-world-evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every two months in viral suppressed people with HIV (PWH)</b> Carmen Hidalgo Tenorio (Spain)	09:00 - 09:00
eP109	<b>Risk of virological failure after switch to a tenofovir-sparing dual therapy in virologically suppressed people with HIV and past HBV infection</b> Alberto Borghetti (Italy)	09:00 - 09:00
eP110	<b>Risk of virological rebound is similar in people with HIV switching to long-acting cabotegravir/rilpivirine or integrase inhibitor-based oral therapy</b> Flavia Badalucco Ciotta (Italy)	09:00 - 09:00
eP111	<b>Subtype-Dependent Clinical and Immunological Patterns of Acute HIV-1 Acquisition: A Retrospective Analysis from Southern China</b> Qiuyue Zhang (China)	09:00 - 09:00
eP112	<b>Switch to BIC/TAF/FTC or DTG + TDF/FTC in virologically suppressed PWH: outcomes in real-world setting and impact of tenofovir resistance</b> Alain Makinson (France)	09:00 - 09:00

eP113	<b>Switching to Generic Dolutegravir: Sustained Gains in Immunity, Viral Control, and Metabolic Stability</b> Ahmed M. Kamel (Egypt)	09:00 - 09:00
eP114	<b>Ten-year results on the effectiveness of DTG+3TC as a switch regimen in the ODOACRE cohort</b> Arturo Ciccullo (Italy)	09:00 - 09:00
eP115	<b>The European REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV</b> Maria Jesus Perez Elías (Spain)	09:00 - 09:00
eP116	<b>The Increasing Use of Two-Drug HIV Regimens</b> Sarah Brown (United Kingdom)	09:00 - 09:00
eP117	<b>TR-DOLA: Real-world data on the use of Dolutegravir (DTG) + Lamivudine (3TC) in treatment-experienced people living with HIV in TURKIYE</b> Tuna Demirdal (Turkey)	09:00 - 09:00
eP118	<b>Treatment switch among US Medicare beneficiaries with HIV</b> James Jarrett (United Kingdom)	09:00 - 09:00
eP119	<b>Trends in opportunistic diseases at antiretroviral therapy initiation, Croatia 2009-2023</b> Šime Zekan (Croatia)	09:00 - 09:00
eP120	<b>Two versus three-drug Doravirine based regimens in real life: a multicentric observational study</b> Adriana Cervo (Italy)	09:00 - 09:00
eP121	<b>Two-year efficacy and durability of cabotegravir and rilpivirine in the SCohoLART study</b> Camilla Muccini (Italy)	09:00 - 09:00
eP122	<b>Unconventional DORAVIRINE antiretroviral regime: a single-center experience</b> Francesco Giovanni Genderini (Belgium)	09:00 - 09:00
eP123	<b>Variability in Laboratory Monitoring After Switching to Long-Acting CAB/RPV: Patterns and Associations with Virological Outcomes</b> Maria de Lagarde Sebastian (Spain)	09:00 - 09:00
eP124	<b>Virological Failure on Long-Acting Cabotegravir + Rilpivirine: Associated Factors and Remaining Options in the Real-World Dat'AIDS Cohort</b> Colin Deschanvres (France)	09:00 - 09:00
eP125	<b>7-year sustained efficacy, safety, and immunological improvement with fostemsavir-based regimens in individuals with HIV and limited treatment options</b> Manyu Prakash (United Kingdom)	09:00 - 09:00
eP126	<b>Comparable efficacy but greater discontinuations due to adverse events with dolutegravir-containing two-drug versus three-drug antiretroviral therapy: a systematic review and meta-analysis</b> Cassandra Fairhead (United Kingdom)	09:00 - 09:00
eP127	<b>Cutoff for Baseline Phenotypic Sensitivity to VH3810109 (N6LS) Did Not Impact Occurrence of Confirmed Virologic Failure in the Phase 2b EMBRACE Study</b> Margaret Gartland (United States)	09:00 - 09:00
eP128	<b>Demographic and clinical characteristics of Phase 3 participants in</b>	09:00 - 09:00

	<b>ARTISTRY-1, an open-label study comparing a bicitegravir/lenacapavir (BIC/LEN) single tablet regimen (STR) with complex antiretroviral therapy (ART) regimens</b> Chloe Orkin (United Kingdom)	
eP129	<b>Efficacy, and safety of ainoovirine plus lamivudine, and tenofovir DF in young people with HIV-1: pooled analyses of RACER, and SPRINT studies, two randomized, active-controlled phase 3 trials</b> Hong Qin (China)	09:00 - 09:00
eP130	<b>Efficacy, and safety of ainoovirine-based antiretroviral regimen in women with HIV-1: the pooled analysis of the RACER, and SPRINT studies, two multicenter, randomized, active controlled phase 3 trials</b> Hong Qin (China)	09:00 - 09:00
eP131	<b>Evaluation of VH3810109 (N6LS) and Cabotegravir Long-Acting, Dual Modality, Injections for HIV Treatment: People With HIV and Staff Perspectives</b> Cassidy A Gutner (United States)	09:00 - 09:00
eP132	<b>Impact of switching from a bicitegravir- or dolutegravir-based regimen with emtricitabine/tenofovir alafenamide to dolutegravir/lamivudine on weight and metabolic profiles: a randomized, open-label, multicenter, parallel-group trial</b> Kensuke Minami (Japan)	09:00 - 09:00
eP133	<b>Patient-Reported Outcomes From People With HIV-1 Receiving Once-Weekly Oral Islatravir in Combination With Lenacapavir: Phase 2 Week 48 Results</b> Arman Papadakis Sali (United States)	09:00 - 09:00
eP134	<b>Subgroup Analysis of Dolutegravir/Lamivudine-in ART-Naïve Adults Living with HIV with CD4 counts below 200 cells/mL: Results from the DOLCE Study</b> Carlos Brites (Brazil)	09:00 - 09:00
eP135	<b>Switch to DOR/TDF/3TC in People With Controlled HIV and history of RNA genotype M184V/I mutation: Interim Results of the DRIVE OFF-ROAD Multicenter Single-Arm Phase II trial</b> Jean-Jacques Parienti (France)	09:00 - 09:00
eP136	<b>Treatment outcomes in people with a late HIV diagnosis: A pooled analysis of participants with advanced HIV disease at diagnosis randomized to receive bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)</b> Jürgen K Rockstroh (Germany)	09:00 - 09:00
eP137	<b>LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT</b> Kaddu Muhamed yahya (Uganda)	09:00 - 09:00
eP138	<b>Physician specialties involved in prescribing BIC/F/TAF and concomitant drugs in people with HIV (PWH) in Germany: implications for potential drug to drug interaction (DDI)</b> Guido Schäfer (Germany)	09:00 - 09:00
eP139	<b>Virological Outcomes in People Living With HIV on INSTI-based cART Receiving Paclitaxel for Kaposi Sarcoma: A Retrospective Cohort Study</b> Niroshan Dayalan (United Kingdom)	09:00 - 09:00
eP140	<b>A French national real-world survey of people with multi-resistant HIV-1 viruses treated with an antiretroviral regimen including fostemsavir</b> Charlotte Charpentier (France)	09:00 - 09:00

eP141	<b>APOBEC-associated mutations in proviral HIV-DNA: assessing their impact on long-acting cabotegravir/rilpivirine treatment suitability</b> Giovanni Massobrio (Italy)	09:00 - 09:00
eP142	<b>Applications and Clinical Utility of Proviral HIV DNA Resistance Testing in Routine Practice: A Real-World Analysis</b> Neva Braccialarghe (Italy)	09:00 - 09:00
eP143	<b>Distribution of HIV-1 Subtypes and Genotypic Resistance Analysis in People Living with HIV: A 9-Year Retrospective Evaluation</b> Aslihan Candevir (Turkey)	09:00 - 09:00
eP144	<b>Drug resistance analysis of HIV-1 variants circulated in migrants MSM and transgender women living in Moscow, Russia in 2020-2025</b> Ilya Lapovok (Russian Federation)	09:00 - 09:00
eP145	<b>Dual Validation through Trend Analysis and Spatiotemporal Profiling: A Decade-Long Roadmap for HIV Genotypic Resistance Testing Scale-Up in China's Universal Free ART Programs (2014-2023)</b> Defu Yuan (China)	09:00 - 09:00
eP146	<b>Durability of lenacapavir in viremic HTE PWH: real-world data from the PRESTIGIO Registry</b> Tommaso Clemente (Italy)	09:00 - 09:00
eP147	<b>Evidence of transmitted resistance to integrase strand transfer inhibitors (INSTIs) within local transmission clusters among antiretroviral therapy-naïve PLHIV in Greece</b> Evangelia Georgia Kostaki (Greece)	09:00 - 09:00
eP148	<b>Factors associated with maintenance of high CD4 counts in heavily treatment experienced multidrug resistance PWH: data from PRESTIGIO Registry</b> Maria Santoro (Italy)	09:00 - 09:00
eP149	<b>High virologic suppression in treatment-naïve people with HIV-1 on ainoovirine- versus efavirenz-based antiretroviral regimen as initial therapy: effect of pretreatment NNRTI resistance from RACER trial, a multi-center, randomized, active-controlled study</b> Hong Qin (China)	09:00 - 09:00
eP150	<b>HIV Drug Resistance in People Living with HIV (PLWH) in Congo: Implications for Optimizing Therapy in Resource-Limited Settings</b> Dominic Rauschnig (Germany)	09:00 - 09:00
eP151	<b>HIV-1 genetic diversity and transmitted drug resistance among newly diagnosed HIV-positive individuals in Eastern European and Central Asian countries</b> Alina Kirichenko (Russian Federation)	09:00 - 09:00
eP152	<b>HIV-2 Drug Resistance in Portugal: NGS data from 2023-2024</b> Fátima Gonçalves (Portugal)	09:00 - 09:00
eP153	<b>HIVANKA: Temporal Trends of Transmitted Drug Resistance and Subtype Distribution in Newly Diagnosed People in Ankara, Turkey (2016-2024)</b> MELIHA CAGLA SONMEZER (Turkey)	09:00 - 09:00
eP154	<b>Impact of PrEP on HIV-1 Diversity and Drug-Resistance Mutations in Newly Diagnosed HIV-1 Individuals in Málaga (Southern Spain) from 2016 to 2023</b> María López Jódar (Spain)	09:00 - 09:00
eP155	<b>Integrase Resistance Mutations in Treatment-Naïve Persons with</b>	09:00 - 09:00

	<b>Advanced Immunodeficiency Initiating Dual Therapy with Dolutegravir and Lamivudine</b> Maria Figueroa (Argentina)	
eP156	<b>Potential for replacing the boosted-PI with doravirine in ART-experienced subjects successfully treated with darunavir-cobicistat plus dolutegravir dual regimen</b> Laura Comi (Italy)	09:00 - 09:00
eP157	<b>Proviral DNA as a Reliable Tool for Resistance Testing in HIV-2: Long-Term Outcomes in a Portuguese Cohort</b> Inês Lopes (Portugal)	09:00 - 09:00
eP158	<b>Selection of antiretroviral resistance in treatment-experienced PWH with virological failure while on B/F/TAF, DTG/3TC or CAB/RPV LA: Virostar 2.0 study</b> Anne-Genevieve Marcelin (France)	09:00 - 09:00
eP159	<b>Selection rate of resistance to Long-Acting CAB/RPV in a real life French cohort with strict inclusion and monitoring criteria</b> Sidonie LAMBERT-NICLOT (France)	09:00 - 09:00
eP160	<b>Switching to bicitegravir/emtricitabine/tenofovir alafenamide in highly treatment experienced people living with multidrug-resistant HIV</b> Jose Luis Casado Osorio (Spain)	09:00 - 09:00
eP161	<b>The profile of surveillance HIV resistance mutations in the migrant population of a tertiary hospital: a 4-year analysis</b> Gonçalo Cruz (Portugal)	09:00 - 09:00
eP162	<b>The role of doravirine in the treatment of multidrug-resistant HIV: data from the PRESTIGIO Registry</b> Tommaso Clemente (Italy)	09:00 - 09:00
eP163	<b>Trends of HIV drug resistance and associated factors: an analysis of the Uganda national HIV drug resistance program data, 2021-2024</b> Bridget Ainembabazi (Uganda)	09:00 - 09:00
eP164	<b>CSF PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF DORAVIRINE: IMPLICATIONS IN NEUROCOGNITIVE IMPAIRMENT</b> Qing Ma (United States)	09:00 - 09:00
eP165	<b>Pharmacogenetics of Dolutegravir and Bicitegravir Plasma and Intracellular Pharmacokinetics</b> Leïla Belkhir (Belgium)	09:00 - 09:00
eP166	<b>Pharmacokinetics and safety of MK-8527 in adults with moderate or severe renal impairment</b> Jesse C. Nussbaum (United States)	09:00 - 09:00
eP167	<b>Real-life switch to long-acting cabotegravir/rilpivirine ensures adequate drug levels without short-term impact on viral reservoir or inflammation: the Long-Icona study</b> Alessandro Tavelli (Italy)	09:00 - 09:00
eP168	<b>An audit of antiretroviral regimens in people living with HIV attending an HIV/sexual health clinic in Sydney's Inner West in response to the REPRIEVE study</b> Rachel Burdon (Australia)	09:00 - 09:00
eP169	<b>Effect of dolutegravir transition in HIV-positive adults at a university-based tertiary care hospital in Thailand</b> Rujipas Sirijatuphat (Thailand)	09:00 - 09:00

eP170	<b>Safety and durability of treatment with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a real-life cohort</b> Nicola Squillace (Italy)	09:00 - 09:00
eP171	<b>Virologic Outcomes of Dolutegravir-Based ART Among Thai people with HIV Previously Treated with Lopinavir/ritonavir based Second-line regimens: A National Program Analysis</b> Anchalee Avihingsanon (Thailand)	09:00 - 09:00
	<b>B2. Clinical Science - Co-infection</b>	09:00 - 09:00
eP172	<b>Immune correlates of protection vs vaccine hesitancy in people living with HIV: to be or not to be (vaccinated)</b> Alejandro Vallejo (Spain)	09:00 - 09:00
eP173	<b>Comparative Analysis of Mpox Cases in People Living with HIV in Lisbon and Rio de Janeiro During the 2022 Outbreak</b> Raffaele Junior Aliberti (Portugal)	09:00 - 09:00
eP174	<b>Enhanced immune response against mpox clade Ib and IIb after a booster dose of MVA-BN vaccine in a high-risk population</b> Valentina Mazzotta (Italy)	09:00 - 09:00
eP175	<b>Estimating Hard-to-reach Populations in South Korea Using Mpox Mathematical Modeling</b> Sol Kim (Korea, Republic of)	09:00 - 09:00
eP176	<b>HIV and mpox co-infection in Israel: a cross-sectional comparative study</b> Zohar Mor (Israel)	09:00 - 09:00
eP177	<b>Mpox infection alters HIV-1 reservoir dynamics in ART-treated people with HIV</b> Guiomar Casado Fernández (Spain)	09:00 - 09:00
eP178	<b>Mpox infection elicits stronger and more sustained T-cell responses than vaccination in people with HIV and PrEP users</b> Olivia de la Calle-Jiménez (Spain)	09:00 - 09:00
eP179	<b>Mpox-Specific Humoral and Cellular Immune Responses up to two years from natural infection or MVA-BN vaccination</b> Valentina Mazzotta (Italy)	09:00 - 09:00
eP180	<b>Asymptomatic CMV Suppression with Letemovir Reduces Plasma Secondary Bile Acid Levels in Individuals with HIV on Long-term Antiretroviral Therapy: ACTG Study A5383</b> John Koethe (United States)	09:00 - 09:00
eP181	<b>Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections in People Living (PLWH) with HIV Who Engage in Chemsex: A Descriptive Ambispective Study in Barcelona</b> Maria Martínez-Rebollar (Spain)	09:00 - 09:00
eP182	<b>Experience using a Portable Fundus Camera to Prevention of Blindness in people living with HIV in Ukraine</b> Maryna Sira (Ukraine)	09:00 - 09:00
eP183	<b>Influence of a 3-month letemovir treatment on gut permeability and inflammation in people living with HIV on antiretroviral therapy</b> Stephane Isnard (Canada)	09:00 - 09:00
eP184	<b>Measles in People Living with HIV: A Comparative Analysis with HIV-Negative Patients</b> David Valentin Mangaloiu (Romania)	09:00 - 09:00



eP185	<b>Missed opportunities for early HIV diagnosis in people living with HIV in a Romanian tertiary care center</b> Cristiana Oprea (Romania)	09:00 - 09:00
eP186	<b>Prevalence of Fungemia in People with HIV: A Systematic Review and Meta-Analysis</b> Asta Maria Blom Nielsen (Denmark)	09:00 - 09:00
eP187	<b>Resistance profiles and therapeutic approach of <i>Klebsiella pneumoniae</i> strains identified in people living with HIV and other hospitalized individuals</b> Cristiana Oprea (Romania)	09:00 - 09:00
eP188	<b>Risk of Pneumocystis Pneumonia by CD4 Level in Ukrainian Adults Living With HIV: A Retrospective Analysis</b> Diana Shevchenko (Ukraine)	09:00 - 09:00
eP189	<b>Severe <i>Rhodococcus equi</i> in Late Presenters With HIV: A Case Series and Therapeutic Challenges</b> Ivana Gmizic (Serbia)	09:00 - 09:00
eP190	<b>Systematic Review and Meta-Analysis of Human Papilloma Virus Prevalence and Geno-type Disparity among HIV-positive Women in Africa</b> Yirga Wondu Amare (Hungary)	09:00 - 09:00
eP191	<b>Association between plasma inflammatory profile and sexually transmitted infections recurrence in PrEP users and people with HIV</b> Yolanda Campanero Núñez (Spain)	09:00 - 09:00
eP192	<b>Assessing the Impact of PrEP on STI Rates: a Real-World Multicenter Cohort from Milan</b> Donatella Maddalena (Italy)	09:00 - 09:00
eP193	<b>Awareness and attitudes toward Doxycycline Post-Exposure Prophylaxis (DoxyPEP) among MSM in Greece: A cross-sectional study</b> Konstantinos Protopapas (Greece)	09:00 - 09:00
eP194	<b>Comparative effectiveness of 250 mg vs 500 mg ceftriaxone in treating uncomplicated gonorrhea in a country of a low prevalence of ceftriaxone-nonsusceptible <i>Neisseria gonorrhoeae</i></b> Tzong-Yow Wu (Taiwan)	09:00 - 09:00
eP195	<b>Doxycycline prophylaxis use among MSM attending a reference center for STI and HIV treatment in Rome</b> Alessandra Latini (Italy)	09:00 - 09:00
eP196	<b>Prevalence of human papilloma virus in tree loci among women with various HIV status in the Kyrgyz Republic</b> Anastasia Pokrovskaya (Russian Federation)	09:00 - 09:00
eP197	<b>Prevalence of human papilloma virus in tree loci among women with various HIV status in the Republic of Belarus</b> Anastasia Pokrovskaya (Russian Federation)	09:00 - 09:00
eP198	<b>Real-world effectiveness of doxycycline Post-Exposure Prophylaxis (DoxyPEP) in at-risk MSM in Greece</b> Konstantinos Protopapas (Greece)	09:00 - 09:00
eP199	<b>Sexually transmitted infections at the time of HIV diagnosis in a sexual health clinic in Spain</b> Inés Armenteros-Yeguas (Spain)	09:00 - 09:00
eP200	<b>AIDS patients with Talaromycosis Marneffeii exhibit inflammatory</b>	09:00 - 09:00

	<b>activation and depletion in their peripheral blood monocytes</b> Pengle Guo (China)	
eP201	<b>Antiretroviral therapy in people with HIV and TB in France: a nationwide retrospective study between 2010 and 2023</b> Hugo Law-Koune (France)	09:00 - 09:00
eP202	<b>Characterisation of Cryptococcal meningitis - a 12-year retrospective study in a hospital in Lisbon, Portugal</b> Daniel Toscano (Portugal)	09:00 - 09:00
eP203	<b>Epidemiological and Clinical Analysis and Outcomes of Tuberculosis Co-infection Among People Living with HIV in the Turkey ClinSurv HIV Cohort: A Large Case Series</b> Okan Derin (Turkey)	09:00 - 09:00
eP204	<b>Factors associated with positive baseline Toxoplasma Gondii IgG antibodies among people living with HIV in recent years</b> Carlo Bieńkowski (Poland)	09:00 - 09:00
eP205	<b>Health Outcomes of Individuals Living with HIV Affected by Chronic Neuroinfections in Sub-Saharan Africa: Early Insights from Mozambique</b> Helena Buque (Mozambique)	09:00 - 09:00
eP206	<b>Incidence of opportunistic infections among people living with HIV in Rwanda. Does Differentiated care delivery matters?</b> Mariam Salim Mbwana (Tanzania)	09:00 - 09:00
eP207	<b>Multivariate predictive model for predicting in-hospital mortality in HIV-associated talaromycosis: a multicenter retrospective study</b> Biao Zhu (China)	09:00 - 09:00
eP208	<b>Neuromeningeal tuberculosis in eighteen PLWHIV</b> NASSIMA BELABAS (Algeria)	09:00 - 09:00
eP209	<b>Plasma IL-6 level predict the risk of in-hospital mortality in HIV-associated Pneumocystis Pneumonia</b> Huan Xia (China)	09:00 - 09:00
eP210	<b>Predictors of Recurrence and Survival in HIV-Associated Nontuberculous Mycobacterial Infections: A 20-Year Retrospective Cohort Study</b> Johannes Zielke (Germany)	09:00 - 09:00
eP211	<b>Dynamic Sequential Organ Failure Assessment (SOFA) Score and quick SOFA (qSOFA) predict 30-day mortality in patients with HIV-associated Talaromycosis: a multicenter cohort study</b> Guanjing Lang (China)	09:00 - 09:00
eP212	<b>The most common nontuberculous mycobacteria species and their antibiotic resistance among people with HIV</b> Dagny Krankowska (Poland)	09:00 - 09:00
eP213	<b>Tuberculosis Meningitis and Other Opportunistic Infections of the Central Nervous System in Persons Living with HIV: An Observational Cohort Study in Brazil</b> Mona Gardet (Brazil)	09:00 - 09:00
eP214	<b>Tuberculosis profile in a cohort of people living with HIV hospitalized at the National Institute for Infectious Diseases "Prof. Dr. Matei Bals" in Bucharest, Romania</b> Anca Negru (Romania)	09:00 - 09:00
eP215	<b>Determinants of Influenza, HBV, and Pneumococcal Vaccination Uptake in People Living with HIV: A Multilevel and Expert Survey</b>	09:00 - 09:00

	<b>Study</b>	
	Hye Seong (Korea, Republic of)	
eP216	<b>Evaluating Immunization Rates in People Living with HIV based on Influenza Uptake</b>	09:00 - 09:00
	Lee Nguyen (United States)	
eP217	<b>Hepatitis A and B immunization rates among MSM who are at high-risk sees potential for improvement</b>	09:00 - 09:00
	Sven Breitschwerdt (Germany)	
eP218	<b>Immunity Gaps to Vaccine Preventable Diseases in People with HIV: Real-World Evidence from Japan</b>	09:00 - 09:00
	Michiko Koga (Japan)	
eP219	<b>Serological response to Engerix®-B vaccination in PLWHIV</b>	09:00 - 09:00
	Rita Patrocínio de Jesus (Portugal)	
eP220	<b>Seropositivity and Vaccination Coverage of HBV, HAV, VZV, Measles, Rubella, and Mumps in People Living with HIV</b>	09:00 - 09:00
	Eunmi Yang (Korea, Republic of)	
eP221	<b>Extracellular Vesicle DNA cargo Mirrors Systemic Immune and Microbial Perturbations in People with HIV and HCV Coinfected Individuals</b>	09:00 - 09:00
	Sergio Grande Garcia (Spain)	
eP222	<b>Factors Associated with HBs Antigen Seroclearance in People Living with HIV and Chronic Hepatitis B</b>	09:00 - 09:00
	Takashi Muramatsu (Japan)	
eP223	<b>Impact of intravenous methamphetamine use on Direct-acting Antiviral Agents (DAAs) treatment in people living with HIV and hepatitis C in Mexico</b>	09:00 - 09:00
	Corazón Barrientos-Flores (Mexico)	
eP224	<b>Lipid dysregulation and risk of metabolic disorders after HCV clearance in HIV/HCV co-acquired clients: a retrospective study</b>	09:00 - 09:00
	Juan Berenguer (Spain)	
eP225	<b>Lipidomic Profiles After HCV Cure in People with HIV Reflect Changes Linked to Significant Liver Stiffness</b>	09:00 - 09:00
	Juan Berenguer (Spain)	
eP226	<b>Long-term persistence alterations in CD4 and CD8 T-cell profile after HCV elimination in people living with HIV</b>	09:00 - 09:00
	Manuel Llamas Adán (Spain)	
eP227	<b>Low HCV Prevalence Among PLWH in Türkiye: Risk Factors and Treatment Gaps</b>	09:00 - 09:00
	Bilge Caglar (Turkey)	
eP228	<b>Overt and Occult Hepatitis B Virus Infection among People Living with HIV/AIDS in Bulgaria</b>	09:00 - 09:00
	Radka Komitova (Bulgaria)	
	<b>B3. Clinical Science - Co-morbidities and ageing</b>	09:00 - 09:00
eP230	<b>“The Platinum clinic”, a collaborative HIV and Geriatric Medicine clinic for older people living with HIV in Dublin, Ireland</b>	09:00 - 09:00
	Clara O'Flaherty (Ireland)	
eP231	<b>A Cross-Sectional Comparison of Use of Frailty Assessment Tools in Older People Living with HIV</b>	09:00 - 09:00
	Chloe Knox (United Kingdom)	

eP232	<b>A retrospective review of referrals to specialist secondary care HIV-led and Gynaecology-led menopause clinics</b> Kimberley Forbes (United Kingdom)	09:00 - 09:00
eP233	<b>Assessing health risks in ageing adults with HIV and stratifying outcomes thru the use of scores and scales</b> Michael Virata (United States)	09:00 - 09:00
eP234	<b>Cognitive and locomotor disorders in people living with HIV between 2007 and 2023: outcomes of the ANRS CO3 AQUIVIH-NA cohort</b> Fabrice Bonnet (France)	09:00 - 09:00
eP235	<b>Evaluation of a Healthy Aging Score in a Cohort of Older Adults Living with HIV in Canada</b> Sharon Walmsley (Canada)	09:00 - 09:00
eP236	<b>Four years frailty transitions in elderly adults living with HIV: Results from the SEPTAVIH Study</b> Clotilde Allavena (France)	09:00 - 09:00
eP237	<b>Frailty Screening in People Living with HIV Aged Over 65: Clinical Characteristics and Predictive Factors from a Real-World Cohort in a University Hospital in Florence, Italy</b> Gasparro Giuseppe (Italy)	09:00 - 09:00
eP238	<b>Gut microbiome and healthy aging in HIV: a sub-analysis of the CHANGE HIV cohort</b> Sharon Walmsley (Canada)	09:00 - 09:00
eP239	<b>Neurocognitive Impairment in Older People Living with HIV: Preliminary Findings from a Geriatric Care Program</b> Liesbeth Delesie (Belgium)	09:00 - 09:00
eP240	<b>One score to rule them all? Or maybe not quite ...</b> Beatrice Barda (Switzerland)	09:00 - 09:00
eP241	<b>Predicting Frailty in Older People Living with HIV Using Machine Learning</b> Jaime Vera (United Kingdom)	09:00 - 09:00
eP242	<b>The Prevalence and Predictors of elevated HOMA-IR in People Living with HIV (PLWH)</b> Shu-Ying Chang (Taiwan)	09:00 - 09:00
eP243	<b>Understanding Frailty and Aging in People Living with HIV in Kazakhstan: A Pilot Investigation</b> Balnur Iskakova (Kazakhstan)	09:00 - 09:00
eP244	<b>A Comparative Analysis of Echocardiographic Findings in People Living With HIV and Healthy Volunteers</b> AYTAN SEYDALIYEVA (Turkey)	09:00 - 09:00
eP245	<b>A Comparative Analysis of HbA1c, Glycated Albumin, and Fasting Plasma Glucose for Glycemic Assessment in People Living with HIV</b> Tun-Chieh Chen (Taiwan)	09:00 - 09:00
eP246	<b>A rapid scoping review of tools and approaches for medication adherence screening and assessment</b> Nicola Galbraith (United Kingdom)	09:00 - 09:00
eP247	<b>Addressing cognitive symptoms in people with HIV: Outcomes from a holistic screening and management pathway</b> Kate Alford (United Kingdom)	09:00 - 09:00
eP248	<b>Association of Biomarker Clusters With Lung Disease and Mortality</b>	09:00 - 09:00

	<b>in People With HIV</b> Ioannis Konstantinidis (United States)	
eP249	<b>Association of Cytomegalovirus Immunoglobulin G Antibodies with Prevalent and Incident Hypertension in People With HIV</b> Josefine Loft (Denmark)	09:00 - 09:00
eP250	<b>Bempedoic Acid and Evolocumab Use in People Living with HIV: A Real-World Snapshot of Lipid-Lowering Strategies in Statin-Intolerant or Reluctant individuals</b> Marianna Menozzi (Italy)	09:00 - 09:00
eP251	<b>Changes in Metabolic Parameters after Switching from Efavirenz to Dolutegravir-based Regimen: A Cohort Study in Thai People Living with HIV</b> Pitchaporn Chongyangyuenvong (Thailand)	09:00 - 09:00
eP252	<b>Clinical features of transgender people living with HIV throughout Europe: multimorbidity and polypharmacy</b> Maria Mazzitelli (Italy)	09:00 - 09:00
eP253	<b>Confusion in the sky: to score or not to score?</b> Beatrice Barda (Switzerland)	09:00 - 09:00
eP254	<b>Determinants of Weight Change in HIV-Positive Individuals Receiving Antiretroviral Therapy</b> EMİNE İLAY DUMAN (Turkey)	09:00 - 09:00
eP255	<b>Eating habits and possible effects of Mediterranean diet on body composition in ageing people living with HIV</b> Maria Mazzitelli (Italy)	09:00 - 09:00
eP256	<b>Effect of extreme weight gain within 5 years in people with HIV on upcoming incident cardiovascular events</b> Stefan Esser (Germany)	09:00 - 09:00
eP257	<b>Effect of extreme weight gain within 5 years in people with HIV on upcoming incident diabetes mellitus</b> Stefan Esser (Germany)	09:00 - 09:00
eP258	<b>Effects of high-dose probiotic supplementation on immune activation and neurocognitive disorders in people living with HIV on successful antiretroviral treatment: the ProCog study</b> Matteo Vassallo (France)	09:00 - 09:00
eP259	<b>Enhancing Transplant Access for People with HIV: A Comparative Study of Liver and Kidney Transplant Outcomes from donors with or without HIV</b> Adriana Cervo (Italy)	09:00 - 09:00
eP260	<b>Epicardial adipose tissue thickness and cardiometabolic risk in people living with HIV: a comparative study of TAF- and TDF-based regimens</b> Özge Eren Korkmaz (Turkey)	09:00 - 09:00
eP261	<b>From wasting to gaining: The impact of BMI changes on dyslipidemia risk in people living with HIV</b> Jisun Chung (Korea, Republic of)	09:00 - 09:00
eP262	<b>Genetic influence of TM6SF2 rs58542926 genotype on significant liver fibrosis in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD)</b> Win Min Han (Thailand)	09:00 - 09:00
eP263	<b>How do people living with HIV sleep?</b> Macha Tetart (France)	09:00 - 09:00

eP264	<b>Hypertension in People with HIV Starting ART: Association with Regimen Class</b> Jose I Bernardino (Spain)	09:00 - 09:00
eP265	<b>Impact of a Mediterranean Diet-Based Nutritional Intervention on Lipid Profile in People Living with HIV: Interim Results at Week 24 from a Randomized Controlled Clinical Trial</b> Esperanza Cañas-Ruano (Spain)	09:00 - 09:00
eP266	<b>Implementation of FIB-4 Screening and Determinants of Liver Fibrosis Among People Living with HIV: A Real-World Cohort Study</b> Olivier Robineau (France)	09:00 - 09:00
eP267	<b>Improved atherosclerotic cardiovascular disease risk-associated dyslipidemia strata in people with HIV-1 switching to a nucleos(t)ide-based antiretroviral regimen: week 144 results from SPRINT, a randomized phase 3 trial</b> Hong Qin (China)	09:00 - 09:00
eP268	<b>Improved body weight, lipid and immune profile and adipose tissue gene expression after a 48-week switch from an INSTI regimen to DOR/3TC/TDF in persons with HIV with INSTI-associated weight gain: The ADDORE study</b> J Capeau (France)	09:00 - 09:00
eP269	<b>Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease in ART-Naïve People Living with HIV Initiating DTG/ABC/3TC vs. BIC/FTC/TAF: A 96-Week Analysis from a Mexican Cohort</b> Ana Luz Cano Díaz (Mexico)	09:00 - 09:00
eP270	<b>Incidental Detection of Gynecomastia and Adipomastia on Chest CT in Male People Living with HIV: An Opportunistic Imaging Assessment</b> Veysel Akca (Turkey)	09:00 - 09:00
eP271	<b>Influence of HIV status on organ procurement and allocation: A Discrete Choice Experiment among Australian Transplant Providers</b> David WJ Griffin (Australia)	09:00 - 09:00
eP272	<b>Insights from Gut Microbiome Profiling: <i>Evtepiea spp.</i> as a Distinctive Marker of Leanness in People with HIV</b> Mackenzie Joe (United States)	09:00 - 09:00
eP273	<b>Longitudinal changes of coronary artery calcium score (CACS) in persons with HIV</b> Maithili Varadarajan (United Kingdom)	09:00 - 09:00
eP274	<b>Long-term changes in triglyceride-glucose index and insulin resistance in virologically suppressed people with HIV-1 switching to a nucleos(t)ide coformulated with lamivudine, and tenofovir DF: 144-week, open-label results from the SPRINT post-study</b> Hong Qin (China)	09:00 - 09:00
eP275	<b>Long-term Lipid Metabolism Benefits of Switching to A nucleos(t)ide-based Regimen in People with HIV-1: 144-Week Results from the SPRINT Extensional Post-study</b> Hong Qin (China)	09:00 - 09:00
eP276	<b>Medication Optimization in Older People Living with HIV: A Multidisciplinary Approach</b> Fatma Nisa Ballı Turhan (Turkey)	09:00 - 09:00
eP277	<b>Metabolic Liver Disease in Newly Diagnosed People Living with HIV: MASHIV-TR COHORT</b> Mustafa Kemal Celen (Turkey)	09:00 - 09:00

eP279	<b>Monocyte polarization is related to Atherosclerosis in People Living with HIV on Suppressive ART</b> Javier Lozano-Gerona (United States)	09:00 - 09:00
eP280	<b>Neurocognitive Screening in people living with HIV: 5-year referral and outcomes review</b> Shimu Allan (United Kingdom)	09:00 - 09:00
eP281	<b>Non-linear relationships between inflammatory markers and erectile dysfunction in a group of young men living with HIV</b> Federico Cesanelli (Italy)	09:00 - 09:00
eP282	<b>Obesity in People Living with HIV: A Retrospective Analysis of a cardiovascular disease Risk Clinic Cohort</b> Alice Alicerces (Portugal)	09:00 - 09:00
eP283	<b>People with HIV at high cardiovascular risk were undertreated with statins independent of gender</b> Maximilian Platte (Germany)	09:00 - 09:00
eP284	<b>Physical inactivity is associated with persistent steatotic liver disease in people with HIV</b> Eloïse Magnenat (Switzerland)	09:00 - 09:00
eP285	<b>Preserved renal function in PWH on a nucleos(t)ide-based antiretroviral regimen: week 144 results from SPRINT study, a randomized phase 3 trial</b> Hong Qin (China)	09:00 - 09:00
eP286	<b>Prevalence and Predictors of Obesity and Metabolic Syndrome in HIV-Positive Individuals: A Cross-Sectional Study from Türkiye</b> EMİNE İLAY DUMAN (Turkey)	09:00 - 09:00
eP287	<b>Prevalence and risk factors of liver fibrosis in metabolic associated fatty liver disease (MAFLD) among people living with HIV (PLWH) in Shanghai</b> Wei Xu (China)	09:00 - 09:00
eP288	<b>Prevalence of Steatotic Liver Disease Phenotypes and Clinically Significant Fibrosis Predictors Among People With HIV in The Middle East Region: A Multicenter Study</b> Ahmed Cordie (Egypt)	09:00 - 09:00
eP289	<b>Progressive Pulmonary Artery Enlargement in Aging, Virologically Suppressed People With HIV: A 7-Year CT Imaging Study</b> Napon Hiranburana (Thailand)	09:00 - 09:00
eP290	<b>Prospective evaluation of cardiovascular risk in PLWH receiving LA-cabotegravir/rilpivirine</b> Marco Bongiovanni (Switzerland)	09:00 - 09:00
eP291	<b>Relationships between lung health indicators and depressive symptoms, anxiety, resilience, and social support among women with HIV</b> Ken M. Kunisaki (United States)	09:00 - 09:00
eP292	<b>Research on the Diagnostic Value in Cerebrospinal Fluid and Blood Biomarkers of HIV-Associated Neurocognitive Disorders</b> Jiaqi Wei (China)	09:00 - 09:00
eP293	<b>Same Patients, Different Risks: A Head-to-Head of ESC and EACS CVD Guidelines in PLWH</b> Katia Falasca (Italy)	09:00 - 09:00
eP294	<b>Semaglutide Improves Markers of Cardiovascular Risk in People With HIV: The SLIM LIVER Study</b>	09:00 - 09:00

	Jordan Lake (United States)	
eP295	<b>Serum Uric Acid Dynamics in Chinese HIV Patients: A 20-Year Cohort Study</b> Xin Huang (China)	09:00 - 09:00
eP296	<b>Severe Acute Chemsex Intoxications in People Living With HIV: Clinical Insights from a Tertiary-Care ID-ICU</b> Ana Sofia Santos (Portugal)	09:00 - 09:00
eP297	<b>Statin initiation following the REPRIEVE Trial: Results of a clinical audit at an urban sexual health clinic in Sydney, Australia</b> Rachel Burdon (Australia)	09:00 - 09:00
eP298	<b>Study on the impact and mechanisms of R-CHOP-Based immunochemotherapy on immune status in ARL people</b> Biao Zhu (China)	09:00 - 09:00
eP299	<b>The FIB-4 is a marker of macrophage activation independently from hepatic disease in people living with HIV on stable and successful treatment</b> Matteo Vassallo (France)	09:00 - 09:00
eP300	<b>Understanding hospitalization among people living with HIV (PLWH) in the combination antiretroviral therapy (cART) era: a single-centre retrospective study</b> Antonella Gallicchio (Italy)	09:00 - 09:00
eP301	<b>Use of statins mitigates the impact of smoking on frailty trajectories in people with HIV: a longitudinal cohort study</b> Jovana Milic (Italy)	09:00 - 09:00
eP302	<b>Weight gain and metabolic complications in a large prospective cohort of overweight and obese people with HIV</b> Lucia Taramasso (Italy)	09:00 - 09:00
eP303	<b>Women living with HIV in Australia: Development of a clinical monitoring tool to address gender-specific care gaps and standardize care</b> Rachel Burdon (Australia)	09:00 - 09:00
eP304	<b>A Multidisciplinary Approach to Enhance Quality of Life in Older People Living with HIV: A Comparative Study</b> Fatma Nisa Ballı Turhan (Turkey)	09:00 - 09:00
eP305	<b>Addressing patient-reported outcome measures (PROMs) in routine care does not improve patient's perspective on the receipt of patient-centered care and self-management behavior</b> Roos D Klungers (Netherlands)	09:00 - 09:00
eP306	<b>Ageing with HIV in France: When PLHIV Needs and Clinical Practice Diverge</b> Daniela Rojas Castro (France)	09:00 - 09:00
eP308	<b>Disability and Physical Activity among Adults Living with HIV in the United Kingdom, Ireland, United States and Canada: A Structural Equation Model Using the Episodic Disability Questionnaire</b> Kelly O'Brien (Canada)	09:00 - 09:00
eP309	<b>Effectiveness of Aerobic Exercise among Adults Living with HIV: An Updated Systematic Review and Meta-Analysis using the Cochrane Collaboration Protocol</b> Kelly O'Brien (Canada)	09:00 - 09:00
eP310	<b>Effectiveness of Progressive Resistive Exercise among Adults Living with HIV: An Updated Systematic Review and Meta-Analysis</b>	09:00 - 09:00



	<b>using the Cochrane Collaboration Protocol</b> Kelly O'Brien (Canada)	
eP311	<b>Factors Influencing the Quality of Life Among Men Who Have Sex with Men Living with HIV at an STD Center in Northern Taiwan</b> HsinHao Lai (Taiwan)	09:00 - 09:00
eP312	<b>Integrating HIV and Mental Health Care in Prison: A Complex but Achievable Goal</b> Frederico Duarte (Portugal)	09:00 - 09:00
eP313	<b>Internalized HIV Stigma and Its Influence on Reproductive Intentions of Women Living with HIV in Kazakhstan</b> Batyrbek Assembekov (Kazakhstan)	09:00 - 09:00
eP314	<b>Internalized Stigma and Its Impact on Mental Health and Quality of Life among People Living with HIV in Mauritius</b> Monica Pudaruth (Mauritius)	09:00 - 09:00
eP315	<b>Mental health in PLWH: psychopathological variables and personality traits in patients compared with non-clinical subjects</b> Federica Alessi (Italy)	09:00 - 09:00
eP316	<b>Neurocognitive impairment is associated with functional performance deficits and compromised adherence during follow up in people living with HIV</b> Jose Luis Casado Osorio (Spain)	09:00 - 09:00
eP317	<b>Oral Lesions in People Living with HIV (LINING HIV)</b> Emmanouil Angelos Rigopoulos (Greece)	09:00 - 09:00
eP318	<b>Outcomes of a mental health screening in a cohort of people with HIV</b> Peacchaima Purusothman (Malaysia)	09:00 - 09:00
eP319	<b>Poor Sleep and MASLD are Common in People with HIV and Contribute to Poor Health-Related Quality of Life</b> Ana N Hyatt (United States)	09:00 - 09:00
eP320	<b>Sexual satisfaction in men with HIV aged ≤50 years explored with standardized validated questionnaires: prevalence and patterns of various sexual dysfunction, and association with psychosocial factors</b> Nicola Squillace (Italy)	09:00 - 09:00
eP321	<b>Social support and mental health in People Living with HIV: A cross-sectional analysis from a Greek cohort</b> Andronikos Spyrou (Greece)	09:00 - 09:00
eP322	<b>KS evolution in HIV aviremic PLWH: a prospective cohort of the French CancerVIH Network</b> Alain Makinson (France)	09:00 - 09:00
eP323	<b>Prevalence of high-risk human papillomavirus and anal precancerous lesions among men who have sex with men living with HIV in Hong Kong</b> T S Kwong (Hong Kong)	09:00 - 09:00
eP324	<b>Real-World Clinical Insights into Underrecognized Differences in Prostate Cancer Among People Living with HIV</b> Kyoko Yoshida (Japan)	09:00 - 09:00
eP326	<b>Update on German-Austrian Guideline on Screening for Anal Dysplasia and Anal Carcinoma in People Living with HIV</b> David Chromy (Austria)	09:00 - 09:00

	<b>B4. Clinical Science - Pregnancy, children and adolescents</b>	09:00 - 09:00
eP327	<b>Unintended pregnancy among adolescents living with HIV in Africa: a systematic review</b> Mackline Hope (Uganda)	09:00 - 09:00
eP328	<b>HIV diagnosis in pregnancy accounts for 18% of all diagnoses and may reduce advanced stage HIV diagnosis in women over 30 years in the Netherlands</b> Colette Smit (Netherlands)	09:00 - 09:00
eP329	<b>Life expectancy of premature babies born to HIV-positive mothers</b> Fatima zohra Bensadoun (Algeria)	09:00 - 09:00
eP330	<b>cART use in pregnancy: a real-life experience in Italy</b> Elena Zaninetta (Italy)	09:00 - 09:00
eP331	<b>MISSED OPPORTUNITY: HIV-1 TRANSMISSION CHAIN ACROSS THREE GENERATIONS</b> Ulrike Elisabeth Haars (Germany)	09:00 - 09:00
eP332	<b>Pregnancy monitoring in HIV-serodifferent couples: Support and medical monitoring</b> Fatima zohra Bensadoun (Algeria)	09:00 - 09:00
	<b>C1. Epidemiology/ public health / models of care</b>	09:00 - 09:00
eP333	<b>A Multidisciplinary Offer to Support Emerging Practices: Feedback from the Lounge in Toulouse Dedicated to People Engaging in Chemsex</b> Ali Fendri (France)	09:00 - 09:00
eP334	<b>Acceptability, feasibility, and systemic challenges of community-based antiretroviral therapy delivery model in Cambodia: A qualitative evaluation using the Framework Method</b> Ziya Tian (Singapore)	09:00 - 09:00
eP335	<b>Adaptation and preliminary outcomes of the Community Health Worker Optimization of Antihypertensive Care in HIV (COACH) program: an intervention to address hypertension among people with HIV (PWH) in Tanzania</b> Preeti Manavalan (United States)	09:00 - 09:00
eP336	<b>AI-ntiretroviral preferences</b> Rachel Burdon (Australia)	09:00 - 09:00
eP337	<b>ANALYSIS OF THE CLINICAL COMPLEXITY OF PEOPLE LIVING WITH HIV BASED ON THE GESIDA STRATIFICATION SYSTEM</b> Carolina Olmos Mata (Spain)	09:00 - 09:00
eP338	<b>ARE WE STILL TOO LATE? MISSED OPPORTUNITIES IN THE DETECTION OF HIV</b> Sara Gómez García (Spain)	09:00 - 09:00
eP339	<b>Closing the HIV Testing Gap: Readiness of Pharmacy staff Providing Other Prevention Screenings</b> Natalie Crawford (United States)	09:00 - 09:00
eP340	<b>Costs Associated With People With HIV in France</b> Alexandre Vimont (France)	09:00 - 09:00
eP341	<b>Decentralization of Care? A Comparison of Primary Care Services and Specialized Services in the Care of People Living with HIV in a State in Southern Brazil</b> Vinícius Gabriel Horst Soares (Brazil)	09:00 - 09:00

eP342	<b>Demographic and Risk Profile Analysis of Users Accessing PrEP Through a Paid Digital Service in the Netherlands: Exploring PrEP Uptake Patterns Beyond Traditional Settings</b> John White (United Kingdom)	09:00 - 09:00
eP343	<b>Enhancing HIV Self-Testing Uptake through Syringe Vending Machines: A Case Study in Tbilisi, Georgia</b> Irma Kirtadze (Georgia)	09:00 - 09:00
eP344	<b>EXPERIENCE OF STRUCTURING A TRANSGENDER-SPECIFIC HIV OUTPATIENT CLINIC AT INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS: AN INTEGRATED CARE PATHWAY MODEL</b> Pisci Bruja Garcia de Oliveira (Brazil)	09:00 - 09:00
eP345	<b>Exploring barriers to pre-exposure prophylaxis among HIV people initiating antiretroviral therapy in Portugal: the POSITIVE CARE study</b> Laura Paixão (Portugal)	09:00 - 09:00
eP346	<b>Exploring the Awareness, Attitudes, and Preferences of People Living with HIV Toward Long-Acting Injectable Treatments</b> Berna Karaismailoğlu (Turkey)	09:00 - 09:00
eP347	<b>General and Family Doctors' perspectives regarding their knowledge, preparedness level and challenges in preventing the Human Immunodeficiency Virus transmission</b> José Ganicho (Portugal)	09:00 - 09:00
eP348	<b>Health care perspectives of People Living with HIV in Central and Eastern Europe (CEE): Results from a Multi-Country Survey</b> Konstantinos Protopapas (Greece)	09:00 - 09:00
eP349	<b>HIV PrEP Need, Availability, and Potential Pharmacy Integration: A Rural-Urban Analysis in the Southern US</b> Siena Senn (United States)	09:00 - 09:00
eP350	<b>HIV viewpoints: survey on the treatment experiences of people living with HIV in Europe</b> Megan Dunbar (United States)	09:00 - 09:00
eP351	<b>Impact of COVID-19 Pandemic on Treatment Outcomes among People Living with HIV in Thailand: A Nested Case-control Study</b> Arnon Techapongsatorn (Thailand)	09:00 - 09:00
eP352	<b>Increase PrEP uptake to reduce HIV incidence in Italy: the case for simplified and differentiated PrEP delivery</b> Nicoletta Frattini (Italy)	09:00 - 09:00
eP353	<b>Inpatient burden and diagnosis-specific trends in a dedicated HIV department (2011-2024): a thirteen-year review</b> Andronikos Spyrou (Greece)	09:00 - 09:00
eP355	<b>Linkage to Care and ART initiation: A Retrospective Analysis to guide implementation of rapid ART initiation in outpatient setting</b> Bonnie Chun Kwan Wong (Hong Kong)	09:00 - 09:00
eP356	<b>Mental Well-being and the Work Environment among Healthcare Workers Taking Care of PLWH - Data from the Euroguidelines in Central and Eastern Europe Network Group</b> Agata Skrzat-Klapaczyńska (Poland)	09:00 - 09:00
eP357	<b>Navigating PrEP prescription: an exploratory study on barriers and facilitators among healthcare providers in North Louisiana</b> Camila Castro (Brazil)	09:00 - 09:00
eP358	<b>Outcomes of rapid anti-retroviral therapy (ART) initiation in</b>	09:00 - 09:00

	<b>London, UK</b> Frances Lander (United Kingdom)	
eP359	<b>Prevalence of HIV Indicator Conditions in People with Late Diagnosis of HIV, 25 years on: Are we still missing opportunities for earlier care?</b> Ella Spear (Australia)	09:00 - 09:00
eP360	<b>Provider willingness to discuss and prescribe pre-exposure prophylaxis (PrEP) with women at risk of HIV in Kazakhstan</b> Tara McCrimmon (United States)	09:00 - 09:00
eP361	<b>Quality improvement project aimed at reducing costs of unnecessary investigations in HIV outpatient clinics</b> Aarzo Bhatia (United Kingdom)	09:00 - 09:00
eP362	<b>Reasons for ART interruption related to the war in Ukraine</b> Kseniia Voronova (Ukraine)	09:00 - 09:00
eP363	<b>Reorganizing a HIV clinic in northern Italy for the implementation of Long-Acting Cabotegravir/Rilpivirine for HIV Treatment with limited resources</b> Layla Pagnucco (Italy)	09:00 - 09:00
eP364	<b>Response patterns to a patient-reported outcomes assessment (MyPRO) among racialized women living with and without HIV in a community health clinic in Toronto, Canada</b> Maggie Czarnogorski (United States)	09:00 - 09:00
eP365	<b>Retention of clients diagnosed through Secondary HIV self-testing: A longitudinal analysis over 12 months in Johannesburg, South Africa</b> Mabjala Rosemary Letsoalo (South Africa)	09:00 - 09:00
eP366	<b>Risk factors for sexually transmitted infections in men attending clinics in Jerusalem compared with Tel Aviv</b> Karen Olshtain Pops (Israel)	09:00 - 09:00
eP367	<b>Serum cryptococcal antigen titer as predictor of disseminated Cryptococcosis in people living with HIV</b> Victoria Pinto (Argentina)	09:00 - 09:00
eP368	<b>Significant discrepancies Between Clinical Practice and Medical Guidelines for HPV management in HIV - data from ECEE Network Group</b> Konstantinos Protopapas (Greece)	09:00 - 09:00
eP369	<b>Stigma in the Healthcare Environment: Invisible Barriers</b> Azucena Bautista Hernández (Spain)	09:00 - 09:00
eP370	<b>Telehealth as a tool for expanding PrEP in Argentina</b> Javier José Ricart (Argentina)	09:00 - 09:00
eP371	<b>Tunisian women living with HIV: assessing characteristics and vulnerabilities</b> Rajah Rezgui (Tunisia)	09:00 - 09:00
eP372	<b>Clinical characteristics and treatment patterns among people living with HIV by ART use in the US, 2021-2024</b> Arlene Nugent (United States)	09:00 - 09:00
eP373	<b>Evaluation of Compliance with EACS Guidelines: Analysis of Error Rates at Baseline, 3, 6, and 12 Months</b> Ece Demirkirkan (Turkey)	09:00 - 09:00
eP374	<b>Factors associated with advanced HIV presentation among</b>	09:00 - 09:00

	<b>individuals referred for inpatient rehabilitation: A continuum of care perspective</b> Simon Rackstraw (United Kingdom)	
eP375	<b>HIV COINFECTION AMONG INDIVIDUALS BELONGING TO KEY GROUPS IN UKRAINE</b> Olena Hridasova (Ukraine)	09:00 - 09:00
eP376	<b>Outcomes of rapid initiation of antiretroviral therapy among people living with HIV: real-world experience from a tertiary care hospital in Thailand</b> Niti Aueaphongkarun (Thailand)	09:00 - 09:00
eP377	<b>"Bridging the Last Mile: A Low-Cost, Gender-Responsive Model Integrating Real-Time Viral Load Dashboards and Task-Shifting in Rural Nigeria"</b> Okeoghene Akusu (Nigeria)	09:00 - 09:00
eP378	<b>Addressing health inequities in HIV testing: Effectiveness of activation of community-based networks and use of app technology to reach and support diverse, marginalized and underserved populations to access HIV self-testing in Canada</b> Sean B. Rourke (Canada)	09:00 - 09:00
eP379	<b>Breaking STI Chains with <i>Con-Tacto</i>: Acceptability of an Anonymous Partner Notification App Among PrEP Users</b> Felix Straga Napolitano (Spain)	09:00 - 09:00
eP380	<b>Challenges in implementing a strategy for the triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B: the experience of the TRI-MOM project in The Gambia</b> SEYDOU DRABO (France)	09:00 - 09:00
eP381	<b>Cost-Effectiveness of DTG/3TC Single-Pill Versus Generic ABC/3TC Plus Dolutegravir in Japan: A Markov Model Analysis</b> Toshibumi Taniguchi (Japan)	09:00 - 09:00
eP382	<b>How Rapid is the Recommended Timing of Antiretroviral Therapy Initiation? Preliminary Findings from a Scoping Review of HIV Clinical Guidelines</b> Moustafa Laymouna (Canada)	09:00 - 09:00
eP383	<b>If we build it, will they come? Pharmacists' perspectives on recruiting people to a pharmacy-based sexually transmitted and bloodborne infection (STBBI) testing service</b> Deborah Kelly (Canada)	09:00 - 09:00
eP384	<b>Introducing the CROSS framework for developing and implementing inclusive and scalable research: Insights from the co-production and delivery of a cross-country HIV survey with migrant women within EACS/WAVE's SERAY project (Strengthening health Equity Research through Active involvement of Non-Governmental Organisations and migrant women)</b> Melvina Woode-Owusu (United Kingdom)	09:00 - 09:00
eP385	<b>Negative Beliefs About Methadone and Barriers to Opioid Agonist Therapy in Kazakhstan: Findings from a Multi-City RDS Study</b> Assel Terlikbayeva (Kazakhstan)	09:00 - 09:00
eP386	<b>Piloting the digital distribution and implementation of the Positive Outcomes PROM in HIV Outpatients</b> Rebekah Morris (United Kingdom)	09:00 - 09:00
eP387	<b>Psychosocial Needs in Migrants with HIV: Implications for Care</b> Joanna Cano-Smith (Spain)	09:00 - 09:00

eP388	<b>The impact of Shared Decision-Making on Long-Acting Injectable Antiretroviral Therapy in People Living with HIV in Taiwan</b> LIAN LIN (Taiwan)	09:00 - 09:00
eP389	<b>Using Mixed-Methods Operations Research to Evaluate Community-Led Monitoring for Improved HIV Service Delivery in Nigeria</b> Joy Egwu (Nigeria)	09:00 - 09:00
eP390	<b>Willingness and Ability of People Living with HIV to use Patient-Reported Outcome Measures in Routine HIV Care: Preliminary Results from the PRO-CARE Study</b> Olivia Borchmann (Denmark)	09:00 - 09:00
eP391	<b>Causes of Death in People Living with Human Immunodeficiency Virus in Türkiye: A Multicentre Retrospective Study</b> Adalet Altunsoy (Turkey)	09:00 - 09:00
eP392	<b>Challenges in Managing People Living with HIV in Critical Care: Experience from Mexico</b> Paulina Carreño Pérez (Mexico)	09:00 - 09:00
eP393	<b>Unstable housing and its associations with mental health and alcohol use among persons living with HIV (PLWH): Findings from the Florida Cohort Wave 4 survey</b> Yan Wang (United States)	09:00 - 09:00
eP394	<b>Demographics of under-housed individuals living with HIV in British Columbia, Canada</b> Christina Wiesmann (Canada)	09:00 - 09:00
eP395	<b>Epidemiological Profile of Pregnant Women Living with HIV in Brazil: A Cross-Sectional Analysis of National Surveillance Data</b> Vinícius Gabriel Horst Soares (Brazil)	09:00 - 09:00
eP396	<b>Epidemiology of Human Immunodeficiency Virus HIV in Tunisia in 2024</b> Arwa Neffati (Tunisia)	09:00 - 09:00
eP397	<b>Estimating HIV incidence and associated risk factors using longitudinal community-based testing data across the WHO European Region: Insights from the COBATEST Network</b> Laura Fernández-López (Spain)	09:00 - 09:00
eP398	<b>HIV seropositivity in key or vulnerable population at higher risk: results of rapid testing program in the Russian Federation during 2020-2024</b> Elena Sklyarskaya (Russian Federation)	09:00 - 09:00
eP399	<b>Impact of the COVID-19 Pandemic on HIV Case Detection in Georgia: An Interrupted Time Series Analysis (2018-2024)</b> Otar Chokoshvili (Georgia)	09:00 - 09:00
eP400	<b>Incidence of HIV and STI After Initiating Pre-Exposure Prophylaxis, Among Men who have Sex with Men in Georgia: Findings from Routine Program Surveillance, 2020-2024</b> Otar Chokoshvili (Georgia)	09:00 - 09:00
eP401	<b>Knowledge, Attitude and Practice on HIV/AIDS among University Students in Kilimanjaro Region aged 18 to 45 years. A Cross Sectional Study</b> Simon Ernest (Tanzania)	09:00 - 09:00
eP402	<b>Migration and HIV in Latin America: a multicenter regional descriptive study</b> María Marta Greco (Argentina)	09:00 - 09:00

eP403	<b>Migration-Linked Transmission of HIV-1 Subtype A6 in Europe: Evidence from Multinational Molecular Cluster Analysis</b> Karol Serwin (Poland)	09:00 - 09:00
eP404	<b>Missed Lessons, Missed Protections: Strengthening Adolescent STI and HIV Awareness Through Targeted Educational Interventions</b> Gunda Waldmann (Germany)	09:00 - 09:00
eP406	<b>Phylogenetic analysis and transmission networks highlight the role of older adults in the transmission of HIV-1 in northern Zhejiang, China</b> xiaohong Pan (China)	09:00 - 09:00
eP407	<b>Pre-exposure prophylaxis (PrEP) and the reduction in new cases of HIV acquisition in men in the state of Sao Paulo, Brazil</b> Mariza Vono Tancredi (Brazil)	09:00 - 09:00
eP408	<b>Seroprevalence of HIV, HBV and HCV Among People Who Use Drugs in Turkey</b> Ali Asan (Turkey)	09:00 - 09:00
eP409	<b>Seroprevalence of Toxoplasma gondii in Individuals Living with HIV/AIDS: An Epidemiological Assessment and Clinical Significance</b> Merve Kılıç Tekin (Turkey)	09:00 - 09:00
eP410	<b>Sex-Based Disparities in Hospitalizations due to Advance Disease among People Living with HIV in a Tertiary Center from 2003-2023 in Mexico City</b> Santiago Agraz Orozco (Mexico)	09:00 - 09:00
eP411	<b>Structural Barriers and HIV Testing Uptake Among Female Sex Workers in Albania: Findings from Integrated Bio-Behavioral Surveillance</b> Elona Gjebrea Hoxha (Albania)	09:00 - 09:00
eP412	<b>The Relationship Between Development Indicators and HIV Epidemiology: A Global Perspective on Social Determinants</b> Özge Eren Korkmaz (Turkey)	09:00 - 09:00
eP413	<b>Trends in HIV awareness, screening practices and attitudes in Tunisia: Insights from MICS Data (2012-2023)</b> Mariem Noura (Tunisia)	09:00 - 09:00
	<b>C2. HIV prevention</b>	09:00 - 09:00
eP414	<b>Addressing HIV-related morbidity and mortality through community-based adolescent prevention and linkage to care in Muyuka subdivision, Southwest region, Cameroon</b> Tezete Evet Adeola ADEOLA (Cameroon)	09:00 - 09:00
eP415	<b>Clinic vs. Self HIV Testing in Southern Africa: A Systematic Review on Progress Towards UNAIDS Targets</b> David Flynn (United Kingdom)	09:00 - 09:00
eP416	<b>Effectiveness of the HIV Testing Month campaign in promoting testing in the general public in Hong Kong</b> Tsz Ho Kwan (Hong Kong)	09:00 - 09:00
eP418	<b>Estimating the health impact and cost-effectiveness of emergency department opt-out testing for blood-borne viruses in Germany</b> Jürgen K Rockstroh (Germany)	09:00 - 09:00
eP419	<b>Expanding HIV Screening Beyond Hospital Walls in Milan: 18 years of the "EasyTest" project</b> Angelo Roberto Raccagni (Italy)	09:00 - 09:00

eP421	<b>HIV Screening Practices and Knowledge of Indicator Conditions Among Resident Doctors: A Cross-Sectional Study</b> Mehmet Buğra Özkara (Turkey)	09:00 - 09:00
eP422	<b>Individuals newly diagnosed with HIV in London, UK: characteristics of previous attenders and 'never-attenders'</b> Sheel Patel (United Kingdom)	09:00 - 09:00
eP423	<b>Involvement of key populations in HIV testing through social networks, Odesa, Ukraine</b> Nataliia Kitsenko (Ukraine)	09:00 - 09:00
eP424	<b>Medical-Driven HIV Testing Persists Over Time in Central and Eastern Europe: Evidence from the Go Holistic Go Beyond Project</b> Ivana Gmizic (Serbia)	09:00 - 09:00
eP425	<b>Missed Opportunities for HIV Testing in Newly Diagnosed Patients at a Tertiary Care Hospital: A Retrospective Analysis</b> Bircan Kayaaslan (Turkey)	09:00 - 09:00
eP426	<b>NEW OPPORTUNITIES FOR COVERING THE POPULATION WITH HIV TESTING IN LVIV, UKRAINE</b> Olena Pavlyshyn (Ukraine)	09:00 - 09:00
eP427	<b>Overview on community-based screening in Tunisia in 2024</b> Arwa Neffati (Tunisia)	09:00 - 09:00
eP428	<b>Use of Regional Mentors to Optimize Maternal Retesting Services for Prevention of Vertical Transmission of HIV: A case of Mwanza, Tabora, and Morogoro in Tanzania</b> Neema Makyao (Tanzania)	09:00 - 09:00
eP429	<b>Wedge-shaped clustered randomized trial to evaluate two tools for identifying individuals at risk for or already infected with HIV: Atenea Study Interim Analysis</b> María Jesús Pérez- Elías (Spain)	09:00 - 09:00
eP430	<b>Female Patients on HIV Post-Exposure Prophylaxis: Clinical outcomes and prevention opportunities</b> Natalia Sánchez-Ocaña Martín (Spain)	09:00 - 09:00
eP431	<b>HIV post-exposure prophylaxis in the integrase inhibitor era: Experience in a low-middle income country</b> Mariana Ariadna Paolini (Argentina)	09:00 - 09:00
eP432	<b>Rapid assessment of access to HIV Post-Exposure Prophylaxis (PEP) in EU/EEA countries</b> Ferenc Bagyinszky (Germany)	09:00 - 09:00
eP433	<b>A Multidisciplinary Approach to Promoting Accessibility and Adherence to Pre-Exposure Prophylaxis (PrEP) in a Portuguese Hospital in Lisbon</b> Bárbara Cardoso (Portugal)	09:00 - 09:00
eP434	<b>Assessing the Interest and Willingness of Nigerian Community Pharmacists to Deliver Pharmacy-Based Pre-Exposure Prophylaxis (PrEP) Services</b> Theodora Chioma Omenoba (Nigeria)	09:00 - 09:00
eP435	<b>Assessment of healthcare access and knowledge of HIV pre-exposure prophylaxis in women sex workers in Lille, Northern France.</b> Emmanuelle Bontemps (France)	09:00 - 09:00
eP436	<b>Automated Data Solutions for PrEP Monitoring and Planning in Ukraine</b>	09:00 - 09:00



	Diana Shevchenko (Ukraine)	
eP437	<b>Awareness and uptake of pre-exposure prophylaxis among pregnant women at risk of HIV in mid-western and central Uganda: a population-based study</b> Bashiri Magada (Uganda)	09:00 - 09:00
eP438	<b>Characteristics of PrEP Users at First Counseling Visit: Persistent Gaps in Reaching High-Risk Populations</b> Drieda Zace (Italy)	09:00 - 09:00
eP439	<b>Chemsex in PrEP users of a community-based center PrEP Point Plus (PPP)</b> Sandro Mattioli (Italy)	09:00 - 09:00
eP440	<b>Comparison of users accessing PrEP in hospital-based or community-based setting: first picture from the PrIDE cohort</b> Valentina Mazzotta (Italy)	09:00 - 09:00
eP441	<b>Engagement of Women of Color in HIV Prevention through PrEP at a Clinic Serving LGBTQ+ Communities</b> Darya Fridman (United States)	09:00 - 09:00
eP442	<b>Evaluation of a multidisciplinary reach-out program, facilitating HIV pre-exposure prophylaxis (PrEP) prescription and retention in care, in a group of trans women (TW) at high risk of HIV infection. Preliminary results from the PrEP à porter study</b> VALENTINA ISERNIA (France)	09:00 - 09:00
eP443	<b>Examining the real-world population-level impact of Scotland's national HIV pre-exposure prophylaxis (PrEP) programme among gay, bisexual and other men who have sex with men</b> Claudia Estcourt (United Kingdom)	09:00 - 09:00
eP444	<b>Experience of Implementing PrEP in a Health Insurance in Buenos Aires, Argentina: Lessons Learned and Challenges</b> Iael Altclas (Argentina)	09:00 - 09:00
eP445	<b>Frequency of Enteric Pathogens in Austrian PrEP Users</b> Nikolaus Urban (Austria)	09:00 - 09:00
eP446	<b>HIV infection in PrEP users: incidence, epidemiological, clinical and virological characteristics. A multicenter ambispective Cohort in Spain (SCOPE Study)</b> Juan Ambrosioni (Spain)	09:00 - 09:00
eP447	<b>Impact of COVID-19 lockdown on HIV pre-exposure prophylaxis (PrEP) service delivery in Uganda: Challenges and coping strategies</b> Sylvia Namanda (Uganda)	09:00 - 09:00
eP448	<b>Impact of Pre-Exposure Prophylaxis (PrEP) Introduction on Homosexual HIV Transmission in Kazakhstan: An Interrupted Time Series Analysis</b> Indira Karibayeva (Kazakhstan)	09:00 - 09:00
eP449	<b>Implementation of PrEP in Italy: Highlights and Challenges. Findings from the PrIDE Survey</b> Silvia Nozza (Italy)	09:00 - 09:00
eP450	<b>Inequality in the Distribution of PrEP in Brazil: An Analysis of Coverage in Relation to HIV Incidence by Age Group, Sexual Orientation, and Race</b> Vinícius Gabriel Horst Soares (Brazil)	09:00 - 09:00
eP451	<b>Interest in and intention to use long-acting PrEP among PrEP-naive</b>	09:00 - 09:00

	<b>MSM and MSM currently using PrEP in Thailand</b> Natthakhet Yaemim Deyn (Thailand)	
eP452	<b>Introducing community-based PrEP delivery in Romania</b> Raluca Pătraşcu (Romania)	09:00 - 09:00
eP453	<b>Introduction of pre-exposure prophylaxis (PrEP) in Kazakhstan: its impact on HIV testing and diagnosis rates among people who inject drugs</b> Indira Karibayeva (Kazakhstan)	09:00 - 09:00
eP454	<b>Mental Health, Stigma and Risk Perception Among CAB-LA PrEP Initiators: a cross-sectional study</b> Davide Moschese (Italy)	09:00 - 09:00
eP455	<b>Mind the Gap: transition from HIV PEP with B/F/TAF to oral PrEP in real-world setting</b> Flavia Passini (Italy)	09:00 - 09:00
eP456	<b>Opportunities to Prevent Human Immunodeficiency Virus (HIV) Acquisition: Global Survey Results on Sexual Health Engagement in Newly Diagnosed People Living With HIV From the VOLITION Study</b> Cassidy A Gutner (United States)	09:00 - 09:00
eP457	<b>Pre-Exposure prophylaxis to prevent HIV transmission among migrant men who have sex with men in Georgia</b> Maia Tsintsadze (Georgia)	09:00 - 09:00
eP458	<b>Prevalence and Correlates of Intimate Partner Violence among Gay, Bisexual, and Other Men Who Have Sex with Men (GBMSM) Using PrEP in Pre-War Ukraine</b> Nikolay Lunchenkov (Germany)	09:00 - 09:00
eP459	<b>Real-World Experience with Oral PrEP in Italy: A Descriptive Study from a Single-Center Cohort (2018-2024)</b> Andrea Carbone (Italy)	09:00 - 09:00
eP460	<b>Reasons for HIV-Preexposure Prophylaxis (PrEP) discontinuation and its predictors in people still at risk for HIV acquisition</b> Virginia Barchi (Italy)	09:00 - 09:00
eP461	<b>Sexual health knowledge, interest and acceptability of PrEP in migrant women: the MIMOSA study</b> Maria Mazzitelli (Italy)	09:00 - 09:00
eP462	<b>Social Media Communication for Recruitment and Adherence to Combined HIV/STI Prevention with a Focus on the Trans Population at a Research Center, São Paulo, Brazil</b> Vinicius Francisco da Silva (Brazil)	09:00 - 09:00
eP463	<b>Systematic search and critical discourse analysis of research on national HIV pre-exposure prophylaxis programmes among gay, bisexual, and other men who have sex with men</b> David Comer (Ireland)	09:00 - 09:00
eP464	<b>Use of whole blood capillary samples to estimate glomerular filtration rate using enzymatic analysis of creatinine among HIV PrEP users</b> Maurice Pelsers (Germany)	09:00 - 09:00
eP465	<b>Would infant lamivudine prophylaxis during breastfeeding be an option to prevent from vertical transmission of HIV ?</b> Laetitia Gay (France)	09:00 - 09:00
eP466	<b>Durable viral load suppression and viral load rebound among people living with HIV in North America and Europe. A systematic</b>	09:00 - 09:00

	<b>review and meta-analysis</b> Mariam Salim Mbwana (Tanzania)	
eP467	<b>HIV Self-Testing by Mail Among Sex Workers: A Virtual Harm Reduction Initiative in Montpellier, France</b> Victor Duperret (France)	09:00 - 09:00
eP468	<b>MEASURING HIV PREVENTION KNOWLEDGE (U=U, PEP, PrEP) AND ATTITUDES IN THE HEALTHCARE SETTING: SERBIAN RESULTS FROM AN ECDC/EACS SURVEY</b> Gordana Dragović (Serbia)	09:00 - 09:00
eP469	<b>Treatment as prevention: the impact of the national care and support program for people living with HIV amid Russia's full-scale military invasion of Ukraine</b> Olha Anatoliivna Klymova (Ukraine)	09:00 - 09:00
	<b>C3. Social Sciences</b>	09:00 - 09:00
eP470	<b>Advancing HIV Cure Research in Latin America and the Caribbean: Perspectives, Priorities, and Advocacy Needs of Civil Society</b> Luciana Kamel (Brazil)	09:00 - 09:00
eP471	<b>Behavioral Change Related to Stigma and Discrimination Among People Living with HIV</b> Monica Pudaruth (Mauritius)	09:00 - 09:00
eP472	<b>Evaluation of Health-Related Quality of Life Over a Six-Month Period in Newly Diagnosed People Living with HIV</b> Hakki Meric Turkkan (Turkey)	09:00 - 09:00
eP473	<b>Evolving Influences on HIV Knowledge in Young Filipino Women: Education, Media, and Stigma</b> Sophia Palma (Hungary)	09:00 - 09:00
eP474	<b>Memory rehabilitation for HIV-Associated Neurocognitive Disorders (HAND) : A review of the literature</b> Signe Andersen (France)	09:00 - 09:00
eP475	<b>Multi-dimensional impulsivity in people living with HIV on effective cART</b> Chloe Knox (United Kingdom)	09:00 - 09:00
eP476	<b>Preliminary findings from a new group-based memory rehabilitation program, <i>Coaching Memory</i>, for HIV-Associated Neurocognitive Disorders (HAND)</b> Signe Andersen (France)	09:00 - 09:00
eP477	<b>Reframing HIV: How Personal Growth and Acceptance Could Improve ART Adherence</b> Andrea Norcini-Pala (United States)	09:00 - 09:00
eP478	<b>Time to Suboptimal Treatment Patterns Among People With HIV on Antiretroviral Therapy in the United States</b> Travis Lim (United States)	09:00 - 09:00
eP479	<b>A Telegram Bot as a Digital Tool for Transgender People in Ukraine: Access to HIV Services and Gender-Affirmative Support</b> Vitalii Apanasenko (Ukraine)	09:00 - 09:00
eP480	<b>Bimonthly long acting cabotegravir and rilpivirine in transgender women with HIV: evidence from the Spanish RELATIVITY cohort.</b> Alberto Díaz-de Santiago (Spain)	09:00 - 09:00
eP481	<b>Integrated biobehavioral survey among transgender and non-binary people in Ukraine, 2024</b>	09:00 - 09:00

	Sofiia Ohorodnik (Ukraine)	
eP482	<b>Effect of SARS-CoV-2 vaccination on HIV viral load in patients under BIC/TAF/FTC therapy: a retrospective observational study</b> Chiara Iaria (Italy)	09:00 - 09:00
eP483	<b>Gamified Education: Utilizing Interactive Play to Enhance HIV/AIDS Awareness and Prevention</b> Olga Feger (Ukraine)	09:00 - 09:00
eP484	<b>Loneliness and HIV in Adults 50+: Voices on Needed Interventions</b> Rosa De Miguel Buckley (Spain)	09:00 - 09:00
eP485	<b>More than just a drink: Identifying and intervening on silent risk profiles for alcohol misuse in People Living With HIV</b> Andronikos Spyrou (Greece)	09:00 - 09:00
eP486	<b>Perspectives on HIV Cure-Related Trials with Analytical Treatment Interruption among People Living with HIV and Healthcare Practitioners</b> Kwanza Price (United States)	09:00 - 09:00
eP487	<b>Reasons for interrupting antiretroviral therapy, results of the study</b> Yaroslava Lopatina (Ukraine)	09:00 - 09:00
eP488	<b>Silent Crisis: Loneliness in Older Adults Living with HIV</b> Joanna Cano-Smith (Spain)	09:00 - 09:00
eP489	<b>Stigma and Quality of Life in People Living with HIV: Psychosocial vulnerability and clinical implications</b> Carolina Olmos Mata (Spain)	09:00 - 09:00
eP490	<b>Cost analysis and diagnostic yield of asymptomatic sexually transmitted infections (STIs) screening in a high-risk cohort of men who have sex with men (MSM)</b> Pierluigi Francesco Salvo (Italy)	09:00 - 09:00
eP491	<b>Feelings, experiences and coping strategies after HIV diagnosis amongst people with recently acquired HIV in Europe</b> Inés Suárez-García (Spain)	09:00 - 09:00
eP492	<b>Leveraging interactive SMS training to equip health workers for inclusive HIV services amid Uganda's anti-gay law implementation</b> Christine Nabukera Rwabyogamu (Uganda)	09:00 - 09:00
eP493	<b>Navigating sexual dysfunction with HIV: experiences of gay, bisexual, and other men who have sex with men in Montreal, Canada</b> Bertrand Lebouché (Canada)	09:00 - 09:00
eP494	<b>Risk reduction strategies for HIV transmission during time among men who have sex with men in Slovenia: Qualitative study</b> Miran Solinc (Slovenia)	09:00 - 09:00
eP495	<b>"Even Me Myself, I Don't See Myself as a Human Being": Migration, Violence, and HIV Exposure Among African Refugee Male Sex Workers in Transit to Italy</b> Marco Barracchia (Netherlands)	09:00 - 09:00
eP496	<b>Assessing Mental Health in an Immigrant-Dominated HIV Cohort Using PHQ-9: A Pilot Analysis from a Greek HIV Unit</b> Vissaria Sakka (Greece)	09:00 - 09:00
eP497	<b>Characterisation of migrant PLWHIV from sub-Saharan Africa in a hospital in Europe - mixed-methods study in the Lisbon region,</b>	09:00 - 09:00

	<b>Portugal</b> Rita Patrocínio de Jesus (Portugal)	
eP498	<b>Where Health Begins: Mobile Health as a Tool for HIV/STI Access Among LGBTQI+ Migrants in Italy</b> Marco Barracchia (Netherlands)	09:00 - 09:00
eP499	<b>Attitudes towards PrEP among women engaged in sex work who use drugs (WESW-UD) in Kazakhstan</b> Tara McCrimmon (United States)	09:00 - 09:00
eP501	<b>Did the AEGIDA Intervention Reduce Sexual Behaviors Associated with HIV Acquisition among Women who Exchange Sex and/or Use Substances in Kazakhstan?</b> Victoria Frye (United States)	09:00 - 09:00
eP502	<b>Health issues in sex workers attending a sexual health clinic in Paris: an observational cohort</b> Sarah Gaston-Dreyfus (France)	09:00 - 09:00
eP503	<b>Internalized Stigma and Mental Health Symptoms among females who engage in sex work and use drugs in Kazakhstan: Baseline insights from the AEGIDA Study</b> Assel Terlikbayeva (Kazakhstan)	09:00 - 09:00
eP504	<b>Intersectional identities and barriers</b> Trajche Janushev (Hungary)	09:00 - 09:00
eP505	<b>Retention Cascade and Predictors in a Sexual Health Program for Sex Workers: Expanded Access Through NGO Collaboration</b> Diana Corona-Mata (Spain)	09:00 - 09:00
eP506	<b>Associations Between Marijuana Use Patterns and HIV Care Continuum Outcomes Among Adults with HIV in Florida</b> Robert Cook (United States)	09:00 - 09:00
eP507	<b>Chemsex Trajectories among GBMSM in Almaty, Kazakhstan: A Reflexive Thematic Analysis Using a Life Course Framework</b> Nikolay Lunchenkov (Germany)	09:00 - 09:00
eP508	<b>Co-designing community-led, comprehensive chemsex harm reduction services for young men who have sex with men in Thailand: sexual health-focused, legal/rights-focused, and on-the-spot models</b> Sudarat Thongsuksangcharoen (Thailand)	09:00 - 09:00
eP509	<b>Describing substance use related to sex (chemsex) among individuals newly diagnosed with HIV at a sexual health clinic in Spain</b> Inés Armenteros-Yeguas (Spain)	09:00 - 09:00
eP510	<b>Peer-to-peer needle and syringe programmes (P2PNSP) as a way of engaging PWID in HIV prevention: 7 case studies</b> Alexei Lakhov (Germany)	09:00 - 09:00
eP511	<b>The Silent Epidemic: Chemsex Practices and Their Implications in Turkiye</b> Gökhan Vatansever (Turkey)	09:00 - 09:00
eP512	<b>Trends in HIV prevalence among key populations between 2009 and 2021</b> Arwa Neffati (Tunisia)	09:00 - 09:00
eP513	<b>AEGIDA: A Behavioral HIV Intervention Associated with Reduced Partner Violence Among Women Who Exchange Sex and Use Substances (WESUS) in Kazakhstan</b>	09:00 - 09:00

	Sholpan Primbetova (Kazakhstan)	
eP514	<b>Barriers to HIV Services for LGBT+ People in Armenia: Legal Gaps, Stigma, and Human Rights Concerns</b> Vaghinak Ter-Hovhannisyan (Armenia)	09:00 - 09:00
eP515	<b>Community and provider-driven strategies to reduce HIV-related stigma in Kazakhstan: opportunities for change</b> Meruyert Darisheva (Kazakhstan)	09:00 - 09:00
eP516	<b>Empowering High-Risk Communities: Peer Educators as Catalysts for HIV Prevention in Kumba, Cameroon</b> Alemju Fontu (Cameroon)	09:00 - 09:00
eP518	<b>HIV and STIs Prevention in Women in Italy: the importance of the educational setting in WomanIST project</b> Dario Bernacchia (Italy)	09:00 - 09:00
eP519	<b>HIV-RELATED STIGMA AND DISCRIMINATION IN ARGENTINA'S POPULATION: RESULTS OF A CROSS-SECTIONAL STUDY EMPLOYING AN ONLINE SURVEY</b> José A. E. Barletta (Argentina)	09:00 - 09:00
eP520	<b>Medical Mistrust as a Barrier to Healthcare Access Among Women Vulnerable to HIV</b> Meruyert Darisheva (Kazakhstan)	09:00 - 09:00
eP521	<b>Overview on the epidemiology of HIV/AIDS among key populations in Tunisia, 2024</b> Arwa Neffati (Tunisia)	09:00 - 09:00
eP522	<b>Prison: An Essential Piece in the 'Towards Zero' Puzzle</b> Pankaj Sethi (United Kingdom)	09:00 - 09:00
eP523	<b>Reaching neglected Vulnerable Populations: Addressing the HIV Knowledge Gap in UK prisons</b> Sophie Strachan (United Kingdom)	09:00 - 09:00
eP524	<b>Religiosity and Perceived Stress Among Filipino People Living with HIV: Evidence from a Community-Led Treatment Hub in Metro Manila, Philippines</b> Emmanuel S. Baja (Philippines)	09:00 - 09:00
eP525	<b>Understanding HIV and Key Population Stigma in Kazakhstan's Healthcare Workforce: A Cross-Sectional Analysis</b> Gaukhar Mergenova (Kazakhstan)	09:00 - 09:00
eP526	<b>HIV/AIDS IN LVIV (UKRAINE) IN WAR CONDITIONS: EPIDEMIOLOGICAL CHANGES</b> Olena Mysano (Ukraine)	09:00 - 09:00
eP527	<b>Impact of the War on HIV Diagnosis Timeliness: CD4 Level Dynamics Among Newly Registered PLHIV in Ukraine</b> Larysa Hetman (Ukraine)	09:00 - 09:00
eP528	<b>Resilience of Harm Reduction and HIV Prevention Services for People Who Inject Drugs in Ukraine Amid War: Insights from 2021-2023</b> Liudmyla Legkostup (Ukraine)	09:00 - 09:00
	<b>Clinical Cases</b>	09:00 - 09:00
eP.C001	<b>Possible CNS compartmentalization and lenacapavir resistance in multidrug-resistant HIV</b> Annalisa Marinosci (Switzerland)	09:00 - 09:00

eP.C002	<b>Virological failure with NNRTI resistance on CAB+RPV-LA in a man with subtherapeutic cabotegravir levels</b> Nian Li (United Kingdom)	09:00 - 09:00
eP.C003	<b>Bictegravir in aging adults living with HIV: sustained virologic control and age-appropriate safety profile</b> Marcello Trizzino (Italy)	09:00 - 09:00
eP.C004	<b>Central nervous system lesions in late-presenting person living with HIV - opportunistic infection or a brain tumour?</b> Filip Glavac (Croatia)	09:00 - 09:00
eP.C005	<b>Case report: late diagnosis of HIV at clinical stage 4 with pulmonary and CNS tuberculosis</b> Oleksandra Bezrodna (Ukraine)	09:00 - 09:00
eP.C006	<b>Evolving genital lesions of unusual etiology in a man who have sex with man: case report</b> Carlo Bieńkowski (Poland)	09:00 - 09:00
eP.C007	<b>CMV-related cholangiopathy as part of IRIS in an HIV-infected patient with invasive pulmonary aspergillosis</b> Alberto Díaz-de Santiago (Spain)	09:00 - 09:00
eP.C008	<b>Bacillary angiomatosis in a HIV patient with high CD4 count: an unexpected manifestation of IRIS?</b> Hayat Kumbasar Karaosmanoğlu (Turkey)	09:00 - 09:00
eP.C009	<b>Disseminated Whipple's disease and Kaposi's Sarcoma with IRIS-PML in an individual with advanced HIV</b> Alexy Inciarte Portillo (Spain)	09:00 - 09:00
eP.C010	<b>Disseminated MAC, Leishmaniasis, and CMV in a patient with advanced HIV: a complex case of IRIS</b> Alberto Díaz-de Santiago (Spain)	09:00 - 09:00
eP.C011	<b>A case of AIDS-associated progressive multifocal leukoencephalopathy with significant improvement in higher brain function following glucocorticoid therapy</b> Motoki Kon (Japan)	09:00 - 09:00
eP.C012	<b>Fatal case of KSHV-associated diseases with airway involvement: Kaposi Sarcoma, Multicentric Castleman Disease, and Diffuse Large B-Cell Lymphoma in a Person living with HIV</b> Vitor José da Silva Classmann (Brazil)	09:00 - 09:00
eP.C013	<b>When the fever won't break: a case of disseminated MAC in advanced HIV</b> ilkay akbulut (Turkey)	09:00 - 09:00
eP.C014	<b>Visceral Leishmaniasis and HIV coinfection: unusual clinical presentation</b> Lorenzo Albertini (Italy)	09:00 - 09:00
eP.C015	<b>A rare and fatal case of cerebral and renal toxoplasmosis in a non-adherent person living with advanced HIV</b> Büşra Akmaz (Turkey)	09:00 - 09:00
eP.C016	<b>Encephalitis caused by ganciclovir-resistant cytomegalovirus in a late-presenting person living with HIV, diffuse large B-cell lymphoma, and multiple opportunistic infections</b> Marija Santini (Croatia)	09:00 - 09:00
eP.C017	<b>Disseminated Mycobacterium Avium Complex (dMAC) and Ophthalmoplegia - a diagnostic challenge</b> Niroshan Dayalan (United Kingdom)	09:00 - 09:00

eP.C018	<b>The first case of lung abscess and bacteremia caused by <i>Rhodococcus hoagii</i> in a patient with advanced HIV infection in Croatia - a therapeutic challenge</b> Nikola Kudoić (Croatia)	09:00 - 09:00
eP.C019	<b>First reported case of <i>Trichophyton mentagrophytes</i> genotype VII infection in a Portuguese HIV-positive patient</b> Fábio Reis (Portugal)	09:00 - 09:00
eP.C020	<b>Maribavir salvage therapy for ganciclovir-resistant cytomegalovirus in two women with HIV-related lymphoma</b> Guillaume THIZY (France)	09:00 - 09:00
eP.C021	<b>Paradoxical Immune Reconstitution Inflammatory Syndrome associated with <i>Pneumocystis jirovecii</i> pneumonia in a person living with HIV: a case report</b> Dara Mbanze (Portugal)	09:00 - 09:00
eP.C022	<b>Treatment of refractory Giardiasis with quinacrine in a young refugee with HIV and HCV coinfection</b> Alberto Diaz De Santiago (Spain)	09:00 - 09:00
eP.C023	<b>HIV-associated chronic inflammatory demyelinating polyneuropathy successfully managed with immunoadsorption</b> Yuanmei Che (China)	09:00 - 09:00
eP.C024	<b>Polymorphic Kaposi Sarcoma in the shadows of isolation and migration</b> Andronikos Spyrou (Greece)	09:00 - 09:00
eP.C025	<b><i>Mycobacterium avium</i> complex infection following immune reconstitution inflammatory syndrome: a diagnostic journey</b> Daniela Rodrigues Nogueira (Portugal)	09:00 - 09:00
eP.C026	<b>Oral ulcerations associated with Epstein-Barr virus in a severely immunocompromised person living with HIV-1</b> Márcia Daniela Silva (Portugal)	09:00 - 09:00
eP.C027	<b>Genital and oral ulcerative vasculitis in a recently diagnosed PWH with negative microbiological workup</b> Alberto Foncillas (Spain)	09:00 - 09:00
eP.C028	<b>An atypical presentation of psychosis in progressive multifocal leukoencephalopathy</b> Natasha Somani (United Kingdom)	09:00 - 09:00
eP.C029	<b>Fatal overlapping CMV encephalitis, adrenal insufficiency, and IRIS in an individual with advanced HIV and disseminated MAI</b> Alexy Inciarte Portillo (Spain)	09:00 - 09:00
eP.C030	<b>Mpox as a chronic active infection in a patient living with HIV/AIDS: clinical and virological implications in a year of evolution</b> Maria Felipe Medeiros (Brazil)	09:00 - 09:00
eP.C031	<b>Emergence of maribavir resistance in an AIDS patient with refractory cytomegalovirus viremia and retinitis</b> Vissaria Sakka (Greece)	09:00 - 09:00
eP.C032	<b>Severe disseminated cryptococcosis, with asymptomatic central nervous system involvement, in a very late presenter</b> Gabriela-Andreea Stoica (Romania)	09:00 - 09:00
eP.C033	<b>A case of an AIDS related multifocal cryptococcus infection</b> Sergei Rakovich (Belarus)	09:00 - 09:00
eP.C034	<b>Unmasking IRIS due to <i>Toxoplasma gondii</i> in a new HIV-positive</b>	09:00 - 09:00



	<b>individual with CD4 <math>\geq 200</math> cells/mm<sup>3</sup> and disseminated tuberculosis</b> Francisco Vale (Portugal)	
eP.C035	<b>Cryptococcal meningitis in a 34-year-old man with advanced HIV and left insular astrocytoma</b> Alexy Inciarte Portillo (Spain)	09:00 - 09:00
eP.C036	<b>Nocardia abscessus diagnosis in a cis gender woman living with HIV</b> Javier José Ricart (Argentina)	09:00 - 09:00
eP.C037	<b>Clinical case of advanced HIV with multiple opportunistic diseases: pneumocystis pneumonia, CMV chorioretinitis, and Kaposi's sarcoma</b> Olena Vinnytska (Ukraine)	09:00 - 09:00
eP.C038	<b>Immune reconstitution inflammatory syndrome with atypical presentation of varicella zoster virus encephalitis</b> Javier José Ricart (Argentina)	09:00 - 09:00
eP.C039	<b>Diagnostic and therapeutic challenges in a case of cerebral mass lesions in a person living with HIV</b> Nathalie De Castro (France)	09:00 - 09:00
eP.C040	<b>Spondilodiscitis caused by M. avium complex in a man living with HIV and poor immunological - recovery after HAART</b> Laura Comi (Italy)	09:00 - 09:00
eP.C041	<b>Multiple concurrent opportunistic infections in newly diagnosed HIV-positive patient</b> Graciana Lucia CARDENAS (Argentina)	09:00 - 09:00
eP.C042	<b>Disseminated <i>Talaromyces marneffe</i> infection presenting as pulmonary cavitary nodules: a case report</b> Jun ZOU (China)	09:00 - 09:00
eP.C043	<b>A case of disseminated <i>Trichosporon asahii</i> infection in a patient with advanced human immunodeficiency virus disease and Kaposi sarcoma</b> Theodoros Michailidis (Greece)	09:00 - 09:00
eP.C044	<b>Coexistence of Multicentric Castleman disease and visceral Kaposi Sarcoma: a case-report</b> Su Jung Choi (Mexico)	09:00 - 09:00
eP.C045	<b>Multicentric Castleman disease as a cause of fever of unknown origin: a case report</b> Su Jung Choi (Mexico)	09:00 - 09:00
eP.C046	<b>Overcoming barriers in care: managing HIV in people with disabilities</b> Thyago César da Silva Pires (Brazil)	09:00 - 09:00
eP.C047	<b>Advanced coronary artery disease in a low-risk HIV patient - a case for early statin intervention</b> Aishriah Kalearasu (United Kingdom)	09:00 - 09:00
eP.C048	<b>Diffuse large B-cell lymphoma in a person living with HIV and a history of leprosy: a diagnostic challenge</b> Umut OZGUR (Turkey)	09:00 - 09:00
eP.C049	<b>Use of PCSK9 inhibitor evolocumab in PLWH with persistent hyperlipidemia despite statin therapy: two case reports</b> Layla Pagnucco (Italy)	09:00 - 09:00
eP.C050	<b>Complete remission of a large B-cell Lymphoma in a person living</b>	09:00 - 09:00

	<b>with HIV: a case report with a 16 year follow-up</b> Kateryna Lytvyn (Ukraine)	
eP.C051	<b>Interaction between GLP-1 receptor agonists and cART in PLWH and obesity: a case report</b> Raffaele Ferri (Italy)	09:00 - 09:00
	<b>Late-breaking Abstracts</b>	09:00 - 09:00
eP.LB001	<b>GPR56 marks exhausted, clonally expanded and cytotoxic CD4+ T cell subset in people living with HIV-1</b> Tom Kraus (Germany)	09:00 - 09:00
eP.LB002	<b>Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland</b> Agnieszka Lembas (Poland)	09:00 - 09:00
eP.LB003	<b>Long-acting cabotegravir plus rilpivirine in viremic PWH: virological outcomes from the French Dat'AIDS cohort</b> Colin Deschanvres (France)	09:00 - 09:00
eP.LB004	<b>Antiviral efficacy of doravirine-based regimens in patients with NNRTI resistance in Europe: a retrospective observational study</b> Pierre Sellier (France)	09:00 - 09:00
eP.LB005	<b>Real-World 5-Year Virological Outcomes of People Living with HIV Initiated on Efavirenz or Dolutegravir or Switched to Dolutegravir Containing Regimens in Botswana, 2012-2025</b> Ava Avalos (Botswana)	09:00 - 09:00
eP.LB006	<b>Drug-Drug Interaction (DDI) Liability of Bictegravir/Lenacapavir (BIC/LEN) Compared With Representative Complex Antiretroviral Therapy (ART) Regimens in the Phase 3 Portion of ARTISTRY-1</b> Priyanka Arora (United States)	09:00 - 09:00
eP.LB007	<b>High Effectiveness and Rare Virologic Failure in Treatment-Experienced Individuals on Long-Acting Cabotegravir + Rilpivirine Therapy Across Europe: Insights from the EuroSIDA Study</b> Wendy Bannister (Denmark)	09:00 - 09:00
eP.LB008	<b>Screening of MPXV, VZV, HSV-1, and HSV-2 causing mucocutaneous vesicular rashes by multiplex HRM-PCR</b> Nadege NZIZA TROUCHAUD (France)	09:00 - 09:00
eP.LB009	<b>HDV in HIV/HBV Coinfection: Risk Factors, Prevalence, and 12-Year Mortality Outcomes</b> Agnieszka Lembas (Poland)	09:00 - 09:00
eP.LB010	<b>Healthcare Providers' Knowledge of Doxycycline Post-Exposure Prophylaxis for the Prevention of Sexually Transmitted Infections in Uganda</b> Aidah Nanvuma (Uganda)	09:00 - 09:00
eP.LB011	<b>Evaluation of brain volume, brain age, and cognitive functions among people living with HIV in the era of effective antiretroviral therapy</b> Müge Toygar Deniz (Turkey)	09:00 - 09:00
eP.LB012	<b>Difference in five-year mortality risk among people living with HIV aged over 50, according to age at diagnosis, in a specialized clinic in Mexico City, CondeAging Cohort</b> Humberto Gudiño Solorio (Mexico)	09:00 - 09:00
eP.LB013	<b>Meaningful changes in [health-related] quality of life in people living with HIV in Nouvelle Aquitaine, France (2018-24): AQUIVIH-</b>	09:00 - 09:00

	<b>NA-QuAliv Study</b> Wejden Yahyaoui (France)	
eP.LB014	<b>Estimation of the cost of complacency in the fight against HIV in Europe</b> Helen Hayes (United Kingdom)	09:00 - 09:00
eP.LB016	<b>Determinants of Successful Integration of Long-Acting Antiretroviral Therapy into Established HIV Clinics: Examining Barriers, Facilitators, and Implementation Strategies</b> Clarence Soliman (Ireland)	09:00 - 09:00
eP.LB017	<b>Beyond the 0.1% threshold: an economic evaluation of HIV indicator condition-based testing in hospital settings</b> Klaske Vliegthart-Jongbloed (Netherlands)	09:00 - 09:00
eP.LB018	<b>Analysis of the population and outcomes of individuals tested for HIV at voluntary counselling and testing points (VCTs) in Poland during the first three years of the armed conflict in Ukraine (2022-2024)</b> Magdalena Ankiersztejn-Bartczak (Poland)	09:00 - 09:00
eP.LB019	<b>Models of care for women living with HIV in Europe: a scoping review</b>  Duaa Rao (Germany)	09:00 - 09:00
eP.LB020	<b>Assessing the Effectiveness of Integrating a Peer Educators Program in Enhancing HIV Services Uptake among students at Malawi University of Business and Applied Sciences, Blantyre, Malawi</b> Billy Khembo (Malawi)	09:00 - 09:00
eP.LB021	<b>Persistent HIV stigma and discrimination in family and medical settings. Findings from university medical center in Hamburg, Germany</b> Anna Koval (Germany)	09:00 - 09:00
eP.LB022	<b>Outcomes of HIV Care clients enrolled in enhanced personal contact intervention using mobile GIS-based Re-engagement APP to improve continuity in care in Lilongwe, Malawi.</b> Petros P.M Tembo (Malawi)	09:00 - 09:00
eP.LB023	<b>Mapping Vaccination Recommendations and Access to Vaccinations for People Living with HIV in Europe</b> Emily Burzynski (Poland)	09:00 - 09:00
eP.LB024	<b>Embedding a community-led mobile app within a national HIV digital ecosystem: the case of Moldova</b> Constantin Cearanovski (Moldova)	09:00 - 09:00
eP.LB025	<b>Global forecast on long-acting PrEP need and readiness across 172 countries: urgent equity and access gaps for key populations</b> Micheal Ighodaro (United States)	09:00 - 09:00
eP.LB026	<b>Women and PrEP: Gap Between Indication and Actual Use in France</b> Jérémy ZEGGAGH (France)	09:00 - 09:00
eP.LB027	<b>No woman left behind: scaling triple elimination of HIV, syphilis, and hepatitis B through community testing in informal settings in Southwest Nigeria</b> Victor Aganaba (Nigeria)	09:00 - 09:00

eP.LB028	<b>High acceptance among hospital attendees supports implementing hospital-wide HIV testing for indicator conditions</b> Klaske Vliegthart-Jongbloed (Netherlands)	09:00 - 09:00
eP.LB029	<b>Understanding HIV testing uptake among cisgender men who have sex with men in the Philippines: assessing the interaction of self-testing preference and perceived accessibility and privacy to HIV testing</b> Olivia Sison (Philippines)	09:00 - 09:00
eP.LB030	<b>IASO (Innovation-Action-Health-Opportunity) program, acceptability and feasibility of screening for HIV and viral hepatitis as part of a collaborative 'outreach' global health project in migrant living areas</b> Christia Palacios (France)	09:00 - 09:00
eP.LB031	<b>Chemsex phenomenon in Andalusia: a cross-sectional study from the perspective of users and healthcare professionals</b> Javier de la Torre Lima (Spain)	09:00 - 09:00
eP.LB032	<b>Sexual health of men who have sex with men in Croatia: results of a biobehavioural survey using respondent-driven sampling with online recruitment and facility-based testing</b> Zoran Dominković (Croatia)	09:00 - 09:00
eP.LB033	<b>Gendered Labor and Sex Work in Taiwan's Gig Economy: Sexual Health Information Needs, Sharing Practices, and Inequalities</b> Chia-Wen Li (Taiwan)	09:00 - 09:00

*Plenary lecture*

09:15 - 09:45

GRAND AMPHITHEATRE

**PL1 - Are we prepared for pandemics?**

Sanjay Bhagani (United Kingdom)

**Are we prepared for pandemics?**

Yazdan Yazdanpanah (France)

09:15 - 09:45

*Plenary lecture*

09:45 - 10:15

GRAND AMPHITHEATRE

**PL2 - ART now & near: how far have we come & how much further must we go?**

Alexandra Calmy (Switzerland)

**ART now & near: how far have we come & how much further must we go?**

Monica Gandhi (United States)

09:45 - 10:15

*Breaks*

10:15 - 11:00

GRAND AMPHITHEATRE

**Coffee break***Oral presentations*

10:45 - 12:00

ROOM 252AB

**O1 - Oral cross track session**

Nicola Mackie (United Kingdom)

Michaela Müller-Trutwin (France)

O1.1

**T-cell modulation following therapeutic vaccination in people living with HIV (PLWH)**

Yunjoo Lee (United States)

10:45 - 10:54

O1.2

**Lymph nodes play a central role in SIV persistence compared to gut (P-VISCONTI study)**

10:54 - 11:03

	Véronique AVETTAND-FENOEL (France)	
O1.3	<b>Mapping patterns of resistance to 2<sup>nd</sup> generation INSTI in clinical practice: results from the ROSETTA-registry</b> Mafalda N.S. Miranda (Netherlands)	11:03 - 11:12
O1.4	<b>Association of Injection Site with Trough Concentrations of Cabotegravir and Rilpivirine Q2M</b> Thierry Prazuck (France)	11:12 - 11:21
O1.5	<b>Beyond COVID-19 in People with HIV: specific miRNA Expression Profile persists after SARS-CoV-2 clearance</b> Sergio Grande Garcia (Spain)	11:21 - 11:30
O1.6	<b>HIV is Associated with CT Measures of Interstitial Lung Disease: Analyses from the Multicenter AIDS Cohort Study</b> Sarath Raju (United States)	11:30 - 11:39
O1.7	<b>Health-related quality of life in ageing people with HIV is not different to that of well-matched controls without HIV: an 8-year longitudinal analysis from the AGE<sub>HIV</sub> cohort study on ageing and comorbidities</b> Kevin Moody (Netherlands)	11:39 - 11:48
O1.8.LB	<b>Tracking HIV DNA fate in secondary lymphoid and hematopoietic organs during acute infection using a humanized mouse model</b> Jean Sebastien Diana (France)	11:48 - 11:57

*Parallel session*

11:00 - 12:00

GRAND AMPHITHEATRE

**PS01 - Integrase inhibitors everywhere: Good or bad?**

Antonios Papadopoulos (Greece)

Christine Katlama (France)

	<b>It always starts from scratch: Integrase resistance and its global implications</b> Jonathan Schapiro (Israel)	11:00 - 11:10
PS01.1	<b>Potential treatment options following virological failure with long-acting injectable cabotegravir and rilpivirine: an analysis based on reported cases</b> Maria Mazzitelli (Italy)	11:10 - 11:19
PS01.2	<b>Weight and Body Composition After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily from BIC/FTC/TAF in Adults Living With HIV-1: Week 48 Results From a Randomized, Double-Blind Phase 3 Study</b> Chloe Orkin (United Kingdom)	11:19 - 11:28
PS01.3	<b>Efficacy and tolerability of BIC/TAF/FTC in people with HIV and solid and hematological neoplasms: a multicenter observational study (BIKONCO Study)</b> Arnau Monforte (Spain)	11:28 - 11:37
PS01.4	<b>Hepatitis B Virus Reactivation in People Living with HIV Switching to Long Acting-Cabotegravir/Rilpivirine therapy: A Cohort Study Analysis</b> Alberto Foncillas (Spain)	11:37 - 11:46

*Parallel session*

11:00 - 12:00

AMPHITHEATRE BORDEAUX

**PS02 - Scaling up PrEP to meet the needs of everyone**

Magdalena Ankiersztejn-Bartczak (Poland)

Claudia Estcourt (United Kingdom)

	<b>The Why and the How of addressing PrEP equity across Europe</b> Oana Sandulescu (Romania)	11:00 - 11:10
	<b>Meeting the PrEP needs of women</b> Sinead Delany (South Africa)	11:10 - 11:20
PS02.1	<b>Extended PrEP cascades and determinants of long-acting PrEP intention and unmet PrEP needs among transgender women, transgender men, and non-binary individuals in 20 European countries</b> Haoyi Wang (Netherlands)	11:20 - 11:29
PS02.2	<b>Gaps and Gains in PrEP Continuity: Clinical and Programmatic Insights from Nigeria's 2024 National Rollout</b> Ramatu Aliyu Magaji (Nigeria)	11:29 - 11:38
PS02.3	<b>Strengthening Community-Based Integrated HIV/STI/VH Prevention, Testing, and Linkage-to-Care: First-Year Outcomes of the CORE Project</b> Laura Fernández-López (Spain)	11:38 - 11:47
PS02.4	<b>Recruitment of Disproportionately Affected Populations in the PURPOSE 5 Study Evaluating Lenacapavir for PrEP in France and the UK</b> Jean-Michel Molina (France)	11:47 - 11:56
<i>Parallel session</i> 11:00 - 12:00		
	<b>PS03 - Senescence, inflammation and ageing in HIV. What is all the fuss about?</b> Cristina Mussini (Italy) Paddy Mallon (Ireland)	ROOM MAILLOT
	<b>Ageing with HIV: from basic science to clinical research</b> Georg Behrens (Germany)	11:00 - 11:15
PS03.1	<b>Associations between gut microbiome, kynurenine pathway of tryptophan metabolism, and symptoms of depression in people with HIV</b> Xiangning Bai (Norway)	11:15 - 11:24
PS03.2	<b>Immune-inflammatory profile with inflammation, innate activation, and endothelial dysfunction in people with HIV is associated with obstructive coronary artery disease</b> Moises Alberto Suarez-Zdunek (Denmark)	11:24 - 11:33
PS03.3	<b>A Randomized, Multi-Center, Double-Blind, Placebo-Controlled ACTG Study to Evaluate the Effects of Cenicriviroc on Arterial Inflammation in People with HIV</b> Janet Lo (United States)	11:33 - 11:42
<i>Breaks</i> 12:00 - 14:30		
	<b>Lunch break</b>	GRAND AMPHITHEATRE
<i>Industry sponsored session</i> 12:30 - 14:00		
	<b>Industry sponsored session</b>	AMPHITHEATRE BLEU

*Special session*

12:30 - 13:30

AMPHITHEATRE BORDEAUX

**SPS1 - WHO: From real promise to complex reality: implementation of WHO recommendations on long-acting PrEP in times of global health funding cuts**

Stela Bivol (Switzerland)

Jean-Michel Molina (France)

<b>Introduction</b>	12:30 - 12:35
<b>WHO Recommendations on long-acting PrEP: from theory to practice</b>	12:35 - 12:50
Viatcheslav Grankov (Denmark)	
<b>Panel discussion</b>	12:50 - 13:25
Denis Godlevskiy (Germany)	
Mila Maistat (Switzerland)	
Chris Obermeyer (Switzerland)	
Liudmyla Legkostup (Ukraine)	
<b>Discussion/Q&amp;A</b>	13:25 - 13:30

*Special session*

12:30 - 13:30

ROOM MAILLOT

**SPS2 - NEAT ID: LAPTOP: Late Presenters, the Science and the Impact**

Anton Pozniak (United Kingdom)

Brenda Crabtree (Mexico)

<b>Welcome and Introductions</b>	12:30 - 12:33
Esteban Martínez (Spain)	
<b>NEAT ID: In Numbers, Background, and Structure</b>	12:33 - 12:38
Esteban Martínez (Spain)	
<b>LAPTOP: Late Presenters, the Science and the Impact</b>	12:38 - 12:58
Georg Behrens (Germany)	
<b>Discussion/Q&amp;A</b>	12:58 - 13:08
<b>NEAT ID: Study Updates, Recruitment, Grants and how to get involved</b>	13:08 - 13:20
Jürgen K Rockstroh (Germany)	
Nikos Dedes (Greece)	
<b>Presenting the NEAT ID Young Investigator of the Year with thanks to the Advisory Group Committee</b>	13:20 - 13:30
Jürgen K Rockstroh (Germany)	

*Parallel session*

14:30 - 15:30

GRAND AMPHITHEATRE

**PS04 - Social and gender inequities in accessing care and prevention**

Grzegorz Jezierski (Poland)

Harriet Langanke (Germany)

	<b>Gender inequities</b>	14:30 - 14:40
	Nathalie Bajos (France)	
	<b>Intersectional stigma</b>	14:40 - 14:50
	Bülent Turan (Turkey)	
PS04.1	<b>Exploring Mental Health Burden in Adults who Acquired HIV during Childhood and Adolescence</b>	14:50 - 14:59
	Beatriz Julieta Blanco Rojas (Spain)	
PS04.2	<b>Economic Drivers of HIV Vulnerability Among African Refugee Male</b>	14:59 - 15:08

	<b>Sex Workers in Italy: A Mixed-Methods Study</b> Marco Barracchia (Netherlands)	
PS04.3	<b>Multidimensional gender affirmation among transgender women living with HIV: an indicator of engaging in transactional sex?</b> Raymond Van Huizen (France)	15:08 - 15:17
PS04.4	<b>Chemsex Substance Use among gbMSM in Switzerland, a Cohort Collaboration Study between the Swiss HIV Cohort Study and the SwissPrEPared Study</b> Bashkim Jaha (Switzerland)	15:17 - 15:26
<i>Parallel session</i> 14:30 - 15:30		
		AMPHITHEATRE BLEU
<b>PS05 - Hepatitis and TB Co-Infection</b> Juan Berenguer (Spain) Aisuluu Bolotbaevaa (Kyrgyzstan)		
	<b>Risk and screening for Hepatocellular carcinoma in people with HIV</b> Jürgen K Rockstroh (Germany)	14:30 - 14:45
PS05.1	<b>Hepatocellular Carcinoma Screening in HIV/HBV Coinfected Individuals: Insights from Spain, Germany, and Poland</b> Juan Berenguer (Spain)	14:45 - 14:54
PS05.2	<b>Kinetics of occult hepatitis B infection in people with HIV switching from HBV-active ART to long-acting cabotegravir/rilpivirine</b> Alessia Magnapera (Italy)	14:54 - 15:03
PS05.3	<b>Analysis of tuberculosis preventive treatment cascade among people living with HIV in the country of Georgia: a mixed methods study</b> Mariana Buziashvili (Georgia)	15:03 - 15:12
PS05.4	<b>Evaluating Plasma Proteome Signatures for Active Tuberculosis Prediction and Immune Profiling in People With HIV</b> Katharina Kusejko (Switzerland)	15:12 - 15:21
<i>Parallel session</i> 14:30 - 15:30		
		AMPHITHEATRE BORDEAUX
<b>PS06 - Cancer screening in people living with HIV: What's new?</b> Botond Lakatos (Hungary) Lene Ryom (Denmark)		
	<b>Lung cancer screening</b> Alain Makinson (France)	14:30 - 14:40
	<b>Cervical and anal cancer screening</b> Mar Masià (Spain)	14:40 - 14:50
PS06.1	<b>Outcomes of cervical cancer screening among women with HIV in the Netherlands</b> Vita Jongen (Netherlands)	14:50 - 14:59
PS06.2	<b>Anal cancer screening in a cohort of women with HIV: uptake and outcome from a prospective study</b> Maria Mazzitelli (Italy)	14:59 - 15:08
PS06.3	<b>Prostate Cancer in People Living with HIV (PLWH): Results from a Large Retrospective Multicentre Analysis in Germany</b> Malte Benedikt Monin (Germany)	15:08 - 15:17
PS06.4	<b>Evolving cancer incidence in persons with HIV in France between 2014-2023: A nationwide study using the French National Health</b>	15:17 - 15:26



**Data System**

Elhadji Leye (France)

*Parallel session*

14:30 - 15:30

ROOM MAILLOT

**PS07 - Innovative mechanisms shifting the paradigm of treatment and prevention**

Elena Bruzzesi (Italy)

François Dabis (France)

**HIV Capsid Dynamics and Lenacapavir's Role in Remodeling Viral Replication**

14:30 - 14:40

Francesca Di Nunzio (France)

**Perspectives of bNAbs and vaccine research**

14:40 - 14:50

Florian Klein (Germany)

PS07.1

**Safety and analytical treatment interruption outcomes in a clinical trial of 2 broadly neutralizing antibodies plus vesatolimod in early-treated South African women with clade C HIV-1**

14:50 - 14:59

Krista Dong (United States)

PS07.2

**Lenacapavir Directs Specific Immunoproteasome-Mediated Degradation of Gag Proteins and Increases the killing of HIV-Infected Cells**

14:59 - 15:08

Pierre Gantner (France)

PS07.3

**Dasatinib enhances NK cell cytotoxicity and reverses functional exhaustion in HIV infection**

15:08 - 15:17

María José Muñoz-Gómez (Spain)

PS07.4.LB

**Characterization of NK Cell Subsets and ADCC Function in a Case of Sustained HIV Remission after allogeneic stem cell transplantation (2<sup>nd</sup> Berlin Case)**

15:17 - 15:26

Timo Trenkner (Germany)

*Breaks*

15:30 - 16:15

GRAND AMPHITHEATRE

**Coffee break***Industry sponsored session*

16:15 - 17:15

AMPHITHEATRE BLEU

**Industry sponsored session***Roundtable Discussion*

16:15 - 17:15

ROOM MAILLOT

**RT2 - HBV reactivation in people living with HIV**

Christoph Boesecke (Germany)

**Risk of HBV reactivation in people living with HIV receiving NRTI sparing dual therapy**

16:15 - 16:25

Tetiana Melnyk (France)

**Roundtable Discussion on HBV reactivation in people living with HIV**

16:25 - 17:15

Juan Berenguer (Spain)

Sanjay Bhagani (United Kingdom)

Karine Lacombe (France)

*Special session*

16:15 - 17:15

ROOM 252AB

**SPS3 - EATG: HIV and other communicable diseases amid permacrisis: can Europe lead the way?**

Christophe Martet (France)

Gus Cairns (United Kingdom)

**Introduction: Epidemiology, surveillance and normative practice**

16:15 - 16:25

Stela Bivol (Switzerland)

**Roundtable discussion**

16:25 - 17:05

Christoph Spinner (Germany)

Julia del Amo (Spain)

Remko van Leeuwen (Netherlands)

**Discussion/Q&A**

17:05 - 17:15

*Special session*

16:15 - 17:15

ROOM 242AB

**SPS4 - SFLS: Access to HIV care and prevention for migrants**

Hugues Cordel (France)

Caroline Andoum (France)

**Introduction**

16:15 - 16:20

**Migration as a social determinant of health and how to create safe places for health care**

16:20 - 16:35

Ursula Trummer (Austria)

**After 10 years of PrEP in France, is it effectively available for Migrants?**

16:35 - 16:50

Nicolas Vignier (France)

**The forgotten half of the equation: extending prenatal screening to Migrant future fathers**

16:50 - 17:05

Pauline Penot (France)

**Discussion/Q&A**

17:05 - 17:15

*Special session*

17:30 - 18:30

GRAND AMPHITHEATRE

**EACS Guidelines session**

Jürgen K Rockstroh (Germany)

Juan Ambrosioni (Spain)

**Part I**

17:30 - 17:30

**Antiretrovirals for treatment and prevention**

17:30 - 17:40

Laura Levi (France)

**Pediatric HIV**

17:40 - 17:50

Paolo Paioni (Switzerland)

**HIV Co-infections**

17:50 - 18:00

Andrea Mastrangelo (Switzerland)

**Part II**

18:00 - 18:00

**Co-morbidities**

18:00 - 18:15

Abiu Sempere (Spain)

Jasmini Alagaratnam (United Kingdom)

**Discussion**

18:15 - 18:30

Alexandra Calmy (Switzerland)

Catia Marzolini (Switzerland)

Steven Welch (United Kingdom)  
Cristiana Oprea (Romania)  
Esteban Martínez (Spain)

Friday, October 17, 2025

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP13 - Knowledge and beliefs about HIV prevention strategies**

Robert Hejzák (Czech Republic)

- |         |  |               |
|---------|--|---------------|
| MeP13.1 | <b>Unpacking Chemsex in Amsterdam: What Distinguishes Non-Users, Non-Problematic, and Problematic Users?</b><br>Dortje van den Dungen (Netherlands)  | 12:05 - 12:10 |
| MeP13.2 | <b>Identification of Migrant Women's Care Needs and Barriers to HIV Testing - The SERAY Study</b><br>Giota Lourida (Greece)  | 12:10 - 12:15 |
| MeP13.3 | <b>Barriers to tobacco smoking cessation support during hospital follow-up of adult people living with HIV/AIDS: a clinicians' perspective</b><br>Fabienne Marcellin (France)  | 12:15 - 12:20 |
| MeP13.4 | <b>Perceived neurocognitive impairment is associated with levels of depression and quality of life in adults seeking memory rehabilitation for HIV associated neurocognitive disorders (HAND)</b><br>Signe Andersen (France) | 12:20 - 12:25 |

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP17 - Viruses establishing infection and Vaccines**

Antonella Castagna (Italy)

- |         |  |               |
|---------|--|---------------|
| MeP17.1 | <b>Genetic and functional characteristics of CXCR4-using viral envelope glycoproteins in acute HIV-1 infection</b><br>Dorine Martres (France)  | 14:05 - 14:10 |
| MeP17.2 | <b>Identification of a broad and potent V3 glycan site bNAb targeting an N332<sub>gp120</sub> glycan-independent epitope</b><br>Malena Rohde (Germany)   | 14:10 - 14:15 |
| MeP17.3 | <b>Safety of a ChAdOx1.tHIVconsvX prime - MVA.tHIVconsvX boost vaccination regimen in people with HIV treated in primary infection: a phase I/II randomized, placebo-controlled trial (HIV-CORE 007)</b><br>Elena Bruzzesi (Italy) | 14:15 - 14:20 |
| MeP17.4 | <b>Assessment of the specific cellular immune response to the recombinant Herpes Zoster vaccine in people living with HIV</b><br>Grazia Alessio (Italy)  | 14:20 - 14:25 |

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP21 - Cabotegravir and rilpivirine in real world**

Silvia Nozza (Italy)

- |         |  |               |
|---------|--|---------------|
| MeP21.1 | <b>Pharmacokinetics and safety data after switching from injectable cabotegravir (CAB) + rilpivirine (RPV) to oral bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)</b><br>Priyanka Arora (United States)            | 15:35 - 15:40 |
| MeP21.2 | <b>Comparable efficacy, but increased adverse events and treatment-emergent resistance with injectable cabotegravir/rilpivirine compared to standard oral antiretroviral therapy: two systematic reviews and meta-analyses</b> | 15:40 - 15:45 |

	Cassandra Fairhead (United Kingdom)	
MeP21.3	<b>Impact of liver fibrosis on cabotegravir and rilpivirine long-acting plasma concentrations</b> Caterina Candela (Italy)	15:45 - 15:50
MeP21.4	<b>Evaluation of Fasting Lipids and Insulin Resistance After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Randomized Phase 3 Studies in Adults Living With HIV-1</b> Alexandra Calmy (Switzerland)	15:50 - 15:55
MeP21.5	<b>Antiretroviral Switch and Weight Gain: Cardiometabolic Implications of Switching to Darunavir/Cobicistat + Lamivudine</b> José Antonio Mata Marín (Mexico)	15:55 - 16:00
MeP21.6	<b>Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living with HIV in Spain: A Substudy of the RELATIVITY Cohort</b> Jara Llenas-García (Spain)	16:00 - 16:05
MeP21.7	<b>Determinants of Discontinuation of Long-Acting Cabotegravir/Rilpivirine: A Cause-Specific Analysis from Real-World Data</b> Miguel Torralba (Spain)	16:05 - 16:10
<i>Moderated ePosters</i>		
12:05 - 12:25		ePoster Exhibition
<b>MeP14 - Innovative and Integrated Approaches to HIV Prevention and Care</b>		
Constance Delaugerre (France)		
MeP14.1	<b>Evaluating the Impact of Integrating HIV Pre-Exposure Prophylaxis (PrEP) into Routine Health Insurance in Switzerland: A Mixed-Methods Analysis</b> Andrea Farnham (Switzerland)	12:05 - 12:10
MeP14.2	<b>High PrEP Uptake Among Men Who Have Sex with Men (MSM) Recruited Via Digital and Physical Community-Led Outreach in Paris, France</b> Anton Eremin (France)	12:10 - 12:15
MeP14.3	<b>Working with Mentor Mothers as an Implementation Strategy for Supporting Perinatal Mental Health of Kenyan Women Living with HIV</b> Janet Turan (United States)	12:15 - 12:20
MeP14.4	<b>Integration of geriatric concepts into HIV care structures: a single-center pilot study in Dakar</b> Alassane NDIAYE (Senegal)	12:20 - 12:25
<i>Moderated ePosters</i>		
14:05 - 14:25		ePoster Exhibition
<b>MeP18 - Mind the Gaps: Socio-demographic Disparities, Resistance, and HIV Elimination Pathways</b>		
Sophie Grabar (France)		
MeP18.1	<b>2023 HIV Cascade of care by specific groups in the Québec HIV Cohort</b> Alexandra de Pokomandy (Canada)	14:05 - 14:10
MeP18.2	<b>Targeting the Gaps: Testing Trends and Intersectional Analysis of HIV Testing Among Women Across Key Populations (2017-2023) in the COBATEST Network</b> Laura Fernández-López (Spain)	14:10 - 14:15

MeP18.3	<b>Harnessing national registry data to identify socio-demographic and socio-economic gaps in HIV care in the Netherlands</b> Vita Jongen (Netherlands)	14:15 - 14:20
---------	--	---------------

MeP18.4	<b>Impact of continental spread of HIV-1 integrase resistance on progress toward the WHO's 2030 elimination goals</b> Victor Pimentel (Portugal)	14:20 - 14:25
---------	---	---------------

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP22 - Screening for Comorbidities**

Casper Rokx (Netherlands)

MeP22.1	<b>Systematic screening for age-related comorbidities: health care optimization among individuals living with HIV in the out-patient clinic in Copenhagen, Denmark</b> Anna Katrine Haslund Roed (Denmark)	15:35 - 15:40
---------	---	---------------

MeP22.2	<b>Evolving dynamics with prolonged life expectancy: The cancer profile in people living with HIV</b> inci Yilmaz Nakir (Turkey)	15:40 - 15:45
---------	---	---------------

MeP22.4	<b>Missed opportunities for anal cancer screening in women living with HIV: results from a survey across the European Region</b> Dagny Krankowska (Poland)	15:50 - 15:55
---------	---	---------------

MeP22.5	<b>Prevalence and Risk Factors of Frailty Among Japanese People with HIV: Implications for Health-Related Quality of Life</b> Hideta Nakamura (Japan)	15:55 - 16:00
---------	--	---------------

MeP22.6	<b>Long Term Trends For Bone Mineral Density and Trabecular Bone Scores In Men Living With and Without HIV: Impact of Tenofovir Disoproxil Fumarate Exposure</b> Henning Drechsler (United States)	16:00 - 16:05
---------	---	---------------

MeP22.7	<b>Screening for bone health in older people with HIV: uptake and outcomes from a large UK outpatient HIV service</b> Rhys Nicholas (United Kingdom)	16:05 - 16:10
---------	---	---------------

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP15 - Clinical Cases - Complex Presentations and Co-Infections in Advanced HIV**

Monika Bociaga-Jasik (Poland)

MeP15.C1	<b>Disseminated histoplasmosis and CMV ileocolitis in a late presenter with advanced HIV and IRIS</b> Alexy Inciarte Portillo (Spain)	12:05 - 12:10
----------	--	---------------

MeP15.C2	<b>Prophylaxis failure or IRIS reality? A case of unmasking <i>Mycobacterium avium</i> complex (MAC)-associated IRIS</b> Nikolaos Mazonakis (Greece)	12:10 - 12:15
----------	---	---------------

MeP15.C3	<b>Disseminated Kaposi sarcoma as initial AIDS-defining illness in a transgender woman with advanced HIV: mucocutaneous, pulmonary, gastrointestinal and nodal involvement</b> Alberto Foncillas (Spain)	12:15 - 12:20
----------	---	---------------

MeP15.C4	<b>Disseminated cryptococcosis and pneumocystosis as a rare and unusual presentation of primary HIV infection: case report and literature insights</b> Lorenzo Ciullini (Switzerland)	12:20 - 12:25
----------	--	---------------

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP19 - Beyond with DTG/3TC**

Silvia Nozza (Italy)

MeP19.1	<b>“Leaving no stones unturned”: 10 years results on the tolerability and metabolic safety of DTG+3TC as a switch regimen</b> Arturo Ciccullo (Italy)	14:05 - 14:10
MeP19.2	<b>Switching to dolutegravir/lamivudine is non-inferior to continuing triple-drug ART in virologically suppressed people with HIV: 2 year results of the DUALING prospective matched nationwide clinical practice study</b> Casper Rokx (Netherlands)	14:10 - 14:15
MeP19.3	<b>Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort</b> Arturo Ciccullo (Italy)	14:15 - 14:20
MeP19.4	<b>48-WEEK RESULTS OF SWITCHING FROM DTG/3TC TO BIC/FTC/TAF IN PWH AND NEUROPSYCHIATRIC COMORBIDITIES</b> Ignacio Perez Valero (Spain)	14:20 - 14:25

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP23 - Clinical Cases - Diagnostic Dilemmas, Immunologic Mysteries & ART Challenges**

MeP23.C.1	<b>ART switch challenges: hepatitis B reactivation in people living with HIV &amp; HBV co-infection and longstanding HBsAg loss</b> Flora Olcott (United Kingdom)	15:35 - 15:40
MeP23.C.2	<b>Management of HIV-related Progressive Multifocal Leukoencephalopathy: insights from metagenomic next-generation diagnosis and pembrolizumab-lenalidomide therapy, a case report</b> Yongzheng Guo (China)	15:40 - 15:45
MeP23.C.3	<b>A challenging diagnosis of VEXAS syndrome in a person living with HIV: a case of recurrent systemic inflammation and cytopenia</b> Buse Kenanoglu (Turkey)	15:45 - 15:50
MeP23.C.4	<b>Hemophagocytic lymphohistiocytosis in HIV: a diagnostic and therapeutic challenge highlighted by a rapidly fatal case</b> Banu Çiçek Aktaş (Turkey)	15:50 - 15:55
MeP23.C.5	<b>Recurrent fever of unknown origin in a patient with advanced HIV-2 infection: think beyond infectious diseases</b> Dara Mbanze (Portugal)	15:55 - 16:00
MeP23.C.6	<b>Unusual HIV seroconversion in PrEP user carrying heterozygous CCR5-Delta32 mutation: did he contract HIV?</b> Hélène Laroche (France)	16:00 - 16:05
MeP23.C.7	<b>The Dancer, the Cave, and the Squatters</b> Alberto Díaz-de Santiago (Spain)	16:05 - 16:10

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP16 - Practical implementation of novel PrEP modalities**

Nicolas Nagot (France)

MeP16.1	<b>Commonly Prescribed Concomitant Medications and Clinical Safety Findings With Lenacapavir for Pre-Exposure Prophylaxis in PURPOSE 2</b>	12:05 - 12:10
---------	--	---------------

	Anchalee Avihingsanon (Thailand)	
MeP16.2	<b>The Potential Impact of Twice-Yearly Injectable Lenacapavir Among Cisgender Gay, Bisexual, and Other Men Who Have Sex With Men (GBMSM) and Other Priority HIV Prevention Populations (Transgender People and Highly Exposed Heterosexual People) in France</b> Henri Leleu (France)	12:10 - 12:15
MeP16.3	<b>Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men who have sex with men in a European country</b> Philip Wikman-Jorgensen (Spain)	12:15 - 12:20
MeP16.4	<b>Evaluation of the completion rate and associated factors in HIV-Post-Exposure Prophylaxis regimen containing Doravirine (DORASPEP): a prospective observational cohort</b> Romuald Cruchet (France)	12:20 - 12:25
<i>Moderated ePosters</i> 14:05 - 14:25		ePoster Exhibition
<b>MeP20 - Prevention and HIV testing - innovative approaches and access</b> Nicolas Nagot (France)		
MeP20.1	<b>A novel way to improve access to Pre-Exposure Prophylaxis (PrEP) in the community via primary care</b> Rachel Kirby (United Kingdom)	14:05 - 14:10
MeP20.2	<b>Comparative benefits of pre-exposure prophylaxis versus test-and-treat to reduce community viral load: a systematic review of PrEP trials</b> Cassandra Fairhead (United Kingdom)	14:10 - 14:15
MeP20.3	<b>Randomized controlled clinical pilot study to evaluate the feasibility and acceptability of a telemedicine approach for HIV prevention with HIV Pre-Exposure Prophylaxis versus standard of care in Germany</b> Florian Voit (Germany)	14:15 - 14:20
MeP20.4.LB	<b>Cabotegravir Injections Are More Acceptable Than Lenacapavir Injections Following a Single Dose: Results From CLARITY, a Randomized Crossover Study of Long-Acting Injectable Antiretrovirals</b> Kimberley Brown (United States)	14:20 - 14:25
<i>Moderated ePosters</i> 15:35 - 16:10		ePoster Exhibition
<b>MeP24 - HIV Infection and Coinfection: Trends, Risks, and treatment</b> Charles Béguélin (Switzerland)		
MeP24.1	<b>Differences in ART regimen initiation among people with recently acquired HIV: 2015-2021</b> Fiona Burns (United Kingdom)	15:35 - 15:40
MeP24.2	<b>Elite controllers in a cohort of people with well-estimated dates of HIV seroconversion: characteristics, time to lose elite status and natural CD4 evolution</b> Nikos Pantazis (Greece)	15:40 - 15:45
MeP24.3	<b>Increasing prevalence of highly viremic persons diagnosed with chronic HIV infection: data from the ICONA cohort study</b> Antonella d'Arminio Monforte (Italy)	15:45 - 15:50



MeP24.4	<b>Epidemiology of HIV infection and HIV/HCV coinfection in marginalized populations of Madrid (2019-2023)</b> Jorge Valencia La Rosa (Spain)	15:50 - 15:55
MeP24.5	<b>Declining HIV Incidence in MSM diagnosed with syphilis: A Retrospective Longitudinal Study</b> Alessandra Latini (Italy)	15:55 - 16:00
MeP24.6	<b>Coverage and determinants of prenatal screening for HIV, syphilis and hepatitis B: a cross-sectional survey in Burkina Faso and The Gambia (TRI-MOM project)</b> Vincent Di Beo (France)	16:00 - 16:05
MeP24.7	<b>Integrated cervical cancer - high-risk human papillomavirus testing - screening strategy with other sexually transmitted infections offered to vulnerable women far from health facilities. Pilot intervention with sex-working women in Paris, France and Yerevan, Armenia</b> Marc SHELLEY (France)	16:05 - 16:10

*Industry sponsored session*

08:00 - 09:00

AMPHITHEATRE BLEU

**Industry sponsored session***Meet-the-expert*

08:00 - 09:00

AMPHITHEATRE BORDEAUX

**MTE3 - Invisible Battles: Mental and Neurological Health****HIV-Related Brain Injury in 2025: Evolving Diagnosis and Treatment**

08:00 - 08:10

Paola Cinque (Italy)

**Mental health challenges in people living with HIV**

08:10 - 08:20

Jordi Blanch (Spain)

**Interactive discussion with the audience**

08:20 - 09:00

*Meet-the-expert*

08:00 - 09:00

ROOM MAILLOT

**MTE4 - Should we have ATI trials and how?**

Sarah Fidler (United Kingdom)

Beatriz Mothe (Spain)

Krista Dong (United States)

**RIO trial participant testimony**

08:00 - 08:05

Johan Marais (United Kingdom)

MTE4.1

**Qualitative Insights into the Lived Experiences of People living with HIV who Participated in an Analytical Treatment Interruption in the RIO Randomised-Controlled Trial**

08:05 - 08:14

Jesal Gohil (United Kingdom)

**Interactive discussion with the audience**

08:14 - 08:50

*Meet-the-expert*

08:00 - 09:00

ROOM 242AB

**MTE5 - Weighing in on weight gain**

Esteban Martínez (Spain)

**What does the data really tell us on weight gain in people living with HIV?**

08:00 - 08:10

Dominique Costagliola (France)

**Therapeutic options for losing weight: GLP -1 receptor agonists and what else?**

08:10 - 08:20

Paddy Mallon (Ireland)

*ePosters*

09:00 - 18:00

ePoster Exhibition

**ePosters on Display**

*Plenary lecture*

09:15 - 09:45

GRAND AMPHITHEATRE

**PL3 - "Five years left!" What targets are in reach in Europe and which will we struggle to make?**

Cristiana Oprea (Romania)

**"Five years left!" What targets are in reach in Europe and which will we struggle to make?**

09:15 - 09:45

Teymur Noori (Sweden)

*Plenary lecture*

09:45 - 10:15

GRAND AMPHITHEATRE

**PL4 - HIV, hepatitis & syphilis prevention of vertical transmission - It's not all about babies**

Justyna Kowalska (Poland)

**HIV, hepatitis & syphilis prevention of vertical transmission - It's not all about babies**

09:45 - 10:15

Jeanne Sibiude (France)

*Breaks*

10:15 - 11:00

GRAND AMPHITHEATRE

**Coffee break**

*Oral presentations*

10:45 - 12:00

ROOM 252AB

**O2 - Oral cross track session**

David Jilich (Czech Republic)

Annette Haberl (Germany)

O2.1

**Review of HIV and Breastfeeding Guidelines Across Europe: Insights from the WAVE Survey 'Same, same, but different: European Guidelines on HIV and breastfeeding'**

10:45 - 10:54

Lila Haberl (Germany)

O2.2

**Long-acting injectable cabotegravir/rilpivirine in young adults with perinatally acquired HIV. RELATIVITY cohort study**

10:54 - 11:03

Jose I Bernardino (Spain)

O2.3

**Impact of a revised late HIV diagnosis definition on late HIV estimates in Europe: A multi-country pilot study**

11:03 - 11:12

Peter Kirwan (United Kingdom)

O2.4

**Estimating HIV incidence and number of people with undiagnosed HIV in the European Union/European Economic Area in 2023**

11:12 - 11:21

Ard van Sighem (Netherlands)

O2.5

**Predictors of linkage to prevention services after HIV Post-Exposure Prophylaxis (PEP): a retrospective analysis from 2019 to 2024**

11:21 - 11:30

Rozenn Esvan (Italy)

O2.6

**Comparison of the Time to Reach Viral Suppression after ART**

11:30 - 11:39

	<b>Initiation Between Transgender Women and Other PWH in France: Results from the ANRS CO4 FHDH</b>	
	Juliette Hemery (France)	
O2.7	<b>Analysis of barriers to testing for HIV prevention and linkage to care among migrants in Europe</b>	11:39 - 11:48
	Denis Onyango (United Kingdom)	
O2.8.LB	<b>Incorporating migration dynamics in the CD4 back-calculation method for HIV incidence estimation</b>	11:48 - 11:57
	Peter Kirwan (United Kingdom)	
<i>Parallel session</i>		
11:00 - 12:00		GRAND AMPHITHEATRE
<b>PS08 - HIV Prevention: Current modalities and Future Horizons</b>		
Sheena McCormack (United Kingdom)		
Šime Zekan (Croatia)		
	<b>HIV testing, PEP and Partner Notification</b>	11:00 - 11:10
	Fiona Burns (United Kingdom)	
PS08.1	<b>“TelePrEP” - An online program for the delivery of remote PrEP services</b>	11:10 - 11:19
	Maria Luisa Cosmaro (Italy)	
PS08.2	<b>Intention to use long-acting injectable Pre-Exposure Prophylaxis among Belgian men who have sex with men - results of an online survey</b>	11:19 - 11:28
	Thijs Reyniers (Belgium)	
PS08.3	<b>Tolerability and Safety of Long-Acting Cabotegravir for HIV Pre-Exposure Prophylaxis: preliminary data from a multicenter prospective observational study</b>	11:28 - 11:37
	Davide Moschese (Italy)	
PS08.4	<b>Preliminary Results of Long-Acting Injectable PrEP with Cabotegravir at San Raffaele Institute in Milan</b>	11:37 - 11:46
	Angelo Roberto Raccagni (Italy)	
PS08.5	<b>Annual Persistence to Twice-Yearly Lenacapavir Versus Daily Oral F/TDF for PrEP in the PURPOSE 2 Trial</b>	11:46 - 11:55
	Onyema Ogbuagu (United States)	
<i>Parallel session</i>		
11:00 - 12:00		AMPHITHEATRE BORDEAUX
<b>PS09 - New drugs in the pipeline</b>		
Gordana Dragović (Serbia)		
Caroline Solas (France)		
	<b>New HIV drugs: virological and pharmacological mechanisms</b>	11:00 - 11:10
	Anne-Genevieve Marcelin (France)	
PS09.1	<b>Safety and Tolerability of N6LS Administered Intravenously or Subcutaneously: Promising Results From Part 1 of the EMBRACE Study</b>	11:10 - 11:19
	Peter Leone (United States)	
PS09.2	<b>Efficacy and Safety of a Twice-Yearly Regimen of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 52 Results</b>	11:19 - 11:28
	Onyema Ogbuagu (United States)	
PS09.3	<b>A French national real-world observatory of people initiating a lenacapavir-based treatment during the post-approval period</b>	11:28 - 11:37
	Charlotte Charpentier (France)	

PS09.4	<b>Fostemsavir in a real-world setting: over one year of data from the PRESTIGIO Registry</b> Rebecka Papaioannu Borjesson (Italy)	11:37 - 11:46
--------	---	---------------

*Parallel session*

11:00 - 12:00

ROOM MAILLOT

**PS10 - How can AI be used to advance in HIV prevention, treatment and care?**

Jens D. Lundgren (Denmark)

Dan Turner (Israel)

**How can AI be used to advance in HIV prevention, treatment and care?**

11:00 - 11:10

Rodolphe Thiébaud (France)

**AI use in HIV prevention, case finding and early treatment uptake in Eastern Europe and Central Asia**

11:10 - 11:20

Tetiana Deshko (Ukraine)

**PS10.1 Artificial Intelligence Meets HIV Education: Comparing Three Large Language Models on Accuracy, Readability, and Reliability**

11:20 - 11:29

Özge Eren Korkmaz (Turkey)

**PS10.2 A machine learning-based prognostic algorithm for serious non-aids events after initiation of antiretroviral therapy**

11:29 - 11:38

Giota Touloumi (Greece)

**PS10.3 Identifying patterns of low-level viremia with increased risk of subsequent viral failure using machine learning**

11:38 - 11:47

Katharina Kusejko (Switzerland)

*Breaks*

12:00 - 14:30

GRAND AMPHITHEATRE

**Lunch break***Industry sponsored session*

12:30 - 14:00

AMPHITHEATRE BLEU

**Industry sponsored session***Oral presentations*

12:30 - 13:30

AMPHITHEATRE BORDEAUX

**RO1 - Mpox - from prevention to clinics**

Ole Kirk (Denmark)

Chloe Orkin (United Kingdom)

**RO1.1 What is the impact of MVA-BN vaccine among people living with HIV in Israel?**

12:30 - 12:37

Zohar Mor (Israel)

**RO1.2 Smallpox Vaccine Reduces Mpox Disease Severity and Symptoms**

12:37 - 12:44

Christoph Boesecke (Germany)

**RO1.3 Immune profiling reveals hyperinflammatory signature in acute Mpox infection**

12:44 - 12:51

Joanne Byrne (Ireland)

**RO1.4 Single-Cell RNA Sequencing of Mpox Lesions Reveals Tissue-Resident Memory T Cell Dynamics and Replenishment in the Skin**

12:51 - 12:58

Simona Saluzzo (Austria)

**RO1.5 Systematic molecular screening for mpox in anal/pharyngeal swabs in high-risk MSM on PrEP: a substudy of the ANRS-DOXYVAC trial**

12:58 - 13:05

	Jade Ghosn (France)	
RO1.6	<b>Breakthrough mpox cases among different vaccination routes and under distinct HIV status</b> Igor Moraes-Cardoso (Spain)	13:05 - 13:12
RO1.7	<b>Disproportionate presentation of Mpox among people with HIV: A multicenter retrospective cohort study in Taiwan</b> Andrew Po-Liang Chen (Taiwan)	13:12 - 13:19
RO1.8.LB	<b>Mpox-related hospitalization and morbidity in people living with HIV and PrEP users: results from the European MASH-1 cohort study</b> Nicolo Girometti (United Kingdom)	13:19 - 13:26

*Oral presentations*

12:30 - 13:30

ROOM MAILLOT

**RO2 - Advancing prevention and care: insights from providers and perspectives from the community**

Casper Rokx (Netherlands)

Magdalena Ankiersztejn-Bartczak (Poland)

RO2.1	<b>The jasmine project: revolutionary digital solutions to prevent violence and HIV among sex workers in France</b> Brunna de Medeiros (France)	12:30 - 12:37
RO2.2	<b>Profiles and follow-up of cis women using HIV pre-exposure prophylaxis (PrEP)</b> Karen Champenois (France)	12:37 - 12:44
RO2.3	<b>Expanding PrEP Access in France: Clinical Challenges and Community Perspectives from the QualiPrEP Study</b> Daniela Rojas Castro (France)	12:44 - 12:51
RO2.4	<b>More HIV pre-exposure prophylaxis options expected to increase overall use among Toronto sexual minority men: Projections from a discrete choice experiment</b> Darrell H. S. Tan (Canada)	12:51 - 12:58
RO2.5	<b>The Power of Choice: Perspectives From Healthcare Providers on Early Switch to CAB+RPV LA After Rapid Suppression With DTG/3TC</b> Cassidy A Gutner (United States)	12:58 - 13:05
RO2.6	<b>Real-world implementation of long-acting injectable cabotegravir and rilpivirine: healthcare providers' perspectives and experiences</b> Clea Tanner (United Kingdom)	13:05 - 13:12
RO2.7	<b>More Than Undetectable: Addressing Psychosocial Needs and Community Support</b> Joanna Cano-Smith (Spain)	13:12 - 13:19
RO2.8.LB	<b>Doxycycline prophylaxis to prevent bacterial STIs: Results of the open-label extension phase of the ANRS 174 DOXYVAC trial</b> Jean-Michel Molina (France)	13:19 - 13:26

*Oral presentations*

12:30 - 13:30

ROOM 252AB

**RO3 - Progress in clinical care**

Clotilde Allavena (France)

Mojca Maticic (Slovenia)

RO3.1	<b>Association Between Upregulated IL32 Expression and Inflammatory Patterns in Treated People with HIV</b> Dana Alalwan (Ireland)	12:30 - 12:37
-------	---	---------------

RO3.2	<b>HPV-16 Clearance at the Anal Site in MSM with HIV: Impact of Immunization and Host Immune Status</b> Elena Bruzzesi (Italy)	12:37 - 12:44
RO3.3	<b>Implementation of EACS 2023 Cardiovascular Prevention Guidance in a Real-Life HIV Metabolic Clinic: A Longitudinal Cohort Study from Modena</b> Marcella Manicardi (Italy)	12:44 - 12:51
RO3.4	<b>LDL Target Achievement in people with HIV Over 40: Impact of Updated EACS Guidelines</b> Giorgia Carrozzo (Italy)	12:51 - 12:58
RO3.5	<b>Advancing HIV Care in Pregnancy: Trends in Virological Suppression, Mother-to-Child Transmission, and Postpartum Retention Over Two Decades</b> Federica Casari (Italy)	12:58 - 13:05
RO3.7	<b>Efficacy and safety of long-acting intramuscular cabotegravir and rilpivirine in women: A substudy of the RELATIVITY cohort</b> María José Galindo Puerto (Spain)	13:05 - 13:12
RO3.8.LB	<b>Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, open-label, non-inferiority trial</b> Esteban Martínez (Spain)	13:12 - 13:19

*Parallel session*

14:30 - 15:30

GRAND AMPHITHEATRE

**PS11 - Emerging Challenges and Opportunities in STI Screening and Management**

Jade Ghosn (France)

Monika Bociąga-Jasik (Poland)

	<b>Should we screen for asymptomatic STI in MSM on PrEP?</b> Charles Cazanave (France)	14:30 - 14:40
	<b>Key questions and evidence gaps in the implementations of Doxyep</b> Fiona Lyons (Ireland)	14:40 - 14:50
PS11.1	<b>Bacterial STIs incidence among MSM with HIV in France: the ANRS PRIMO cohort</b> Sophie Novelli (France)	14:50 - 14:59
PS11.2	<b>Clinical Features of Syphilis in MSM on Doxycycline Post-Exposure Prophylaxis (doxy-PEP): Real-World Data from a Single-Center Cohort</b> Cristina Gómez-Ayerbe (Spain)	14:59 - 15:08
PS11.3	<b>Bacterial Sexually Transmitted Infections over a 4-year-period of follow-up in MSM on PrEP enrolled in the prospective ANRS-PREVENIR cohort</b> Jade Ghosn (France)	15:08 - 15:17
PS11.4	<b>PrEP and STIs screening policies: one size fit to all?</b> Enrico Schlitzer (Italy)	15:17 - 15:26

*Parallel session*

14:30 - 15:30

AMPHITHEATRE BLEU

**PS12 - Innovations, personalised medical services and social impacts**

Daniela Rojas Castro (France)

Ben Collins (United Kingdom)

	<b>Personalised medical approaches - is it the best approach to end the epidemic?</b>	14:30 - 14:45
	Udi Davidovich (Netherlands)	
PS12.1	<b>Public Knowledge, Views, Perceptions and Attitudes towards HIV and People with HIV in Europe - Combined Results of an HIV Public Opinion Survey Conducted in 11 European Countries</b>	14:45 - 14:54
	Konstantinos Protopapas (Greece)	
PS12.2	<b>Risk of Income Loss in People Living With and Without HIV - a Comparative Swedish Nationwide Study Between 2019 to 2021</b>	14:54 - 15:03
	Isabela Killander Möller (Sweden)	
PS12.3	<b>Self-Reported Wellbeing and Integration Levels of Migrants with HIV in Italy: A Cross-Sectional Analysis from the ICONA Cohort</b>	15:03 - 15:12
	Andrea Giacomelli (Italy)	
PS12.4	<b>Transgender People with HIV in Italy: Higher Risk of Disengagement from Care and Adverse Outcomes in the ICONA Cohort</b>	15:12 - 15:21
	Davide Moschese (Italy)	

*Parallel session*

14:30 - 15:30

AMPHITHEATRE BORDEAUX

**PS13 - Ensuring access to HIV prevention and care for migrant populations in Europe**

Deniz Gökengin (Turkey)

Tetiana Melnyk (France)

	<b>The new EU framework for migration and its potential impact on migrant health</b>	14:30 - 14:40
	Denis Onyango (United Kingdom)	
	<b>Post-migration HIV acquisition in migrants receiving HIV care in Europe</b>	14:40 - 14:50
	Romain Palich (France)	
PS13.1	<b>Community-Based Screening for HIV and Viral Hepatitis Using Dried Blood Spots in a Migrant Population in Spain: the HEPINMIGRA study</b>	14:50 - 14:59
	Jara Llenas-García (Spain)	
PS13.2	<b>Seroprevalence of HIV, HBV, HCV, and Syphilis Among Syrian Refugees in Istanbul: Results from a Population-Based Prospective Study</b>	14:59 - 15:08
	Asuman İnan (Turkey)	
PS13.3	<b>The Impact of War on HIV and TB Epidemics in Ukraine: Challenges in Detection, Late Presentation, and Disease Burden</b>	15:08 - 15:17
	Tetiana Koval (Ukraine)	
PS13.4	<b>The impact of Russia's war in Ukraine on opioid agonist treatment (OAT) services, a primary HIV prevention strategy among people who inject drugs (PWID)</b>	15:17 - 15:26
	Daniel J. Bromberg (United States)	

*Parallel session*

14:30 - 15:30

ROOM MAILLOT

**PS14 - HIV-exposed uninfected children: A topic of clinical significance?**

Karoline Aebi-Popp (Switzerland)

Mariana Mardarescu (Romania)

PS14.1	<b>Outcomes of HIV-Exposed Uninfected Children Born to HIV-Positive Mothers at Bichat-Claude Bernard Hospital: The ENIVIH Study</b>	14:30 - 14:39
	ANTOINE Bachelard (France)	

<b>PRO</b>	14:39 - 14:54
Claire Thorne (United Kingdom)	
<b>CON</b>	14:54 - 15:09
Pablo Rojo Corneo (Spain)	
<b>Discussion</b>	15:09 - 15:30

*Breaks*

15:30 - 16:15

GRAND AMPHITHEATRE

**Networking break***Special session*

16:15 - 17:15

AMPHITHEATRE BLEU

**SPS5 - ANRS: Global public health funding cuts: a new challenge for HIV in Africa?**

Soufia Bham (Senegal)

Yazdan Yazdanpanah (France)

<b>Introduction</b>	16:15 - 16:20
<b>Europe's response to support research &amp; innovation in Africa and maximize the EU's attractiveness for scientific excellence</b>	16:20 - 16:25
Michael Makanga (Belgium)	
<b>Modelling the potential impact of US government financial support withdrawal in Africa</b>	16:25 - 16:30
Romain Silhol (United Kingdom)	
<b>Real life impact of financial cuts decisions on people and communities: case of Burundi</b>	16:30 - 16:35
Jeanne Gapiya (Burundi)	
<b>Future-proofing HIV care in South Africa and beyond, amid a changing funding landscape</b>	16:35 - 16:40
Harsha Somaroo (South Africa)	
<b>Roundtable discussion/Q&amp;A</b>	16:40 - 17:10

*Special session*

16:15 - 17:15

AMPHITHEATRE BORDEAUX

**SPS6 - University of Liverpool Drug Interaction Team: Pharmacology of antiretrovirals in special populations**

Saye Khoo (United Kingdom)

Catia Marzolini (Switzerland)

<b>Introduction</b>	16:15 - 16:20
<b>Optimising treatment: the mind matters</b>	16:20 - 16:35
Jordi Blanch (Spain)	
<b>TB treatment: more or less?</b>	16:35 - 16:50
Gerry Davis (United Kingdom)	
<b>Case on adolescents living with HIV</b>	16:50 - 17:05
Paolo Paioni (Switzerland)	
<b>Discussion/Q&amp;A</b>	17:05 - 17:15



*Roundtable Discussion*

16:15 - 17:15

ROOM MAILLOT

**RT3 - HIV related stigma in healthcare settings - What next?**

Teymur Noori (Sweden)

**Setting the stage**

16:15 - 16:25

Katie Darling (Switzerland)

**Roundtable Discussion on HIV related stigma in healthcare settings - What next?**

16:25 - 17:15

Ricardo Fernandes (Portugal)

Florence Thune (France)

Joseph Larmarange (France)

*Special session*

16:15 - 17:15

ROOM 252AB

**SPS7 - ESCMID STI Study Group (ESTISG) and Sexually Transmitted Infections (STI) journal: 2025 Update on gonorrhea**

Anna Maria Geretti (United Kingdom)

Justyna Kowalska (Poland)

**Introduction**

16:15 - 16:20

**What is the best approach to screen for gonorrhea**

16:20 - 16:35

Thibaut Vanbaelen (Belgium)

**Current status of AMR in *N. gonorrhoeae* and new challenges**

16:35 - 16:50

Ismail Maatouk (Switzerland)

**Where are we with OMV vaccines for gonorrhea ?**

16:50 - 17:05

Jean-Michel Molina (France)

**Discussion/Q&A**

17:05 - 17:15

*Meet-the-expert*

16:15 - 17:15

ROOM 242AB

**MTE6 - The Rationale behind Remnants and Replication: Managing low-level viremia**

Huldrych Günthard (Switzerland)

Annemarie Wensing (Netherlands)

MTE6.1

**Low-level viremia during antiretroviral treatment is not associated with impaired immunological recovery in the second-generation INSTI era**

16:15 - 16:24

Tommaso Clemente (Italy)

**Interactive discussion with the audience**

16:24 - 17:15

Saturday, October 18, 2025

*Roundtable Discussion*

08:00 - 09:00

AMPHITHEATRE BORDEAUX

**RT4 - Guidelines versus Gospels (Guidelines, Evidence, and Reality)**

Pierre Delobel (France)

**Roundtable Discussion on "Guidelines versus Gospels (Guidelines, Evidence, and Reality)"**

08:00 - 09:00

Iain Reeves (United Kingdom)

Juan Ambrosioni (Spain)

Dagny Krankowska (Poland)

*Parallel session*

09:15 - 10:15

AMPHITHEATRE BORDEAUX

**PS15 - Co-Chairs Choice**

Milesz Parczewski (Poland)

Karine Lacombe (France)

Jean-Michel Molina (France)

Bruno Spire (France)

PS15.1

**Trends and Timing of HIV Diagnoses Among Migrants: A 15-Year Analysis from the Swiss HIV Cohort Study**

09:15 - 09:24

Jessy J. Duran Ramirez (Switzerland)

PS15.2

**Doxycycline postexposure prophylaxis and the 4-component meningococcal B vaccine among persons living with HIV at high risk for bacterial sexually transmitted infections in Switzerland**

09:24 - 09:33

David Wimmersberger (Switzerland)

PS15.3

**Chemsex, novel chemsex substances, associated risks for STIs, and an extended PrEP cascade among HIV-negative MSM, trans\* individuals in 20 European countries: A latent class analysis**

09:33 - 09:42

Kai J Jonas (Netherlands)

PS15.4

**Metabolic and Body Composition Outcomes at 48 Weeks among People with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide Switching to Doravirine with or without Tenofovir Disoproxil Fumarate: ACTG A5391 (the DO-IT Trial)**

09:42 - 09:51

John Koethe (United States)

PS15.5.LB

**Oral Weekly Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV-1: 96 Week Outcomes from a Phase 2 Study**

09:51 - 10:00

Amy Colson (United States)

PS15.6.LB

**Low risk of HBV reactivation in HBcAb-positive/HBsAg-negative persons with HIV switching to non-tenofovir-based antiretroviral therapy**

10:00 - 10:09

Lorin Bgré (Switzerland)

*Breaks*

10:15 - 10:45

AMPHITHEATRE BORDEAUX

**Coffee break***Special session*

10:45 - 11:30

AMPHITHEATRE BORDEAUX

**SPS8 - EuroTest special session: Blood borne virus testing in Emergency Departments across Europe**

*Special session*

11:45 - 13:15

AMPHITHEATRE BORDEAUX

**SPS9 - EACS Standard of Care session**

Milesz Parczewski (Poland)

Cristiana Oprea (Romania)

	<b>Setting the Scene - Using the Standards of Care to improve the Quality of Care and Outcomes</b>	11:45 - 11:50
	Jürgen K Rockstroh (Germany)	
	<b>ECDC/EACS Standards of HIV Care: Where are we at?</b>	11:50 - 12:10
	Teymur Noori (Sweden)	
	<b>Q&amp;A</b>	12:10 - 12:15
SPS9.1	<b>PrEP Standards of Care: Results of the First European Clinical Audit</b>	12:15 - 12:35
	Francesca Roper (Denmark)	
	<b>Panel / audience Discussion on implementation of Standards of Care across Europe</b>	12:35 - 13:00
	Sanjay Bhagani (United Kingdom)	
	Fiona Burns (United Kingdom)	
	Annette Haberl (Germany)	
	Milesz Parczewski (Poland)	
	Jürgen K Rockstroh (Germany)	
	<b>Impact and future direction of Standards of Care</b>	13:00 - 13:10
	Konstantinos Protopapas (Greece)	
	<b>Summary and closing</b>	13:10 - 13:15
	Cristiana Oprea (Romania)	

*Ceremony*

13:15 - 13:45

AMPHITHEATRE BORDEAUX

**Closing remarks**

Milesz Parczewski (Poland)

Karine Lacombe (France)

Jean-Michel Molina (France)

Bruno Spire (France)

	<b>Conference Closing Remarks</b>	13:15 - 13:25
	<b>Rapid Oral Abstract awards</b>	13:25 - 13:30
	<b>Art Exhibition awards</b>	13:30 - 13:35
	<b>Introduction to EACS 2027/21st European AIDS Conference</b>	13:35 - 13:45